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Abstract 
An investigation of the interaction of stable opioidfligands and unstable 
opioid peptides with opioid receptors in guinea pig brain, guinea pig 
myenteric plexus and mouse vas deferens has been carried out. 
The initial aim of the study was to further characterise K opioid receptors, 
using binding assays and isolated tissue bioassays. The second aim was to 
determine the true affinity and potency of small dynorphin peptides for the 
K opioid receptor and to determine if metabolism of the peptides to non K 
opioid receptor-preferring products contributes to their observed in vitro 
pharmacology. 
The K-opioid receptor binding site in guinea pig brain has been characterised 
using [3H] CI977, (5R-(5a, 7 a,S ~)-N -methyl-N -[7 -( 1-pyrrolidinyl)-1-
oxaspiro[ 4,5]dec-8-yl]-4-benzofuranacetamide monohydrochloride). In Tris 
buffer, the maximum number of binding sites (Bmax) labelled by this ligand 
was 79.3±7.2 fmol/mg protein and the affinity for the sites was 0.42±0.12 
nM. In the presence of the stable GTP analogue Gpp(NH)p and NaCl the 
determined affinity did not significantly change but the Bmax was reduced 
by 46%. Similar effects were observed at 0°C. It was concluded that both 
conditions induce the formation oflow agonist affinity states of the receptor 
which are not detected in the ligand binding assay. 
Several 14-alkoxymorphinans have been implicated in the differentiation of 
opioid K-receptor subtypes in isolated tissues and guinea pig brain. In the 
present study further evidence was obtained in favour of this. Furthermore, 
the 14- alkoxymorphinans appeared to have differential affinity foro opioid 
receptors in the guinea pig brain and mouse vas deferens with affinity 
values in competitive binding assays of <lOOnM compared with affinities in 
the mouse vas deferens of>2!1M. 
The endogenous peptide dynorphin A (1-8) displayed similar affinities at 11, ll 
and 11: opioid binding sites in guinea pig brain, determined by radioligand-
binding assays. Contrastingly, antagonism by the 11: opioid receptor 
selective norbinaltorphimine in the guinea pig ileum and mouse vas 
deferens, implicated that dynorphin 1-8 exerts its effects via the 11: opioid 
receptors. The potency of this peptide was however weak, with an ICso of 
approximately 100nM in mouse vas deferens and 40nM in guinea pig 
myenteric plexus. Addition of an inhibitor cocktail, consisting of 301-lM 
bestatin, 301-lM captopril and 0.31-lM thiorphan to prevent the degredation of 
the peptide, enhanced the binding of dynoiphin 1-8 (4 fold at 11, 2 fold at ll 
and 20 fold at 11: opioid sites). However, in the mouse vas deferens, agonism 
was now seen to occur preferentially via the ll opioid receptors . 
Studies of dynorphin 1-8 metabolism in the mouse vas deferens revealed a 
favourable production of the !lill preferrring peptide [Leu5]enkephalin, 
particularly in the presence of peptidase inhibitors. This may be 
responsible for the ll-receptor activity seen under these conditions. Addition 
of a selective inhibitor of E.C.3.4.24.15., an endopeptidase thought to 
contribute to the cleavage of the Leu5-Arg6 bond to release 
[Leu5]enkephalin, afforded a greater recovery of dynorphin 1-8 and a drop in 
the production of[Leu5]enkephalin. 
A quest for learnin' mae hae bin healthy, 
but a wee tad foresicht wud hae din a muck le bit o' gid !! 
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1.0 Introduction 
1.01 Historical 
Pain or ponos as the Greeks called it, has been a factor in human existence 
since before records of life began. Identification of pain has been paralleled 
by a search for its alleviation. Herbalism, witchdoctors and magic have 
been rife for centuries in an attempt to conquer both external (physical 
damage) and internal (once thought to be induced by evil spirits) pain. 
Opium, obtained from the latex of unripe seed capsules of the poppy variety 
Papaver somniferum, ranks with aspirin as being the most widely used 
analgesic of all time. The first reference to opium, seems to have been an 
inscription carved on a tablet by a member of the Sumerian tribe around 
4000 BC. They referred to it as HUL GIL, HUL being thought to have 
meant joy and GIL to have meant plants [1]. 
-CHs 
Figure 1.0 Morphine 
In Greek mythology, the poppy was dedicated to four deities: Naxos, the 
Goddess of the night, Thanatos, the God of death, Hypnos, the God of sleep 
and Morpheus, the God of dreams [1]. An active constituent of opium, 
morphine (Figure 1.0), isolated in 1803 by the German pharmacist 
Seturner, was named after the God of dreams. In addition to this there are 
several other alkaloid constituents in opium including codeine, thebaine, 
narcotine and papaverine [2]. 
The recognition of the pain relieving properties of morphine, led to the 
question of why an exogenous compound should activate receptors within 
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the body. It was proposed by Martin and eo-workers [3] that 'morphine- like 
compounds might mimic an ongoing biochemical process'. Evidence for this 
came in 1972 when analgesia produced by electrical stimulation in rat brain 
stem was reversed by the antagonist naloxone (Figure 1.01), a molecule 
based on the structure of morphine, at a concentration of 1 mg Kg-1 [4]. 
This was followed in 1973 by the identification of putative receptors by 
pharmacological methods [5,6]. 
Figure 1.01 Naloxone 
In 1975 the isolation of two opioid-like substances from the brain and the 
pituitary opened a new door in the comprehension of antinociception 
pathways [7,8,9,10]. The name enkephalin [11] was given to the two 
pentapeptides isolated from porcine brain differing only in their carboxy-
terminal amino acid residue. The variable C-terminal amino acid is either 
leucine, affording the enkephalin [Leu5]enkephalin, or methionine affording 
[Met5]enkephalin [12] (Figure 1.02). These peptides were proposed to be 
neurotransmitters. Consequently, several larger peptides have been 
discovered and are found to be present in neurones throughout the CNS, 
possessing their amino-terminus pentapeptide in the sequence of either 
[Met5]enkephalin or [Leu5]enkephalin. These peptides exhibit opioid 
activity, and include for example, !3-endorphin, Peptide E, metorphamide, 
dynorphin ~ 7 in addition to dynorphin 1~8 as shown in Figure 1.02 [13,14]. 
Since the biochemical demonstration of opiate receptors [5,6] and the 
discovery of opioid peptides [12], the possibility of multiple types of opiate 
receptors has been investigated. Differences in pharmacological profiles 
and naloxone antagonism sensitivity in vivo and in vitro supported the 
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hypothesis of more than one form of opioid receptor. The inability of some 
opioid compounds to substitute for each other in the suppression of 
withdraw! symptoms in the tolerant chronic spinal dog, led Martin to 
postulate [3] that there were distinct types of opiate receptors in the CNS. 
These were characterised by the ability of agonists to precipitate signs of 
analgesia, sedation and psychomimetic effects at Jl, K: and cr receptor sites 
respective1y [15,16]. Since then the cr receptor has been excluded from this 
group which now includes the o receptor [3]. The nomenclature of these 
receptor~as derived from morphine (Jl), S.KF 10047 (cr), ketocyclazocine (K:) 
and o, the receptor which is enkephalinl!:referring and which predominates 
in mouse vas geferens (MVD) [17]. 
A report by Chavkin & Goldstein in 1981 described a receptor specific for 
endogenous dynorphins. This receptor was demonstrated in guinea pig 
myenteric plexus longitudinal muscle (GPMP) [18] and was separate from 
that of [Leu5]enkephalin which exerts its effects through the Jl receptor. 
This dynorphin specific site was thought to be the K: receptor. The 
extraordinarily high potency of dynorphin 1-13 and a. neo-endorphin on 
guinea pig myenteric plexus, with such activity also being observed in the 
mouse vas deferens [19,20,21], provided further evidence for a receptor, 
highly selective for dynorphin [22]. 
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R= 
-NH--< 
:1---NH' 
Dynorphin 1-8 
Figure 1.02 Showing the structures of the enkephalins and dynorphin 1-8 
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1.02 Opioid Receptor Properties 
There is good evidence to support the physiological role of opioid receptors in 
the mediation of antinociception [3,15,16]. However other effects 
associated with opioid ligands include shock, loss of appetite, diuresis, 
decreased gastrointestinal function, thermoregulation, cardiovascular 
modulation and mental disorders [25]. The activation of opioid receptors 
with characteristics resembling the Jl receptor have been shown to result in 
the inhibition of pain at the level of the brain, spinal cord and periphery 
induced by chemical, pressure, heat or electrical stimuli [26]. These effects 
are also demonstrated by the activation of 1C receptors [27,28] though an 
important part ofJC analgesia occurs in the spinal cord [29,31]. 
Differences in the responses between the ll and JC agonists, in addition to 
those resulting from 8 receptor activation [30], can also be demonstrated in 
the spinal cord. The activation of Jl receptors results in euphoria with the 
side effects of sedation, respiratory depression, constipation and nausea. In 
contrast, 1C activation results in dysphoria, psychomimetic effects, sedation 
and diuresis [26,32]. Other JC effects include tolerance and reduced 
intestinal motility, which although associated with activation of other 
opiate receptors are to a lesser extent in the case of 1C activation [29]. This 
observation therefore incited the interest into the possible identification of 
selective K ligands which would precipitate analgesia but not the 
complicating side effects seen clinically with other opiates [29]. 
1.03 Distribution o{Opioid Receptors 
Opiate receptors and endogenous opioids are widely distributed in the dorsal 
horn of the spinal cord [33]. At this level opioids activate postsynaptic and 
presynaptic receptors. They have been shown to inhibit transmitter 
release from nociceptive primary afferent nerves [34] by either stimulation 
of some spinal brain areas which project to the spinal cord or by direct 
action on spinal neurons [35]. In the brain, 1C receptors are present in high 
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concentrations [19,36,37,38] and there is much evidence for subclasses ofK 
receptors both here and in the periphery, discussed later [35,39,40,41,42]. 
In addition to this, K and I) receptors have been differentiated, and studies 
have shown separate distributions of enkephalinergic and dynorphinergic 
systems [ 43]. This has been achieved by the use of selective antisera 
developed against [Leu5]enkephalin and dynorphin 1-17 respectively, 
implying they act via different systems which may exert different 
pharmacological effects. 
A population of K receptors has been recognized in the dorsal horn and 
concentrated in lamina II (substantia gelatinosa). Dynorphin containing 
neurons are also localized predominately in lamina II in addition to lamina I 
as well as the deeper IV and V [26]. The presence of such receptors· in the 
substantia gelatinosa was of interest, this being the site of receipt and 
processing of primary afferent nociceptive information. It has also been 
shown that K receptors are rich in periaqueductal grey and thalamus [26]. 
1.04 Endogenous Peptide Interaction 
Recently it has been demonstrated that dynorphin activation of excitatory 
presynaptic K receptors, on substance P containing primary afferent 
nerves, may contribute to hyperalgesia observed in inflammatory 
processes [172] with the consequent nociceptive actions of dynorphins. 
This can be blocked by naloxone which could explain why this antagonist is 
reputed to possess analgesic effects at low doses in some instances. 
Dynorphin peptides can produce dosel:._elate<)partially reversible hindlimb 
paralysis following intrathecal administration [44]. However, due to a lack 
of protection by prior administration of nor-BNI or naloxone or by the 
absence of paralysis reversal by antagonist administration, it was thought 
that this motor dysfunction is a non opiate mediated action [ 44,45]. 
Other transmitters may also be involved with opioid receptors. An example 
of this is the analgesic actions of nitrous oxide, N20, whose effects may be 
mediated via spinal and supraspinal K opioid receptors [46]. This theory 
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was based on the observation that N20 analgesia was reduced by 
administration of the mixed Kill antagonist naltrexone, and the more K 
selective nor-BNI but not by the non competitive, highly 11 selective ~-FNA. 
These effects were observed via both the brain and the spinal receptors 
determined by administration either intracerebroventricularly or 
intrathecally respectively. 
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___________ (TMl) 
______________ (TM2) 
VVFVVGLVGNSLVMFVIIRYTKMKTATNIYIFNLALADALVTTTMPFQSAVYLMNSWPFGDVLCK 
_____________ (TM3) 
_____________ (TM4) 
IV IS ID YYNMFTSI FT LTM MS VD RYIA VC H PV KALD FRT PLKAKI IN IC IWL LASS VGI S AI V LGGT K 
_______________ (TM5) 
VRE D VD V I E CS L QF PD DE YS WWD LFM KI C VFV F AFV I PVLI I IVC YT LM I LRKLS VR LL S GS RE KD R 
-------------- (TM6) _____________ (TM7) 
NLRRI TKLVLVVV AV FI I C WT PI HI F I L VEAL GSTS H ST AALS S YYF C IALGYTN SS LN PV L Y AFLD E 
[V] 
NFKRCFRDFCFPIKMRMERQSTNRVRNTVQDPASMRDVGGMNKPV 
[Y] 
Figure 1.03 lllustrating the cloned K receptor amino acid sequence from mouse brain [23], and the amino acid variances 
in the cloned K receptor sequence from rat brain shown below in brackets [24]. These two clones both contain 380 
residues, and have 97% similarity. TM =proposed transmembrane domains [23,24], there being seven in total. 
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1.05 Receptor Classification 
To investigate the endogenous opioid peptides, a characterisation of their 
receptors is essential. The activation of different receptors affords variable 
effects and side effects in vivo as described above and this in turn forms a 
basis for receptor classification. Following this the selectivity of the ligands, 
both exogenous and endogenous, can be demonstrated in radioligand binding 
assays and isolated tissue bioassays in which their competition with 
antagonists provides an insight to their receptor preferences. Studies of the 
endogenous peptides, including the enkephalins and the dynorphins 
[19,37,38,47,48], required proteolytic enzyme inhibition [19,48] both in 
vivo and in vitro. As a consequence stable analogues have been developed, 
examples of which include the Jl~elective DAMGO [49], and the 15 selective 
DPDPE [50]. 
The conclusive evidence for opioid receptors with different structures has 
been provided by their cloning and expression. Mouse brain 15 receptors 
[51,52] were the first to be described. These receptors were shown to 
display the motif of seven transmembrane domains, determined by 
hydropathic analysis. Subsequently the cloned rat brain Jl receptor [53] 
) 
has been described, and in mouse brain two opioid receptors, identified as 15 
and K have been shown to be associated with GTP binding proteins (G 
proteins) [23]. A full sequence of the K receptor has been reportedly cloned 
from rat [24] and mouse brain [23] (Figure 1.03). 
Comparison of 15 and K cloned receptors [23] suggest that the different 
clones originate from distinct gene products but the basis of subtypes 
within each class remains to be determined. It is not yet known whether 
they are genetically distinct _of' simply subject to regional and species 
dependant post translational modification. An important advance would be 
the identification of the K receptor types with analgesic effects separate 
from the unwanted sedation and psychomimetic effects [53]. Further 
cloning studies will facilitate structure-function relationships and indicate 
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the influence of the receptors on signal transduction, desensitization, down 
regulation and regulation of gene expression. 
CH3 
I 
Figure 1.04 U69593 
1.06 Cha,rac;terisation of the K Opioid Receptor 
Non-peptide compounds, selective for the K receptor, have been designed 
due to the lack of selectivity of the prototypic ethylketocyclazocine for the K 
receptor over jl and o opioid receptors [54]. The first compounds included 
the benzodiazepam, tifluadom and the benzomorphan, bremazocine. 
These too were not fully selective at the K opioid site and cross reactivity 
occurred with other opioid receptor groups [37]. Suppression of ll receptors 
was effected by DAMGO and o receptors by DADLE, another stable 
enkephalin analogue. Recent developments have seen the advent of more 
selective and potent compounds such as the Upjohn compound U69593 
[55], shown in Figure 1.04, the Parke-Davis compounds PD 117302 [56] 
illustrated in Figure 1.05 and most lately CI977 [57] , the structure of 
which being shown in Figure 1.06. In addition to this, many others based on 
similar structures have been examined over the years. 
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CI977 demonstrates a similar population of binding sites to U69593 in 
guinea pig fore brain but is 10 fold more potent [58]. It has a far lower level 
of non specific binding than U69593 therefore has been utilised in the study 
of tissues with low receptor populations [59] and in ontogeny studies [60]. 
The potency and affinity of CI977 has been described at the K receptor to 
be comparable to that of the benzomorphans [57]. 
CH:l 0 
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Figure 1.06 CI977 
In order to characterise receptors, antagonists are necessary. Naloxone 
unfortunately shows little preference between Jl, o and K opioid receptors 
but selective antagonists are now available. Thus the K preferring 
norbinaltorphamine (nor-END [25,61,62], as illustrated in Figure 1.07, has 
been utilised and been shown to possess a 400 fold Kill selectivity and that 
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for K/o of 250 fold [61]. No agonism has been detected by nor-BNI in any 
tissue, tested up to 3!lM. Its actions in vivo are less potent, which when 
given subcutaneously, can be explained by slow transport and diffusion 
across the blood brain barrier [193]. Administration by this route required 
a period of two hours to pass before maximum effects were observed. 
However the slow diffusion cannot be the only determining factor since its 
activity after intrathecal or intracerebroventricular administration did not 
peak until after an hour [193]. Other examples of selective antagonists 
include naltrindole, a o selective antagonist, and CTOP a ll selective 
antagonist which have been characterised similarly. 
HO 
Figure 1.07 Norbinaltorphamine (Nor-BNI) 
1.07 Heterogeneity of the K Opioid Receptor 
The concept of K receptor subtypes emerged not long after the 
characterisation of the K receptor itself [35,36,63] from in vitro binding and 
pharmacological studies which were designed to resolve the complexity of 
the Kti_ike effects. The first division of K receptors [36] used 
[3H]ethylketocyclazocine, [3H]bremazocine and [3H]dynorphin, introducing 
the idea of a dynorphin resistant K site. 
12 
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1.08 Identification of K Opioid Subtypes 
Differences were detected in the K sites present in guinea pig brain and rat 
spinal cord, and similarly such discrepancies were also reported when 
radioligand binding in rat spinal cord was compared to that in guinea pig 
cord, which implied receptor heterogeneity [35]. Initial separation of 
properties was based on the sensitivity of the two high affinity sites labelled 
with [3H]ethylketocyclazocine after the suppression of 1.1 and o receptors, to 
the mixed Jl/0 selective enkephalin analogue DADLE. Furthermore the 
binding of [3H]bremazocine after suppression of 1.1 and o sites displayed 
heterogeneity, affording shallow displacement slopes [36,64,65]. These 
observations led to the characterisation of a K 1 site, being DADLE 
insensitive (DAL1), and the K2 site, being DADLE sensitive (DAL8) [35], 
both of which could be labelled with [3H] ethylketocyclazocine. 
Both K1 and K2 sites were shown to be sensitive to naloxone antagonism and 
were therefore be described as opiate receptors. Although the 1<:2 site was 
demonstrated to produce cross reactivity with the Jl{o ligand DADLE, this 
receptor was insensitive to other !.! and o ligands and therefore was a 
separate receptor aside from these two these groups [66]. Dynorphin 1-17 
has been reported to bind 30 times better to K 1 than K2, whereas the 
endogenous opioid peptide derived from proopiomelanocortin, f3 endorphin, 
bound 20 fold better to K2 than K 1• This implicated K2 as the reputed E site 
[67,68,69] first demonstrated in rat vas deferens [70] and since illustrated 
in rat [71,72,73], chicken, cow, pig and guinea pig brain [73]. 
Furthermore, an extremely high selectivity of [Met5]enkephalin-Arg6-Phe7 
for K 2 over K 1 [35,74] has been shown, and this peptide along with 
[Met5]enkephalin-Arg6-Gly7-Leu8 have been proposed to be the endogenous 
ligands for this site. All other compounds including the enkephalins and 
dynorphins have been reported to be much less potent at this site [75]. The 
13 
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Ki values of diprenorphine and etorphine but not naloxone, at K 1 and K2 sites 
exhibit differences. In studying the action of K agonists in the spinal cord of 
several species, a high population of K sites can be detected using 
autoradiography [76]. This visualises the presence of ~. 8, K1 and K2 in 
guinea pig spinal cord, with the population of K2 greatly exceeding K 1 [66]. 
In vivo evidence for recaptor subtypes has been demonstrated in rats 
trained to discriminate the K opioid agonist ethylketocyclazocine from saline 
· [77]. The rats could not discriminate dynorphin A and related pep tides from 
the saline and are therefore indicating a degree ofreceptor heterogeneity. 
The recaptor subtype K 1 has been shown to be sensitive to the 
arylacetamides U50488 and U69593, whereas the K2 site appears to be 
insensitive to these compounds [78,79]. Binding studies have shown 
[3H]bremazocine recognizes both K1 and K 2 sites in the guinea pig brain, 
whereas U69593 binds K 1 exclusively. This fact makes possible the 
separation of K 1 and K 2 populations. Ethylketocyclazocine is thought to 
have slight selectivity for K 1 over K 2 but also binds to 11 and 8 receptors, 
illustrated by the total binding capacity of [3H]ethylketocyclazocine which 
is equal to the sum of Jl, 8 and K 1 binding capacities. [3H]Bremazocine has 
a higher total binding capacity than [3H]ethylketocyclazocine, detecting K1 
and K2 indescriminatively [80]. 
In rat cerebellum [81] the K population is made up almost exclusively of the 
benzomorphan K2 sites and the lack of binding of U69593 in this tissue is 
probably a result of its low affinity for K2. In addition, this could explain the 
failure to demonstrate antinociception upon intrathecal administration of 
U69593 [82]. In contrast guinea pig cerebellum predominately expresses 
K 1 like properties [81], the K 1 distribution being localised in discrete areas 
[78,79] in rat and guinea pig brain with K2 having a wider distribution. 
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Autoradiography in guinea pig forebrain, shows high densities of 
[3H]ethylketocyclazocine binding, being approximately 30 times greater 
than that of [3H]U69593 [78]. At4°C, [3H]ethylketocyclazocine sites are 
patchy and their density increases towards the lateral regions of the 
caudate putamen whereas the [3H]U69593 sites are evenly distributed and 
most are medial. Regions which are heavily labelled at 4°C with 
[3H]ethylketocyclazocine such as the cerebellum are not associated with 
[3H]U69593 binding at 25°C. Therefore it is proposed that there are two 
subtypes. At 25°C, ethylketocyclazocine predominately binds to the [3H] 
U69593 sensitive sites, and at 4°C preferentially binds to the [3H]U69593 
insensitive sites. 
Displacement of [3H]bremazocine by U69593, PD 117302, naloxone and 
DAMGO in guinea pig spinal cord homogenates has afforded shallow slopes 
indicating the displacement of the radioligand is proceeding at more than 
one site [35,83]. This contrasted with the observation that the 
displacement in guinea pig brain homogenates produced slopes of unity. 
Again K1 and K2 was suggested, but in the brain, the K 2 site population 
labelled with [3H]bremazocine is less than 20% of the total sites therefore 
characterisation is poor. In the spinal cord the K 1 subtype is found mainly 
in the cervical and thoracic segments of rat tissue [83] and the sacral 
spinal cord of the guinea pig [35], contributing to 40% of the total opioid 
receptors in the latter tissue. 
The K2 sites are distinguishable from classical K sites in tissues such as rat 
lumbosacral spinal cord [ 40], where the Kd of ethylketocyclazocine is 50 
fold lower. It is therefore apparent that selective K2 ligands are needed to 
assess the role of this receptor [84]. 
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1.09 Additional Subtypes 
In addition to K 1 and K 2 subtypes, additional K subtypes have been 
proposed. Clark and colleagues [41] observed two U50488 sensitive K 1 
subtypes and a novel K3 subtype. Dynorphin A potently inhibits 
[3H]ethylketocyclazocine binding in guinea pig cerebellum but competition 
by dynorphin B and a. neo-endorphin exhibited competition at two sites 
named K 1a and K 1b [85]. In addition, another subtype insensitive to 
U50488, has been described. The subtype K 1b was more sensitive to 
dynorphin B and a. neo-endorphin with a selectivity of over 200 fold, this 
observation being the same for [3H]U69593labelled sites. 
[3H]NalBzoH, a potent 11 antagonist has been shown to effect analgesia at 
high doses without cross reactivity with morphine [42]. Of its specific 
binding, 35% is exhibited at 11 receptors, the remainder not being associated 
with 11, o or K 1 (illustrated as U50488 insensitive sites in the guinea pig 
cerebellum). This binding was naloxone reversible, and its selectivity varied 
from the proposed K2 site [79] therefore it was proposed that the 
[3H]Na1BzoH binding site is JC3 [86]. Dynorphin A has been reported to 
compete with higher affinity at 11 than Ka whereas ethylketocyclazocine is 
30 fold more potent at K3 than K2• Furthermore, dynorphin 1-17 is 8 fold 
more potent at K2 than K3• No cross tolerance between K 1 and K3 was 
observed and neither sites showed cross tolerance with morphine. In view 
of the lower affinity of nor-BNI at K3, it was suggested that this may be all 
isoform [29]. Such receptor subtypes have been observed under non 
identical experimental conditions, therefore such variance may be a 
contributory factor in these observations. 
Another proposal to explain such observations is the occurence of four sites 
[87]. Two of these sites, K1a and K1b, have been proposed to both bind 
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U69593, characterising them as 1e1 sites. These sites showed heterogeneity 
in that 1e1a had a higher affinity for a. neo-endorphin, U69593, 
ethylketocyclazocine and naloxone than 1Clb· The receptors 1e2a and 1e2b 
were characterised by their lack of affinity for U69593, but 1e2a was shown 
to possess high affinity for U50 488, bremazocine and ethylketocyclazocine 
as well as the endogenous peptides [Leu5]enkephalin, dynorphin 1-8 and a. 
neo-endorphin. The subtype 1e2b was reported to possess low affinity for 
[Leu5]enkephalin, dynorphin 1-8, U50 488, moderate affinity for DAMGO 
and high affinity for DADLE, bremazocine, ~-endorphin 1-31 and a. 
neoendorphin. It has been suggested that the opioid receptor 1e2b may be 
the reputed e site, as proposed previously to be 1e2 but showing slightly 
different properties to those described for E and 1e2 due to different 
experimental methods used to surpress other opioid receptors[88]. 
Overall, the study of 1C subtypes has produced several contrasting opinions. 
These have mainly been due to the lack of highly selective 1C ligands until 
recently, therefore influences from other receptor groups may have 
inhibited the true characterisation. Different research groups performed 
discriminating experiments under different buffer conditions using different 
ligands, therefore these factors too may alter the results. Only when the 
separate 1C receptors have been cloned and expressed may the complete 
range of subtypes, if any, be known. 
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Peptide 
Proopiomelanocortin products 
~-endorphin 
C'fragment 
y-endorphin 
a-endorphin 
Proenkephalin . products 
[Met5]enkephalin 
[Met5]enkephalin-Argf> 
[Met5]enkephalin-Lys6 
[Met5]enkephalin-Arg$-Phe 7 
[Met5]enkephali~-Argf>-Arg7 
[Met5]enkephalin-Arg$-Gly 7-Leu 8 
[Leu5]enkephalin 
PeptideE 
Alternative name 
C-fragment,~-LPH61-'l1 
o-endorphin, ~-LPH61-87 
~-LPH61-77 
~-LPH61-76 
Methionine enkephalin 
pro-methionine enkephalin 
MEAP 
MERGL 
Leucine-enkephalin 
Amino acid Sequence 
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys 
Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-V al 
Thr-77Leu-Phe-Lys-Asn-Ala-Ile-Ile 
Lys-Asn-Ala-87His-Lys-Lys-Gly-91Gin 
Tyr-Gly-Gly-Phe-Met 
Tyr-Gly-Gly-Phe-Met-Arg 
..................................... -Lys 
..................................... -Arg-Phe 
..................................... -Arg-Arg 
...... : .............................. -Arg- Gly-Leu 
Tyr-Gly-Gly-Phe-Leu 
Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-
Arg-Pro-Glu12.Trp-Trp-Met-Asp-Tyr-Gln-
Lys-Arg20_ Tyr-Gly22.Gly-Phe-Leu. 
y 
BAM-12P 
BAM-20P 
BAM-22P 
Metorphamide 
PeptideF 
Prodynorphin products 
[LeuS]enkephalin 
P-neo-endorphin 
a.-neo-endorphin 
Dynorphin 32 
Peptide E (1-12) 
Peptide E (1-20) 
Peptide E (1-22) 
Adrenorphin 
Dynorphin A Dynorphin 1-17 
Dynorphin B Rimorphin 
[Leu5]enkephalin-Arg6 Dynorphin 1-6 
[Leu5]enkephalin-Arg6-Arg7 Dynorphin 1-7 
[Leu5]enkephalin-Arg6-Arg7.IJeS PH-BP 
Peptide E (1-8) NH2 
Tyr-Gly-Gly-Phe-Met-Lys-Lys-Met-Asp-Gl u-
Leu-Tyr-Pro-Leu-Glu-Val-Glu-Glu-Glu-Ala-
Asn-Gly-Gly-Leu-Val-Leu-Gly-Lys-Arg-Tyr-
Gly-Gly-Phe-Met 
Tyr-Gly-Gly-Phe-Leu 
..................................... -Arg-Lys-Tyr-Pro 
............................................................. -Lys 
Tyrl-GJy-Gly-Phe-Leu-Arg-Arg~BIJe-Arg-Pro­
Lys-Leu-Lys13.Trp-Asp-Asn-17Gin-Lys-Arg-
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-
Lys-Val-Val-Thr32 
Dynorphin 32 sequence (1-17) 
Dynorphin 32 sequence (20-32) 
Tyr-Gly-Gly-Phe-Leu-Arg · 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg 
Try-Gly-Gly-Phe-Leu-Arg-Arg-Il 
.._. Table 1.01 illustrating the opioid receptor activating peptides derived from the three propeptides. 
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Figure 1.08 Schematic representation ofproopiomelanocortin (POMC) 
1=Lys-Arg 
2=Arg-Lys 
3=Arg-Arg 
I>:> 
o 4=Lys-Lys 
MSH=melanocyte stimulating hormone 
ACTH=adrenocorticotrophic hormone 
CLIP=corticotrophin like intermediate lobe peptide 
LPH=lipotropin 
~ -LPH 
4 
~ ~ J OOH 
a -endorphin 
I 
'Y -endorpbin -
~ -endorphin 1-27 
~ ·endorphin 1-3r 
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I [Leu5]enkephalin 
~ [Met5]enkephalin 
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[Met5]enkephalin-
Arg-Gly-Leu 
Figure 1.09 Schematic representation ofproenkephal~ 
1=Lsy-Arg 
3=Arg-Arg 
~ 4=Lys-Lys 
BAM=bovine adrenal medulla(peptide) 
1 3 1 
I BAM-12P 
BAM-20P----1 
BAM-22P ----' 
Peptide E 
Metorphamide 
1 1 
1 2 1 
a -neoendorphin 
I [Leu5]enkephalin 
1 3 1 
1----d:)'Ilo1rphi1n 1-8 
1---- dynorphin 1-17 
dynorphin A 1-32 ------+----1 
DynorphmB 
(rimorphin) 
Leumorphin 
Figure 1.10 Schematic representation ofprodynorphin (proenkephalin B) 
1=Lys-Arg 
t::5 2=Arg-Lys 
3=Arg-Arg 
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1.10 Opioid Peptide Processing 
Research has led to the discovery of three classes of opioid precursors (a) 
pro-opiomelanocortin, (b) proenkephalin/. and (c) prodynorphin. All the 
enkephalins, endorphins and dynorphins have been seen to be released from 
these precursors [89]. These peptides include those containing either the 
[Met5]enkephalin or [Leu5]enkephalin sequence at their N-terminus. In 
addition, other opioid receptor active fragments present in these precursors 
also occur. 
1.11 The Pro-opiomelanocortin (POMC) System 
POMC is the common precursor peptide for ~-endorphin, an opioid active 
peptide, thought to be the endogenous ligand for the reputed e receptor [70]. 
Adrenocorticotrophic hormone and several melanocyte stimulating 
hormone-containing peptides are also released from this precursor and its 
full amino acid sequence has been derived [90]. Each of the peptides in the 
precursor molecule is bound by a pair of basic amino acid residues, acting 
as the site of cleavage. The pituitary is responsible for the production of the 
vast proportion of the POMC peptide, and within the pituitary the highest 
levels of processing have been detected in the intermediate lobe [91]. In 
this tissue the ~-endorphin is post-translationally processed by a-N-
acetylation which leads to a complete loss of activity at opioid receptors. In 
addition it is shortened at its C-terminus by 4-5 amino acid residues [89]. 
Thus the end products of POMC processing in the intermediate pituitary ) 
are N-a-acetyl-~-endorphin 1-27 and N-acetyl-~-endorphin 1-26 [91]. In 
contrast the major product in the anterior pituitary is ~-lipotropin [89], the 
N-acetylation being less extensive [92]. 
In radioligand binding experiments, ~-endorphin 1-31 and ~-endorphin 1-27, 
namely the processing end products in the pituitary and the brain, are seen 
to interact with 11 receptors preferentially over 8 opioid receptors, with 
negligible affinity for K sites [93]. The N-acetylation process can be 
regarded as an inactivation route since the products lack affinity for 
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IJ-, K or o receptors. The general fragmentation and the sequence of the 
fragments can be seen in Figure 1.08, adapted from [89] and Table 1.0. 
1.12 The Proenkephalin System 
Proenkephalin A contains a potential of four [Met5]enkephalin fragments 
and one [Leu5]enkephalin fragments [94,95]. A wide variety of larger 
enkephalin-containing-peptides has been isolated from bovine adrenal 
medulla [94,96]. In this tissue, the processing appears to occur 
predominantly at the C-terminus. The five enkephalin sequences are 
immediately bound on the C-terminus by two basic amino acid residues, 
suggesting that they are ultimately destined to be released as 
pentapeptides [94]. There is also a series of peptides which contain the 
[Met5]enkephalin sequence at the N-terminus, and exhibit opioid activity 
such as Peptide F [97] which contains one such. sequence at each end. 
Another is Peptide E which possesses the [Met5]enkephalin sequence at the 
N-terminus and the [Leu5]enkephalin sequence at the C-terminus and 
displays a non selective profile in isolated tissue assays acting at both 1-1 
and K opioid receptors [89]. Peptide E has a significantly longer half life in 
plasma than [Met5]enkephalin, [Met5]enkephalin-Arg6-Phe 7, 
[Met5]enkephalin-Arg6-GJy7-Leu8, or metorphamide [98], these being other 
proenkephalin peptides found in the precursor [89,99]. They can all be seen 
to be generated by proteolytic cleavage at a single arginine residue. These 
fragments are illustrated in Figure 1.09 and Table 1.0. 
The involvement of the 1-1 opioid receptors in supraspinal analgesia is well 
documented [100]. Thus all the proenkephalin A products which display 
affinity and efficacy at the 1-1 receptor have the potential to elicit analgesia 
when injected intracerebroventricularly into mice [101]. Injection of 
[Met5]enkephalin or [Leu5]enkephalin causes only weak effects probably as 
a result of their rapid metabolism [102]. The complete sequence analysis of 
bovine proenkephalin A has been achieved [94], the peptide consisting of 
263 amino acid residues with a molecular weightof30 000 D. 
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The processing of proenkephalin A appears to be more complete in the 
brain than in the adrenal medulla. Thus the bovine adrenal medulla 
contains large amounts of high molecular weight enkephalin-containing __ 
peptides, and low amounts of free enkephalins [103]. In the brain however, 
free enkephalins are the predominant product. 
The distribution of processing of each peptide from the precursor is thought 
to be different. This is illustrated by the very different distributions of 
metorphamide and [Met5]enkephalin-Arg6-Phe7 in the brain [89] implying 
the different peptides may have distinct physiological functions in different 
regions. The ultimate products of proenkephalin A varying from the 
enkephalins to the much larger peptides exhibit a range of selectivities over 
all the three opioid receptors types. 
1.13 The Prodynorphin (Proenkephalin B) System 
The structure of porcine prodynorphin has been deduced from cloned DNA 
sequences [104], and it has been found to contain three [Leu5]enkephalin 
sequences present within fragments of the prohormone, each flanked by 
pairs of basic amino acids [89,104] as shown in Figure 1.10 and Table 1.0. 
Two of these fragments, namely ~-neo-endorphin and dynorphin 1-17 are 
contained within pairs of basic amino acid residues whereas cleavage at a 
single arginine residue is responsible for the release of a-neo-endorphin. The 
formation of dynorphin B, (rimorphin) [105,106], results from a cleavage of 
_ Thr13.Arg14 of leumorphin. By a similar cleavage, the liberation of 
dynorphin 1-8 [14,107] from dynorphin A is observed. 
Prodynorphin derived peptides are most abundant in the neuronal lobe of 
the rat pituitary [89] although the distribution of the products is extensive 
throughout the brain. The ratio of dynorphin 1-8 to dynorphin A is 
particularly high in the striatum and midbrain suggesting some further 
processing in these areas [14, 109]. The highest concentrations of 
dynorphin 1-8 have been identified in the substantia nigra and spinal cord. 
[Leu5]enkephalin has been reported to be synthesised via a dynorphinergic 
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pathway in the substantia nigra [110]. As a result, the concentrations of 
a- and ~-neo-endorphin are considerably higher than dynorphin A, fragment 
1-8 or dynorphin B. The production of [Leu5]enkephalin from a 
dynorphinergic neuron may have important physiological implications, as it 
allows the neuron to produce both a 1C (dynorphins) and a o 
([Leu5]enkephalin) ligand from the same peptide. It has been proposed that 
the processing of dynorphin 1-13 to dynorphin 1-8 and [Leu5]enkephalin 
occurs in various regions of the brain [89]. 
All the fragments ofprodynorphin containing greater than seven amino acid 
residues, exhibit varying degrees of selectivity towards the 1C receptor 
[38,4 7]. Some observations of the structural requirements of the 1C 
receptor activition infer the necessity of an Arg7 residue or a basic.amino 
acid at position 10 or 11 [19,47]. The affinity for this receptor rises up to 
dynorphin 1-13 which is the most selective. In contrast to the POMC 
derived product ~-endorphin, and the majority of proenkephalin A derived 
peptides, the prodynorphin peptides are observed to be only weakly 
analgesic. This is probably due to their rapid metabolism preventing a true 
picture oftheir effects [38,111]. 
Further investigation is required to determine whether [Leu5]enkephalin is ol\1!1 
released from its single copy in proenkephalin ~r whether it irJfs a result 
ofprodynorphin processing, in which there are three copies. In many areas 
of rat brain the ratio of [Leu5]enkephalin to [Met5]enkephalin-Arg6-Gly7. 
LeuB, a proenkephalin A product, is 1:1, indicating its origin to be 
proenkephalin A [110]. In other regions such as in the substantia nigra it 
has been shown that the [Leu5]enkephalin is of prodynorphin origin [110], 
therefore showing that both precursors are probably involved. 
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Figure 1.11 Illustrating a proposed mechanism for the receptor activation of a G protein [114]. 
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1.20 G Proteins and Opioid Receptors 
Cells receive much of their information through signalling pathways using 
guanosine triphosphate (GTP) binding proteins (G proteins) which convey 
signals from cell surface receptors to intracellular effector proteins [112]. 
Effectors include transporters, ion channels and enzymes responsible for 
the synthesis of second messengers. G proteins are thus involved in 
regulating synthesis and release ofneurotransmitters and the sensitivity of 
synaptic receptors to various binding ligands. In addition, they also control 
cellular metabolism, cell differentiation and growth. It is likely that more 
than 100 receptors communicate via G proteins, and more than 20 distinct 
G proteins are known. 
1.21 G Protein Structure 
-G protein coupled receptors have been characterised as having seven 
particularly hydrophobic stretches, sites for N-linked glycosylation near the 
amino end, 3 short extracellular loops, 2 short cationic cytoplasmic loops 
and a longer cytoplasmic loop connecting hydrophobic sections 5 and 6 
[112]. A pair of cysteine residues in the first two extracellular loops, 
thought to be linked via a disulphide bond, are also common to all receptors. 
Each G protein is a heterotrimer consisting of the GTP binding a subunit 
and the regulatory ~ and y subunits [112]. Each a subunit is thought to 
possess a distinct receptor binding domain which is conserved with respect 
to its function but is thought to be selective for each receptor, this area 
lying in the carboxy terminal. There are several groups of G protein which 
are classified by the actions of the different a subunits. Examples of these 
include Go and Gi which are associated w<th the opening ofK+ channels, some 
forms of Gi also affording a decrease in adenylyl cyclase and Gs which 
affords an increase in adenylyl cyclase [112]. Gt regulates the levels of 
cGMP in the retina [113], and Gq regulates blood pressure as a result of 
angiotensin receptor activation with phospholipase Cas a effector. 
I 
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1.22 Mode of Action of G Proteins 
The general mode of action of G proteins as second messenger systems 
connected to receptors is illustrated in Figure 1.11, based on a 
diagrammatic explanation by Hepler and Gilman [114]. In brief, when an 
agonist binds to the receptor, it induces a conformational change of that 
receptor protein. As a consequence, this in turn alters the conformation of 
its associated heterotrimer G protein, by an unknown mechanism. Such a 
change in the G protein promotes the dissociation of the GDP molecule from 
its binding site on the a subunit. Due to the higher intracellular 
concentration ofGTP in comparison to GDP, the site immediately becomes 
filled with a GTP molecule. 
The binding of GTP to the a subunit induces a conformational change with 
two consequences. Firstly the G protein dissociates from the receptor-
agonist complex, reducing the affinity of the receptor for the ligand and so 
releasing it, leaving its binding site empty. Secondly the GTP reduces the 
affinity ofthe a subunit for the ~y subunits which leads to their dissociation. 
The free a subunit-GTP migrates to the effector molecule, E1, to induce the 
regulatory response. In some systems it is thought that the ~y complex 
may also interact with an independant effector, ~. or modulate the a-GTP 
interaction with E1 [114]. The a subunit possesses an intrinsic GTPase 
activity therefore the hydrolysis of GTP to GDP occurs causing the 
dissociation and deactivation of the effector complex followed by 
reassociation with the ~y complex and the receptor. 
1.23 Interactions with Opioid Receptors 
Opioid receptors have also been shown to be negatively coupled to 
adenylate cyclase under the control of a Gi protein [115]. A direct influence 
of opiates on intracellular levels of cAMP was first determined in NG 108-15 
cells, in which the cAMP forming enzyme, adenylate cyclase, was shown to 
be inhibited by the binding of opiates to cell surface receptors [116]. 
Furthermore, morphine withdraw! results in an increase in brain levels of 
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cAMP [112,117]. Additionally, the K receptor agonist U50488H has been 
reported to inhibit adenylate cyclase activity by the activation of receptors 
which are negatively coupled to adenylate cyclase via a pertussis toxin 
sensitive Gi protein [66]. There is good evidence in support of G proteins 
being involved in opioid receptor coupling to ion channels with IJ- and o 
receptors being linked to K+ channels [115]. The authors described how the 
1-t selective DAMGO and the 8 selective DPDPE were capable of increasing 
the conductance of an inwardly rectifying potassium conductance which 
was accompanied by membrane hyperpolarization. It was observed that 
there was no stimulation of protein kinase C or cAMP dependant protein 
kinase by the addition of these agonists. Furthermore, using similar 
techniques, it has also been demonstrated that K and IJ- receptors are linked 
to Ca2+ channels[118]. It has therefore been suggested that the 
endogenous opioid actions may result from an influx of cations, which in 
turn induces neurotransmitter release. 
Studies have shown that sodium ions [119,120] and guanine nucleotides 
[121] reduce IJ- opiate agonist binding to rat brain and rabbit cerebellum 
membranes [122], resulting in a rightward shift of the dose response curve. 
This effect has also been demonstrated with K agonist binding in guinea pig 
cerebellum membranes [122], however it must be pointed out that these 
effects are associated with agonists only, antagonist binding being 
unaffected by these conditions. 
Marked differences in the sensitivity of K opioid binding sites in the guinea 
pig cerebellum to ions and nucleotides have been detected in comparison to 
the sensitivity of IJ- and o opioid sites in rat brain. Ethylketocyclazocine, a 
ligand shown to be both an agonist [123] and an antagonist [263] in guinea 
pig myenteric plexus is not sensitive to monovalent ions and nucleotides in 
the guinea pig cerebellum. This contrasts with the shifts observed with the 
selective K agonists such as U69593 and also opposes opioid receptor 
--------- -~-~- ------------····-- --
~sitivi!y:_ill___rat brain therefore it can be proposed that 
ethylketocyclazocine acts as an antagonist in guinea pig cerebellum even 
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after Jl and 8 suppression [124]. 
Competition studies at K opioid sites in guinea pig cerebellum labelled with 
the antagonist [3H]diprenorphine have been examined [122]. Dynorphin 1-
11 derivatives, shown to be K selective, and the stable K arylacetamide 
U50488, in the presence of NaCl plus Gpp(NH)p afforded rightward shifts 
in the binding affinity at the K receptor of 20-35 fold when compared to 
those determined in the absence [117]. In the rabbit cerebellum, a tissue 
consisting almost exclusively of Jl receptors, afforded shifts of greater than 
100 fold. Such shifts have also been observed with other compounds 
implying Jl agonists are more sensitive to the dissociation of the receptor 
from G proteins than the K opioid agonists. Such differences could provide 
an alternative method for examining new compounds [117]. 
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1.30 Enzymic degi'Qdation of opioids 
The full activity of the endogenous opioid peptides as analgesics is generally 
not fully characterised due to their rapid metabolism within the body. The 
interest in the stabilisation of these peptides in the spinal cord and the 
brain has increased with the aim of developing a method of endogenous 
analgesia. Likewise, it would be hoped that such a discovery would be 
accompanied by a reduction in the side effects associated with opioid 
analgesia including respiratory depression, constipation and tolerance, seen 
upon the addition of exogenous morphine like compounds. 
The identification of enzymes responsible for the metabolism of the opioid 
peptides [102,125,126,127,128,130,131,132,133] resulted in the 
development of specific inhibitors. However, the main drawback in their 
capacity to stabilise opioids in vivo is that the enzymes involved are 
generally non specific, with other neuropeptides being affected. This does 
not however totally exclude the possibility of their use as pharmacological 
tools. In addition, such enzymes have a wide distribution and their presence 
is not usually confined to the CNS hence peripheral actions of the inhibitors 
result when administered systemically. 
The precursors of the bioactive opioid peptides have been discussed, but a 
full characterisation of the enzymes responsible for their processing and 
deactivation is necessary before any clinical use is feasible. The following 
review is designed to concentrate on the enzymic attack of the small opioid 
peptides, in particular dynorphin 1-8, and the release of[Leu5]enkephalin as 
a consequence of the Leu5-Arg6 cleavage [125,128,131,133,134]. Many 
enzymes are deactivating, that is, they cleave dynorphin 1-8 in positions 
which result in inactive peptide fragments. These include the 
endopeptidase E.C.3.4.24.11 [126], aminopeptidase M [102] and 
angiotensin converting enzyme enzyme [132]. This is followed by a look at 
the enzymes proposed to release [Leu5]enkephalin from dynorphin 1-8 
namely endopeptidase E.C.3.4.24.15. [125], endo-oligopeptidase M [133], 
Pz-peptidase [134] and endopeptidase E.C.3.4.24.16. [135]. 
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1.31 Endopeptidase E.C.3.4.24.11. 
In 1974 Kerr and Kenny [136], reported a neutral peptidase located in the 
microsomal fraction of the kidney brush border, distinguishable from other 
peptidases known at that time. This was the first endopeptidase isolated 
from the brush border, (given the number E.C.3.4.24.11.) to belong to the 
group of neutral metal-chelator-sensitive peptidases similar to the bacterial 
metalloendopeptidase thermolysin [137]. This endopeptidase was later 
• u 
rediscovered and described as enkephalinase [125,129,138,139], which was 
proposed to be the main deactivating enzyme of enkephalin at that time. 
This name is counterproductive since a wide range of neuropeptides have 
been shown to be metabolised by this endopeptidase [129,126]. Substrates 
include opioid peptides derived from proenkephalin and prodynorphin 
precursor peptides such as [Met5]enkephalin, [Leu5]enkephalin, 
[Met5]enkeph:- .amide, dynorphin 1-8, dynorphin 1-17 and ex- and 13-
endorphin. In each case, the enzyme cleaves at the Gly3-Phe4 bond 
[126,140]. Outwith the opioids other cleavages are known such as the 
Pro7-Phe8 bond in bradykinin [141] plus numerous others including 
endothelins [141] and brain [142,143] and atrial [143,144,145] natriuretic 
,. ., 
peptide. It became evident that the enzyme designated enkephalinase is 
identical to the enzyme characterised as E.C.3.4.24.11. and will be referred 
to as such. 
In 1979 Gorenstein and Snyder proposed that E.C.3.4.24.11. was identical 
to another well known endopeptidase, angiotensin converting enzyme 
(ACE) [146], since both were metalloendopeptidases and sensitive to 
dithiothreitol. This was contradicted in the same year by Swerts and eo-
workers [147] who showed that the enzymes demonstrated contrasting 
properties. ACE is activated by Cl- ions, with no such enhancement 
observed for E.C.3.4.24.11., and also, potent ACE inhibitors have very little 
effect on the E.C.3.4.24.11. [14 7] making these enzymes distinct. 
Endopeptidase E.C.3.4.24.11. has been shown to be almost wholly 
membrane bound, and there has been evidence to suggest that it possesses 
one Zn2+ in the active site [125,148]. Furthermore it has been 
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demonstrated to cleave preferentially on the amino side of hydrophobic 
amino acid residues [149]. The bulk of the enzyme lies in the mitochondrial 
and microsomal fractions and its regional distribution in the brain shows 
good correlation with opiate receptors [150,151,152], the synaptosomal 
membranes being rich in both' opioid _ ''receptors and E.C.3.4.24.11. 
[153]. The areas of highest concentration are however the salivary gland, 
thyroid, lungs, testes and kidneys [153]. E.C.3.4.24.11. has a pH optimum 
in Tris/HCl buffer of 7.0, a molecular weight of 93 000 D [148] and is 
inhibited by metal chelators such EDTA [139,224]. The endopeptidase has 
also been shown to be strongly inhibited by compounds such as 
dithiothreitol [138,139] and mercaptoethanol [138,155] which reduce 
disulfide bonds, but is unaffected by thiol blocking agents such as N-
ethylmaleimide [138,139]. 
The enzyme has been cloned and the amino acid sequence described in 
samples from rat [156], rabbit and human [157]. Human E.C.3.4.24.11. 
displays a high degree of homology with the rat enzyme (94%), having only 
42 of the 742 amino acid residues differing and only 6 of these being non 
conservative changes [157]. Rabbit enzyme has 93% homology to that of 
the human. 
In 1980 Roques and colleagues [158] synthesised thiorphan, [(DL-3 
mercapto-2-benzylpropanoyl)-glycine], an enzyme inhibitor designed to 
interact with critical residues in the E.C.3.4.24.11. active site, based on a 
hypothetical model with the binding being assumed to be analogous to 
carboxypeptidase A as shown in Figure 1.12. Both the R and S forms of 
thiorphan are active as E.C.3.4.24.11. inhibitors [159] and more recently 
new inhibitors have been designed using the thiorphan structure as a 
template [160] but as yet none have been developed which are more potent. 
Thiorphan was shown to preserve enkephalins in uiuo therefore it could be 
assumed that the endopeptidase probably plays a role in the endogenous 
degredation of enkephalins [158]. Injection of thiorphan into mice alongside 
/ 
the enkephalin analogue [D-Aia2-Met5]enkephalin markedly increased the 
afforded analgesia with long lasting effects. In contrast, no analgesia was 
observed when [D-Ala2-Met5]enkephalin was injected alone [158]. 
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Figure 1.12 lllustrating the hypothetical active site of endopeptidase E.C.3.4.24.11. adapted from a proposal by 
Turner [154], accomodated by (a) one of its substrates, [Leu5]enkephalin, and (b) the inhibitor thiorphan. 
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1.32 Aminopeptidase M (E.C.3.4.11.2.) 
The degr
1
edation of enkephalins has been proposed by several authors 
[102,130,161] to commence with a fast hydrolysis of Tyrl-Qly2 by 
aminopeptidases. In 1980 Hersh and eo-workers [162] purified an 
aminopeptidase from bovine brain which catalysed such a hydrolysis 
followed by the sequential release of amino acid residues from the amino 
terminus. This was therefore proposed to be one of the principal 
inactivating routes of the opioid peptides [130,163,164] prior to the 
identification of E.C.3.4.24.11.. Soluble forms of this aminopeptidase can 
be isolated from monkey, rat [165,166] and human brain [167] which also 
catalyse the hydrolysis of theN-terminal tyrosine from y-, a-, ~-endorphins 
yielding des-tyrosyl derivatives at one third of the rate of the hydrolysis of 
[Met5]and [Leu5]enkephalin [162]. No further hydrolysis is seen with the 
endorphins in contrast to the smaller enkephalins where Gly2 is released 
following the Tyrl [162]. 
Two similar membrane bound aminopeptidases have been shown to 
hydrolyse enkephalins [162,168], both exhibiting inhibitory sensitivity to 
puromycin [168]. These two aminopeptidases can be separated by ion 
exchange chromatography [169], and are designated by the nomenclature 
MI and MII in the order of elution from the column. Furthermore both are 
sensitive to competitive inhibition by bestatin [(3R,2S)-3-amino-2-hydroxy-
4-phenylbutanoyl-(8)-leucine] [163], as illustrated in Figure 1.13. Bestatin 
is a bacterial peptide discovered and characterised by Umezawa and 
associates [171,172] which can be shown to inhibit other aminopeptidases 
(A,B and leucine aminopeptidase) in the nanomolar range. 
[Leu5]enkephalin, in addition to several other opioid peptides, is a poor 
substrate for MI but is efficiently metabolised by MII implying its 
metabolism is probably as a consequence of the latter [169, 173,17 4]. 
The aminopeptidase MII exists, with only 10% of its total content being 
membrane bound [175]. This form of aminopeptidase has a molecular 
weight of 100 000 D [165,166,176] and a pH optimum of 7.0 [165]. The 
enzyme is temperature dependant, having maximal activity at 40°C [165]. 
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Aminopeptidase MII has been described to contain one Zn2+ per molecule 
[165] and consequently is strongly inhibited by EDTA. Furthermore, this 
loss of activity can be fully restored by dialysis with divalent cations. The 
aminopeptidase is unaffected by cysteine protease inhibitors such as 
iodoacetic acid, the thiol blocking agent p-mercurisulphonic acid [178] or 
serine thiol and carboxy protease inhibitors such as leupeptin and 
pepstatin. In contrast the aminopeptidase inhibitors, puromycin and 
bestatin, inhibit the actions of the enzyme strongly [179] allowing an 
increase in, for example, the recovery of substance P-induced enkephalin 
release in the spinal cord [180]. 
The distribution of aminopeptidase MII does not strongly correlate with 
opiate receptors in all brain regions, however the highest concentrations 
were found in striatum, hypothalamus and cortex, the three regions 
containing the highest levels of opiate receptors. This lack of correlation v 
could be predicted since the aminopeptidase is known to be unselective and 
metabolise peptides other than opioids [169]. The rat brain aminopeptidase 
M activity is primarily localized on blood vessels and on some cell surfaces 
such as in the anterior pituitary and adrenal medulla [180]. In the 
periphery it is found on proximal tubules in the kidney. This all suggests 
that it plays a role in the limitation ofpeptides crossing membranes [180]. 
In 1983, Chaillet et al studied the hydrolysis of [3H][Met5]enkephalin in 
brain slices, reflecting an in vivo situation. In the presence of 0.1JlM 
thiorphan [173], a powerful inhibitor of E.C.3.4.2.4.11., 92% of the 
hydrolysis products was [3H]tyrosine, the cleavage product of 
aminopeptidase M. This hydrolysis was inhibited by 0.2JlM bestatin [173], 
this being a similar concentration required to inhibit soluble and membrane 
bound isolated forms of aminopeptidase M. This inhibitory action was not 
however complete indicating the presence of multiple enzymes. The 
intravenous administration of [3H][Met5]enkephalin into mice with the 
E.C.3.4.24.11. inhibitor thiorphan plus bestatin, resulted in an increase in 
antinociception in the writhing test and hot plate test when compared to 
the administration ofthiorphan alone. These results infer that the peptide 
is being stabilised and hence the increase in analgesia was observed [181]. 
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1.33 Angiotensin Converting Enzyme ( E.C.3.4.15.1., ACE) 
Research into the properties of angiotensin converting enzyme, ACE, 
extends back to the 1950s when an enzyme was identified, associated with 
the activation of the endogenous peptides angiotensin I and II. Early 
studies showed that this enzyme could be inhibited by EDTA and activated 
by Cl" ions [182]. The de~~tion products recovered from the metabolism 
of enkephalins in vitro implied the Gly3-Phe4 bond was subject to enzymic 
hydrolysis. This and other properties suggested this enzyme could be 
identical to ACE, and it was proposed that its high concentration in the 
pituitary may be related to its role in opjate' peptide turnover. The brain 
distribution of ACE is unrelated to that of opi~M receptors therefore is 
probably not specific for enkephalins [132]. In 1981 Schwartz and 
colleagues [183] found that E.C.3.4.24.11. cleaved enkephalins at the same 
site as ACE. Although ACE is the more abundant in the brain, inhibition 
and kinetic studies suggest that in the CNS, aminopeptidase and 
E.C.3.4.24.11. were thought to be more important in opioid metabolism 
than ACE [183]. 
ACE has been studied in its purified form from pig kidney or intact human 
endothelial cells and has been associated with many actions, accompanied 
by its wide distribution. It exists as a single polypeptide chain, has a 
molecular weight of 140-150 000 D [184,185], an isoelectric point of 5.2 
[185] and can be solubilised by detergents [186] or trypsin [185]. ACE is 
found to be membraneoound in endothelial, epithelial and neuroepithelial 
cells. It has also been determined in high concentrations in the lungs and 
capillary beds of the retina and brain [187]. For ACE to be involved in 
synaptic transmission, it would need to be located on terminal membranes, 
and this has been shown by immunohistochemical means [188]. 
Inhibitors of ACE such as captopril (SQ 14 225, [28]-1-[3-mercapto-2-
methylpropionyl]-L-proline]), illustrated in Figure 1.14, have been designed ca.A,,... / 
)!as orally activeAhypertensive agent [189] but also induce the rapid onset of 
short lasting analgesia when injected intracerebroventricularly [190]. This 
effect can be blocked by prior administration of the opioid antagonist 
naltrexone [191], therefore the analgesia is probably a result of the 
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protection of enkephalins in vivo. Inhibitors are now used frequently in the ,1 
treatment of hypertension and congestive heart failure, and are associated 
with an elevation in the mood of patients [190]. 
ACE is a Zn2+ metalloendopeptidase and like carboxypeptidases [192], the 
zinc polarises the carbonyl group on scissile amide bonds making the 
cleavage of the peptide bond easier [182]. It is comparable to pancreatic 
carboxypeptidase A, but releases dipeptides instead of single amino acids 
from the carboxyl end of the substrate [189]. Substrates include 
angiotensin I, bradykinin, [Met5]enkephalin, [Met5]enkephalin-Arg6-Phe7, 
[Met5]enkephalin-Arg6.Qly7-Leu8, ~ neo-endorphin, dynorphin 1-8 and 
1 
· dynorphin 1-6 [185]. In some cases, ACE has been shown to be capable of 
releasing tripeptides from peptides such as des-Arg9-bradykinin, Substance 
P and in particular LHRH which has its carboxy end blocked with an amino 
group [194]. With the dynorphin series, ACE has a preference for smaller 
peptides such as dynorphin 1-6 and 1-8, exhibiting no hydrolytic action on 
the larger dynorphin 1-13 and 1-17. This is most probably a result of 
active site specifications [195]. 
Studies in brain slices of potassiunl' evoked [Met5]enkephalin release, show 
that in cases of inhibition by thiorphan (E.C.3.4.24.11), puromycin 
(aminopeptidase) and captopril (ACE) separately, only thiorphan afforded 
an increase in the recovery of enkephalin. This can be hypothesised to 
result from a higher specificity of the endopeptidase E.C.3.4.24.11. for 
opioid peptides in comparison to the other enzymes, and the endopeptidase 
can be proposed to play a key role in enkephalinergic pathways . .of 
~K&.-3A.Ztll. [196]. This was emphasised in the metabolism of extended 
enkephalins and others which do not infer ACE but E.C.3.4.24.11. in the 
cleavage of the Gly3-Phe4 bond. 
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Figure 1.14 Illustrating the hypothetical active site of angiotensin converting enzyme (ACE) as proposed by Petrillo 
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1.34 Endopeptidase E.C.3.4.24.15. 
In 1983, Orlowski et al [198] reported the purification of an endopeptidase 
from the soluble cytoplasmic fraction of rat brain homogenates. In 1987, 
Acker and eo-workers [10] determined such an enzyme to be a 
metalloendopeptidase, optimally active at neutral pH and given the 
nomenclature E.C.3.4.24.15 .. 
E.C.3.4.24.15. is a metalloendopeptidase containing one Zn2+ per molecule 
[198] and found predominantly associated with the soluble fractions (75-
80%) of brain homogenates with the highest concentration present in the 
cerebellum [200]. The other 20% is membrane bound, with the highest 
concentration being determined in the mitochondrial subfraction 
[199,200,201] followed by synaptosomal membranes [199,201]. High 
activity in the brain and pituitary implicate the involvement of the 
metalloendopeptidase in the metabolism of peptide hormones and 
neuropeptides [202]. The soluble enzyme shows high sensitivity to heat 
denaturation with greater than 90% of the total activity lost at 57°C for 
60mins [203]. Removal of the metal ion by EDTA is fully reversible, With 
complete reactivation possible by the inclusion of the divalent cations Zn2+ · 
or Co2+. The molecular weight varies from 67 000 D [198,204] to 70 000 D 
[204] in rat testes and brain respectively. 
E.C.3.4.24.15. has an active site substrate requirement of at least 5 amino 
acid residues, 3 residues on the carboxy side of the bond to be hydrolysed, 
the other 2 on the amino side [198,200,203]. The endopeptidase cleaves 
preferentially on the carboxy side of hydrophobic amino acid residues, such 
residues being a requirement for the putative P1 and P2 amino acid 
constituents [199]. [The P and S nomenclature of Schechter and Berger 
1967 used to describe positions P of residues in the substrate and 
corresponding subsites S of the active site of the enzyme]. The enzyme 
does not cleave proteins and peptides with more than 20 amino acid 
residues, as indicated by the resistance of the opioid peptide BAM-22P to 
E.C.3.4.24.15. deg9l'i1ation [200]. The endopeptidase catalyses the / 
processing and degrjdation of several neuropeptides indicating a function in / 
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the metabolism of bioactive peptides [205]. The enzyme is implicated in 
the release of [Leu5]enkephalin from dynorphin 1-8, a. and ~ neo-endorphin 
and [Met5]enkephalin from BAM 12P and [Met5]enkephalin-Arg6-Phe7 
[200]. In addition, it is associated with the hydrolysis of the Phe5-Ser6 bond 
of bradykinin [198], ArgB.Arf!!J ofneurotensin [198,206] and the Tyr4-Tie5 of 
angiotensin I and 11 [200]. 
E.C.3.4.24.15. is inhibited by metal chelators such as o-phenanthroline 
[198] and EDTA [204], as well as thiol blocking agents such as N-
ethylmaleimide [198]. High concentrations of dithiothreitol inhibit the 
endopeptidase, whereas low concentrations are seen to activate it, this 
being thought to be a consequence of the reduction of an essential thiol 
group [198]. Cysteine protease inhibitors such as iodoacetic acid [198,204] 
and protease inhibitors such as p-mercurisulfonyl phosphate [204] have no 
action on the enzyme. A series ofN-carboxymethyl peptides containing the 
series Ala-Ala-Phe-pAB [203] were synthesised as potential inhibitors, the 
phenylalanine residue being important for the substrate interaction with a 
hydrophobic pocket. N-[1(R,S)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-pAB 
(cFP-AAF-pAB), illustrated in Figure 1.15, demonstrated the strongest 
competitive blocking of the enzyme with an inhibition constant, Ki, for its 
racemic mixture of 0.03J.!M [202,203]. The normally released enkephalins 
in incubations of peptides such as dynorphin 1-8, ~ neo-endorphin, a. neo-
endorphin and [Met5]enkephalin-Arg6·Leu 7 with rat synaptosomal 
membranes is prevented by the inclusion of the E.C.3.4.24.15. inhibitor 
cFP-AAF-pAB [199]. 
Evidence has been reported describing the susceptibility of cFP-AAF-pAB 
to slow deg@tion by E.C.3.4.24.11. in the brain and rapid degredation in 
peripheral tissues [176]. The de~dation of this inhibitor and Glt-Ala-Ala-
Phe-pAB, a substrate of E.C.3.4.24.11. was studied in crude homogenate 
preparations from kidney, lung, spleen and brain (the kidney having the 
highest concentration of E.C.3.4.24.11. and the brain lowest). The 
E.C.3.4.24.15. inhibitor was degraded in each tissue but the activity was 20 ) 
fold greater for~ubstrate [207]. Later reports have shown the inhibitory 
potency of the resistant cFP-A(D)AF-pAB to be 50 fold less than that of 
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/ 
cFP-AAF-pAB but this inhibitor was totally resistant to degt;edation by / 
E.C.3.4.24.11. due to the D-Ala residue [176]. Alternatively the 
replacement of the Ala-Ala-Phe with Ala-Pro-Phe makes the inhibitor 
resistant to E.C.3.4.24.11. [208]. 
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1.35 Endo-oligopeptidase A (E.C.3.4.22.19.) 
Prior to the discovery of endo-oligopeptidase A in 1973 [209] isolated from 
nervous tissue, most tissue endopeptidases had been found to hydrolyse 
large peptides. There were however a few, like the intestinal brush border 
amino-oligopeptidases [210], which were known only to attack small 
peptides. Endo-oligopeptidase A has been shown to have a similar 
distribution to the enkephalins, and it was found to hydrolyse several small 
peptides in the size range of 8-13 amino acids [209,211,212]. Its cleavages 
include the Phe5-Ser6 bond in bradykinin [209], Gly6-Leu7 in LHRH [127], 
Phe4-Leu5 in dynorphin 1-7 [213,214] and the Phe4-Met5 in 
[Met5]enkephalin-Arg6-Phe7. Additionally it has been shown to release 
[Leu5]enkephalin from dyporphin 1-8, dynorphin B, a and ~ neo-endorphin 
(M~:>Je.,ka,jJI..c.l,., ~ 
[212] andt,BAM 12P [213]. In all cases where [Leu5]enkephalin and >' 
[Met5]enkephalin are released, there are two basic residues after the point 
of cleavage which could be a directing factor [212,214], whereas in the 
hydrolysis of [Met5]enkephalin-Arg6-GJy7-LeuB-Lys9 in which the basic 
residues are separated by the dipeptide Gly-Leu, a minor amount of 1-4 is 
produced [212]. 
Enzymes involved in neuropeptide processing and degredation are usually 
. '-
found in secretory granules and cytoplasmic membranes respectively 
[215]. Thus, the enzyme isolated from soluble fractions of rabbit brain 
homogenates, identified as endo-oligopeptidase A [209,211,216] ought to be 
a poor candidate for neuropeptide metabolism. More recent studies have 
detected high levels of endo-oligopeptidase A in the brain [217] with 
significant amounts of the activity in crude mitochondrial fractions 
including the synaptosomal membranes [133]. Anti endo-olitk_eptidase A 
IgG, raised from the cystolic enzyme, also recognizes the membrane 
/~-
associated form without differentiation, therefore it is thought the two 
forms are identical. 
Endo-oli~tidas.:. A has a molecular weight of 71 000 D [218] - 75 000 D 
[205,212], is Ca2+ dependant and has a pH optimum of 7.2 [211,212,218]. 
The enzyme can be inhibited by metal chelators such as EDTA [212] and o-
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phenanthroline [212], and its thiol endopeptidase properties demonstrated 
by inhibition with thiol blocking agents. An unusual property of endo-
oligopeptidase A is its activation by dithiothreitol [219], a compound known 
to reduce disulfide bonds, in a similar manner to that of the previously 
discussed E.C.3.4.24.15. [198]. 
1.36 Pz-Peptidase (E.C.3.4.99.31.) 
Another endopeptidase, Pz-peptidase, has been recognized for more than 20 
years to be the enzyme responsible for the cleavage of the synthetic 
collagenase substrate Pz-Pro-Leu-Gly-Pro-D-Arg [220], called since Pz-
peptide [221], (where Pz = phenylazobenzyloxycarbonyl). An in vivo up-
regulation of Pz-peptidase activity is associated with increased collagen 
degredation therefore this enzyme has been proposed that the enzyme 
plays an endogenous role in collagen metabolism [134]. Additionally, studies 
of the metabolism of the opioids indicate that this enzyme is capable of 
hydrolysing the Leu5-Arg6 bond of dynorphin 1-8 [209]. 
The major question regarding Pz-peptidase is the nature of the catalytic 
site. The effects of the inhibitors exclude it from being a serine or aspartate 
type of endopeptidase [222], but it has the characteristics of both cysteine 
and metalloproteinases, being inhibited by iodoacetic acid and EDTA 
respectively (this action being Ca2+ dependant) [223]. Inactivation by 
removal of the metal ion with EDTA or 1,10 phenanthroline, can be fully 
reversed by dialysis with Zn2+ [224]. Some forms of Pz-peptidase from 
different species show no inhibition by EDTA which is probably due to 
species differences in the strength with which the metal ion is held rather 
than an exposure ofisoenzymes [223,224]. 
Inhibition of Pz-peptidase by 5mM dithiothreitol is fully reversible upon 
dilution to 0.1mM, consistent with such an inhibition being due to weak 
interactions between thiol compounds and essential metal ions. The 
presence of 0.25mM dithiothreitol or 5mM mercaptoethanol, has been 
shown to potentiat~nzymic activity in some cases [233] as seen with 
E.C.3.4.24.15. [198]. Thiol blocking agents such as N-ethylmaleimide 
produce only partial inhibition of Pz-peptidase, evidence that the active 
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form of the enzyme contains more than one free thiol group, 
.probably positioned outside the active site. In addition, one or more 
essential histidine residues have been detected [223]. Chicken liver Pz-
peptidase has a molecular weight of 75 000 D and an optimum pH of 7.0 
[134]. The E.C.3.4.24.15. inhibitor, cFP-AAF-pAB, and other related 
inhibitors have similar Ki values for each of the two endopeptidases Pz-
peptidase and E.C.3.4.24.15., providing evidence in favour of these two 
enzymes being related [223]. 
1.37 Endopeptidase E.C.3.4.24.16. 
Studies of the hydrolysis of a Pz-peptidase substrate Mcc-Pro-Leu-Gly-Pro-
D-Lys-Dnp in whole rat brain homogenate, illustrated the cleavage· by Pz 
peptidase and E.C.3.4.24.15. to be identical. In addition to these two 
enzymes, further activity can be determined in the rat brain homogenate 
which is insensitive to cFP-AAY-pAB but which catalyses similar cleavages 
to those of E.C.3.4.24.15, providing evidence in favour of the presence of 
another enzyme [255]. Investigation of this active fraction by dose 
response curves of cFP-AA Y-pAB exhibit shallow slopes and a Ki of O.&.LM, 
this being much higher than a Ki of 16nM reported by Orlowski [202] for the 
inhibition of E.C.3.4.24.15 .. Another inhibitor of E.C.3.4.24.15., cFP-AAF-
Abz, had to be increased 100 fold compared to that required to fully inhibit 
E.C.3.4.24.15., to reduce the activity of this alternative endopeptidase 
[202,203]. However, even at such high concentrations, only 50% of the 
enzyme activity can be blocked [226]. The metabolism of neurotensin by 
E.C.3.4.24.15. recovers the fragments neurotensin 1-8 + 9-13, this cleavage 
being completely inhibited by the specific inhibitor cFP-AAY-pAB. When 
repeated with the cFP-AAY-pAB insensitve fraction, the fragments 
recovered are neurotensin 1-10 + 11-13 thus distinguishing the enzymes. 
This new enzyme is designated as endopeptidase E.C.3.4.24.16 .. 
The distribution of the enzyme was determined by the hydrolysis of the Pz-
peptidase substrate Mcc-Pro-Leu-Gly-Pro-D-Lys-Dnp remaining after 
inhibition with cFP-AAY-pAB. In the rat, the highest concentration occurs 
in the liver (55nmol Mcc-Pro-Leu produced /h/mg protein), followed by the 
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kidney, bladder and testes with the lowest activity being found in the 
brain(15nmol/h/mg protein) and heart (7nmol/h/mg protein). This is distinct 
from E.C.3.4.24.11. which is prominent in the lung [153], ACE which is in 
its highest concentration in the ileum, lung and liver [227] and 
E.C.3.4.24.15. found mainly in the brain [200,201]. This lead to the 
proposal that the inhibition of Mcc-Pro-Leu-Gly-Pro-D-Lys-Dnp hydrolysis 
which is sensitive to cFP-AAY-pAB is due to E.C.3.4.24.15. and that which 
is non sensitive to E.C.3.4.24.16. [225]. 
E.C.3.4.24.16. is found colocalised with neurotensin receptors on a discrete 
population of cerebral neurones in mice embryos. Preliminary tests showed 
neurotensin could be protected by various dipeptides which mimicked the 
Pro-Tyr bond cleaved by E.C.3.4.24.16., such as 5mM Pro-Tie or Pro-Met 
which inhibited neurotensin hydrolysis by 70-80% and Pro-Phe by 50-60%. 
Pro-Tie had no inhibitory effect on E.C.3.4.24.11, E.C.3.4.24.15, ACE and 
aminopeptidase M [228]. E.C.3.4.24.16. is also known to cleave other 
neuropeptides· such as angiotensin I, substance P, bradykinin and 
dynorphin1-8 in vitro [128,228]. 
Dynorphin 1-8 is cleaved primarily at Leu5-Arg6 bond and to a lesser extent 
at Phe4-Leu5 by E.C.3.4.24.16 .. Other peptides known to compete for the 
active site of the enzyme include bradykinin, angiotensin II, LHRH, 
substance P, dynorphin 1-13, dynorphin 1-7, [Met?]enkephalin-Arg6-Phe7 
and [Met5]enkephalin-Arg6-Gly7-Leu8 [135,226] with E.C.3.4.24.16. 
hydrolysing at the same point in each substrate as E.C.3.4.24.15.. No 
inhibition ofE.C.3.4.24.16. is detected [225] by the addition of the inhibitors 
captopril (ACE), phosphoramidon (E.C.3.4.24.11) or kelatorphan (the mixed 
inhibitor first described in 1984 [229]). In addition, the hydrolysis of the Pz-
peptide Mcc-Pro-Leu-Gly-Pro-D-Lys-Dnp by E.C.3.4.24.16., can be 
completely inhibited by neurotensin. E.C.3.4.24.16. is a metallopeptidase 
and is potently inhibited by metal chelators such as o-phenanthroline and 
EDTA [128,230,231] with Zn 2+ being the favoured cation in restoring the 
activity of its apoenzyme [231]. 
Phosphamide peptides were successfully designed as potent inhibitors of 
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bacterial collagenases and a compound resembling these, phosphodiepryl 
03 (= N-(phenylethylphosphonyl)-Gly-L-Pro-L-aminohexanoic acid), 
potently inhibits the hydrolysis of E.C.3.4.24.16. substrates. Two 
examples, Mcc-Pro-Leu-Gly-Pro-D-Lys-Dnp and neurotensin, are inhibited 
with Ki values of0.3nM and 0.9nM respectively. 
The Ki for the inhibition of E.C.3.4.24.15. by phosphodiepryl 03 is 5nM, 
therefore this is the most potent inhibitor of E.C.3.4.24.15. to date [230], 
being stronger than cFP-AAF-pAB which has a Ki of0.03!JM [202]. 
1.38 Comparison of E.C.3.4.24.15., endo-oligopeptidase A, Pz-peptidase 
and E.C.3.4.24.16. 
There is a large amount of evidence supporting the theory that 
E.C.3.4.24.15., endo-oligopeptidase A, Pz-peptidase and E.C.3.4.24.16. are 
one and the same enzyme, with their slight variances in properties being a 
result of species differences. 
Such proposals commenced in 1989 when a view was expressed [232] that 
Pz-peptidase and endo-oligopeptidase A were identical on the basis of 
identical molecular weights, inhibitory profiles. Additionally, an antiserum 
raised versus endo-oligopeptidase A has been shown to inhibit the 
hydrolysis of Mcc-Pro-Leu-Gly-Pro-D-Lys(Dnp) by Pz-peptidase [212,233]. 
In the same year, evidence was published [221] supporting the theory that 
Pz-peptidase was identical to E.C.3.4.24.15., both having similar active site 
structural requirements and molecular weights. Additionally, the partially 
purified Pz-peptidase hydrolyzed the E.C.3.4.24.15. substrate Dnp-Pro-Leu-
Gly-Pro-Trp-D-Lys and this hydrolysis could be inhibited by cFP-AAF-pAB 
with a Ki of 16.6nM [221]. This is similar to the Ki of 27nM reported for 
E.C.3.4.24.15. [202]. Pz-peptidase is capable of hydrolysing the 
E.C.3.4.24.15. substrates Bz-Gly-Ala-Ala-Phe-pAB and Boc-Phe-Ala-Ala-
Phe-pAB with Km values 0.53!JM and 0.19!-lM respectively [221], again 
similar to those reported for purified E.C.3.4.24.15. which are 0.49!-lM and 
0.22!JM [198]. 
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E.C.3.4.24.15. and Pz-peptidase are both Zn2+ metallopeptidases, each 
being inhibited by the removal of the cation with EDTA or o-phenanthroline 
[198,212,224] and reactivated by dialysis with divalent cations. 
Furthermore, although the Zn2+ cation has not been detected in endo-
oligopeptidase A, this enzyme can be inhibited by metal chelators [212] and 
reactivated with divalent cations also. It has been suggested that the 
' 
metal ion is probably not detected due to it being tightly bound, which also 
explains the chelator inactivation being far slower than Pz-peptidase or 
E.C.3.4.24.15. [224]. All three enzymes share common hydrolysis points 
such as Phe5-Ser6 in bradykinin and the release of enkephalins from 
dynorphin 1-8, dynorphin B, a and ~ neo-endorphin, BAM 12P and 
[Met5]enkephalin-Arg6-Phe7 [200,209,212,213]. They all have molecular 
weights between 70 - 75 000 D in their different forms and have optimum 
activity at neutral pH. None of the enzymes are inhibited by the 
E.C.3.4.24.11. inhibitor phosphoramidon, and an unusual property common 
to Pz-peptidase and E.C.3.4.24.15. is the activation by low concentrations 
of dithiothreitol and inhibition by high doses [198,233,234]. This has also 
being suggested in connection with purified endo-oligopeptidase A [219]. 
The combination of the three enzymes is designated as Thimet Peptidase 
(E.C.3.4.24.15.) [221,224]. 
The suggestion that these three enzymes are all isoforms of the same 
genetically derived protein has been contradicted [235,236]. An antiserum 
raised against endo-oligopeptidase A could not precipitate E.C.3.4.24.15. 
activity, therefore making these enzymes ~ distinguishable. This 
evidence was accompanied by the proposal that the release of enkephalins 
from metorphamide and dynorphin 1-8 did not occur when the endo-
oligopeptidase A fraction is removed by immunoprecipitation [235], 
implying that enkephalins are not E.C.3.4.24.15. products. This opposed 
the view that the hydrolysis of dynorphin 1-8 occurs by E.C.3.4.24.15. [204] 
which had previously been shown to procede at a much faster rate than 
that of endo-oligopeptidase A. The purity of this antise~as not indicated 
therefore it is proposed that it was probably not monospecific [237]. Since 
polyclonal antisera differ drastically in properties from monospecific ;5uch 
as inhibitory profiles, the suggested lack of involvement ofE.C.3.4.24.15. in 
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the hydrolysis of dynorphin 1-8 is probably false. 
Although they originally proposed that these three enzymes were identical, 
Tisljar and Barrett [181] purified two forms of thimet peptidase, one from 
rat liver mitochondria and the other from testis cytosol. These isoenzymes 
have different substrate specificity and inhibition profiles by antisera, 
therefore may be products of distinct genes. However both are thiol 
dependant metallopeptidases with closely related physiochemical 
properties. These are given the distinguishing names of thimet peptidase I 
and II for those found in the cytosol and mitochondria respectively. 
There are few differences in the inhibition profiles of E.C.3.4.24.15. and 
E.C.3.4.24.16. by metal chelators, ions or small peptides, both being 
activated by Zn2+ and mercaptoethanol (1mM). The main difference seen is 
in the inhibition by 4mM Pro-Ile in which E.C.3.4.24.15. is unaffected 
whereas E.C.3.4.24.16. is inhibited by 60% in rat brain. The enzymes can 
be separated by chromatography, with slight differences in molecular 
masses, these being 68 and 70 000 D for E.C.3.4.24.15. and E.C.3.4.24.16. 
respectively. Other differences such as solubilisation profiles [226], and 
the fact that 80% of E.C.3.4.24.15. is found in the cytosol as opposed to 
E.C.3.4.24.16. where 80% is membrane bound [135] provide further 
evidence in favour ofthese two endopeptidases being distinguishable. 
It will only become apparent if any of these enzymes are identical or 
whether they are of different genetic origin when their amino acid sequences 
have been derived. 
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MATERIALS AND METHODS 
Chapter Two 
2.0 Materials 
2.01 Animals 
Male CSI albino mice (30-35g) were supplied by Nottingham University 
Medical Centre, Nottingham and male Dunkin-Hartley guinea pigs (300-
400g) were supplied by David Hall, N ewchurch, Burton-on-Trent. 
Animals were fed on a standard laboratory diet and kept on a 12 hour 
light/dark cycle at a constant 20°C. 
2.02 Peptides 
DPDPE ([D-Pen2,D-Pen5]enkephalin = (Tyr-NH-CH(C(CH3)2S)-CO-Gly-
Phe-NH-CH(C(CH3)28)-COOH) [50]), tyrosine, Tyr-Gly, Tyr-Gly-Gly, 
dynorphin[l:-13, [Leu5] enkephalin, [Leu5]enkephalin-Arg6 and dynorphin 1-
7 were all purchased from the Sigma Chemical Company, England. 
DAMGO ([D-Ala2,MePhe4,Gly-ol5]enkephalin = (Tyr-D-Ala-Gly-MePhe-
NH(CH2)2-0H) [49]) was from either the Sigma Chemical Company, 
England or Novabiochem, Nottingham. 
Tyr-Gly-Gly-Phe, DADLE ([D-Aia2, D-Leu5]enkephalin), [Met5] enkephalin-
Arg6-Phe7 and [Met5]enkephalin-Arg6-Giy7-Leu8 were all purchased from 
Cambridge Research Biochemicals, Cambridge. Dynorphin1 1-8 was also 
supplied by Cambridge Research Biochemicals, Cambridge or 
N ovabiochem, Nottingham. 
Dynorphinll-8 radioimmunoassay (RIA) kit (containing [125I]dynorphinl-8, 
dynorphin[!·8, Rabbit anti dynorphin [1-8, Goat anti rabbit lgG, Normal 
rabbit serum) was bought from Penninsula Laboratories lnc, UK. 
2.03Drugs 
Naloxone was supplied by the Sigma Chemical Company, England, whereas 
the enzyme inhibitors thiorphan and bestatin were both purchased from 
Cambridge Research Biochemicals, England. 
53 
Chapter Two 
The following drugs were kindly donated; 
N-[(R,S)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-p-aminobenzoate(c-FP-
AAF-pAB) by Dr. M. Orlowski, Mt. Sinai School of Medicine, New York, 
U.S.A. and kelatorphan, (N-[3(R)-[(hydroxyamino) carbonyl]-2-benzyl-1-
oxopropyl]-L-alanine) by B. P. Roques, Dept de Chimie Organique, Faculte 
de Pharmacie, 75006 Paris, France. 
Captopril was provided by Merck, Sharpe and Dohme, England, 
ethylketocyclazocine (EKC) by Sterling Winthrop and nor-binaltorphjmine 
(nor-BNI) by Dr A.G. Hayes from Glaxo Pharmaceutics, England. U69593 
((5a,7a.,8P)-( + )-N -methyl-N -(7 -(1-pyrrolidinyl)-1-oxaspiro[ 4,5] dec-8-
yl)benzeneacetamide) was donated by Upjohn Company, England whereas 
CI977 (5R-(5a., 7 a.,sp )-N -methyl-N -[7 -(1-pyrrolidinyl)-1-oxaspiro[ 4,5]dec-8-
yl]-4-benzofuranacetamide monohydrochloride) and PD 117302 ((±)-trans-
N -methyl-N -[2-( 1-pyrrolidinyl)cyclohexyl] benzo [p] thiophene-4-acetamide) 
were gifts from Dr John Hunter, Parke Davis Research Unit, Cambridge. 
HS332= N-(cyclopropylmethyl)-3-hydroxy-4,14-dimethyloxy-morphinan-6-
one, HS341= N -(cyclopropylmethyl)-3-hydroxy-4, methoxy-14-
ethoxymorphinan-6-one, HS357 = N -(cyclopropylmethyl)-3-hydroxy-4, 
methoxy-14-hydroxymorphinan-6-one, HS365= N-(cyclopropylmethyl)-3-
hydroxy-4, butoxy-14-methoxy-morphinan-6-one and HS367= N-(allyl)-3-
hydroxy-4,14-dimethyloxy-morphinan-6-one were all supplied by Prof. 
Helmut Schmidthammer, University oflnnsbruck, Austria. 
2.04 Chemicals 
Sigmacote, Chloramine T, sodium metabisulphite, sodium phosphate, 
Trizma base (Tris[hydroxymethyl]aminomethane) and Gpp(NH)p 
(5'Guanylimidodiphosphate) were purchased from the Sigma Chemical 
Company, England. Ecoscint A, scintillation fluid was bought from National 
Diagnostics, Hull, England. Acetonitrile and trifluoroacetic acid, both HPLC 
grade, were supplied by Fisons Chemical Company, Loughborough, Leics. 
All other chemicals were analytical grade. 
54 
Chapter Two 
2.05 Radiochemicals 
[3H]U69593 (54Ci/mmol), [3H]RX 783006, (DAMGO (60Ci/mmol)), 
[3H]DPDPE (34.3Ci/mmol) and [3H]diprenorphine (47Ci/mmol) were 
supplied by Amersham International plc, UK or Du Pant, NEN Research 
Products, England. [125I]dynorphinl-8 (833Cilmmol) was purchased from 
Penninsula Laboratories Inc, UK. 
[3H]CI977 (21.1Cilmmol) was kindly donated by Dr John Hunter, Park 
Davis Reseach Unit, Cambridge. 
2.06 Physiological Solutions 
The formula of Krebs solution for bioassays in the mouse vas deferens 
preparation was as follows; 
NaCl, 118.0mM; NaHC03, 25.0mM; KCl, 4.69mM; CaCl2, 2.55mM; 
KH2P04, 1.18mM; Glucose, ll.lmM. 
The formula of Krebs solution for the guinea-pig myenteric plexus 
longitudinal muscle preparation (MPLM), was as above, but with the 
addition ofMgSO 4• 7H20, 1.18mM. 
Tris buffer solution; 6.05g/l Trizma base in distilled water, adjusted to pH I 
7.4 with 4N HCI. In specified cases, lOO mM N a Cl was included. 
2.07 Equipment 
Gilson HPLC system including Gilson Holochrome U.V. variable wavelength 
detector and a Spherisorb ODS2 reverse phase column (25cm x 4mm x 5J.!) 
which was supplied by FSA chromatography, Loughborough. 
Grass S88 Multifunction Solid State, Square Wave Stimulator was supplied 
by Grass medical instruments, Quincy, Mass., U.S.A. and the Minaxi 
Tricarb 4000 Series Liquid Scintillation Counter was bought from United 
Technologies, Packard. The PW48 000 gamma counter, was supplied by 
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Phillips, UK 
A Kinematica Polytron PTA lOTS homogeniser unit-setting 7, was supplied 
by Kinematica of Switzerland and the Brandel Cell Harvester M-48R was 
supplied by Brandel, USA. 
A Beckman Optima TL Ultracentrifuge was used in the preparation of 
homogenates for binding assays which was supplied by Beckman, High 
Wycombe, Bucks. A Universal Centrifuge was used for the r25I]dynorphin 
1-8 metabolism studies and was bought from Hettich, Germany. 
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2.10 Methods 
2.11lsolated Tissue Studies 
2.12 Preparation of Mouse Vas Deferens for Electrical Stimulation 
Male CS! albino mice (30-35g) were killed by cervical dislocation. The vasa 
deferentia were removed and mounted in l.Sml organ bath, with water 
heated jackets, previously siliconised with,sigmacote to reduce the adhesion / 
of the peptides onto the glass surface. An initial resting tension was set up 
at 0.5g. Tissues were bathed constantly in Krebs solution at 37°C, and 
aerated with 5% C02 in 95% 0 2• 
After a recovery period of 90-120 minutes, field stimulation between 
platinum ring electrodes at upper and lower ends of the bath was initiated, 
consisting of three pulses at supramaximal voltage of 1 ms duration at 
intervals of 250ms; the trains were repeated at 0.1 Hz. Contractions were 
recorded isotonically. 
2.13 Preparation of Guinea Pig Myenteric Plexus Longitudinal Muscle for 
Electrical Stimulation. 
Male Dunkin-Hartley guinea-pigs (300-400g) were killed by cervical 
dislocation. The ileum was immediately removed, placed in Krebs solution 
at 37°C, and aerated with 5% C02 in 95% 0 2. Strips of myenteric plexus 
longitudinal muscle (MPLM) were removed as described by Paton and Vizi 
[108] and mounted in 3ml water jacketed organ baths previously coated 
with silicon. The resting tension was set at 1.0g. Tissues were bathed in 
Krebs solution at a constant 37°C and aerated with 5% C02 in 95% 0 2. 
After a recovery period of 60 minutes each MPLM was stimulated through 
platinum ring electrodes using square wave pulses at supramaximal voltage 
at a frequency of 0.16Hz with a pulse width of 400ms. Contractions were 
recorded isotonically. 
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2.14 Determination of Agonist Potencies 
Tissues were stimulated as described as above until an even contraction 
/ 
was maintained. Agonists were then added cumulatively, until the inhibition 
of contraction was maximal. The stimulation was removed and the tissue 
washed by overflow with Krebs solution. The tissue was examined at 
regular intervals, during which continuous washing was undertaken, until 
maximal contraction was. restored. The tissue was then allowed to rest for 
approximately 15mins'Prior to the application of further agonists where 
. / 
appropnate. 
The concentration of agonist required to reduce the twitch height to half the 
maximal value (IC5o) was then calculated from dose-response curves, to 
give the agonist potency. In experiments where peptidase inhibitors were 
used, the tissues were pre-incubated with the inhibitors for a period of 30 
minuWs.prior to the addition of the agonists. The concentrations used were 
/ 
based on those described previously [65,158,159]: 
captopril 
thiorphan 
bestatin 
cFP-AAF-pAB variable between 0.3JlM and 100!lM 
kelatorphan 
2.15 Measurement of Antagonist Affinities 
Antagonists were preincubated with vasa deferentia for the following lengths 
of time prior to the addition of the agonist; 
nor-BNI 
naloxone 
14-alkoxymorphinans 
30mins [159,238] 
15mins [146] 
15 mins 
Dose-response curves for the agonists were obtained before the addition of 
the antagonists and then repeated in the presence of various 
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concentrations of antagonist. ICso values were determined and Schild plots 
constructed, determined as below. Antagonists were washed from the ~ 
tissue by continuous overflow until the response to the agonist was fully 
restored, and the tissue was allowed to rest for 15mins before proceeding. 
All dose-response curves were measured cumulatively. 
2.20 Binding Assays 
2.21 Homogenisation 
Guinea pigs were killed by cervical dislocation and the brain removed. The 
cerebellum was separated from the rest of the brain. The brain or 
cerebellum was weighed and then homogenised in 10 times weight/volume 
Tris buffer for 10 seconds using a polytron homogeniser set at unit 7.0. 
After centrifugation (25 000 x g, 15mins) at 4°C, the pellet was resuspended 
in 10 times weight/volume buffer and incubated at 37°C for 30 minutes to 
remove endogenous ligands. The homogenate was recentrifuged as above 
and the pellet resuspended 1/60 in Tris buffer (weight/volume) for the assay. 
The final protein concentration of brain tissue was approximately 68 mg/g 
tissue (wet weight), and of the cerebellum was 74 mg/g tissue (wet weight), 
determined by the Lowry method [239]. 
2.22 Competitive Displacement Binding Assays 
To 960Jll of the final homogenate dilution, 20Jll aliquots of unlabelled 
competing ligand in increasing concentrations, and 20Jll of a standard 
dilution oflabelled primary ligand were added to a final volume of 1ml. Total 
binding was determined by adding 20Jll of the labelled ligand to the 
homogenate in the absence of any competing ligand. The final mean 
concentrations for [3H]CI977 was approximately 1.3nM, for 
[3H]diprenorphine was 0.2nM, for [3H]DAMGO a concentration of 1.6nM, 
for [3H]DPDPE of l.OnM and for [3H]U69593 of 2.0nM. Non specific 
' 
binding was determined in the presence of lOJlM naloxone. In cases where 
dynorphin 1-8 was the cold ligand, different combinations of peptidase 
inhibitors were included in the specified cases. 
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captopril 
bestatin 
thiorphan 
cFP-AAF-pAB 
lOOJ.!M 
30J.!M 
0.3J.!M 
0.3J.tM or lOO!lM 
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The test mixture was incubated at 25°C for 30 minutes unless otherwise 
stated, then filtered through Whatman GF/B glass fibre filters (particle 
retention size 1.2J.t), previously soaked in Tris buffer for 15mins, under 
vacuum using a Brandel Cell Harvester M48-R. The filters were rinsed 
twice with 3ml ofice cold Tris buffer solution. 
Each filter disc was placed in a scintillation vial insert tube and the 
radioactivity retained was counted after the addition of 3ml Ecoscint 
scintillation fluid. To reduce chemiluminescence, and to allow time for the 
scintillant to soak into the filter, the vials were left at room temperature for 
at least 8 hours prior to counting. 
2.23 Time Course Assay 
To the final brain homogenate (960f..tl) described above, 20J.tl aliquots of a 
stock dilution of hot ligand, namely [3H]CI977, were added at various times, 
between 0 and 480 minutes, prior to filtration. Two tests were run in 
parallel, one set as control to determine total binding, and one set containing 
lOJ.!M naloxone. Protein concentrations were determined by the Lowry 
method [239], and ranged from 68-72 mg/g wet tissue. 
The test mixtures were incubated for the stated times at 25°C in a water 
bath or at 0°C in an ice bath for [3H]DPPDE, [3H]DAMGO and [3H]CI977,. 
then filtered and counted as above. The time at which equilibrium was 
observed was that used for the incubation of the saturation and competition 
analysis samples. 
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2.24 Saturation Analysis 
To the final homogenate (96~1), as above, aliquots of each labelled ligand 
examined (20!lll were added to final concentrations in the range of 0.03 to 
7.5nM. There were two tests run in parallel, one as control to determine 
total binding, and one containing naloxone (10!lM) to determine non-specific 
binding. The total activity was determined by mixing a 20111 aliquot of each 
hot ligand dilution with 3ml scintillation fluid. The final homogenate 
mixtures were incubated at 0°C or 25°C, then filtered and counted as 
described above. 
2.30 Metabolism Studies 
2.31 Radioimmunoassay (R!A) o{Dynorphin 1-8 
The method followed was that described by the supplier of the RIA kit, 
namely Pe;£unsula Laboratories Inc. Standard cold dynorphin 1-8 dilutions 
were prepared over the range of 0.5-128 pg/assay tube and 100111 of 
primary antibody (rabbit ant! dynorphin 1-8) was added to all tubes except 
non-specific binding. These were incubated overnight at 4°C. 100111 of 
[125J]dynorphin 1-8 (15 000 counts) was then added to each tube, vortexed, 
covered and incubated overnight at 4°C. 
Aliquots of goat anti rabbit lgG (100!lM) were added to each tube followed 
by 100111 of normal rabbit serum. The tubes were vortexed and left at room 
temperature for 120 minutes. 0.5ml of RIA buffer was added, mixed, and 
the tubes then centrifuged at 1700 x g for 20 minutes. The supernatant 
was aspirated and the pellet counted on the gamma counter. 
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2.32 Iodination of Peptides 
Peptides were iodinated following a modification of the procedure described 
by Hunter and Greenwood [240]. Briefly 5j.Lg of peptide was dissolved in 25 
j.tl of sodium phosphate buffer (pH 7.5), which was then mixed with 5j.ig of 
sodium iodide in an equal amount of buffer. 
To this, 50j.ig of chloramine T dissolved in sodium phosphate buffer (pH 7.5) 
was slowly added, during which period the mixture was being agitated. The 
reaction was terminated after 2 minutes by the addition of 10mg of sodium 
metabisulphite dissolved in 50j.il of buffer. The reaction mixture was 
vortexed, and spun down on the bench top laboratory centrifuge for 5 
minutes at 2000 x g. Aliquots (50j.Ll) of the supernatant were injected onto 
the HPLC column and separated isocratically with 18% B in A, where A is 
0.1 o10 trifluoroacetic acid and B is 50% acetonitrile in 0.1 df& 
trifluoroacetic acid. 
2.33 Determination of Dynorphin 1-8 Metabolism in Guinea Pig Brain 
Homogenates by RIA 
Homogenates of guinea pig brain minus the cerebellum were prepared as 
above and incubated with dynorphin 1-8 added to a final concentration of 
10nM, for 30 minutes at 25°C. Peptidase inhibitors were added to specified 
samples, to the same final concentrations described above. The reaction 
was terminated by the addition of phosphoric acid to a final concentration of 
50j.tM. Samples were centrifuged and filtered through cellulose nitrate 
membrane filters (pore size 0.45j.tM). The filtrate {lOj.tl) was diluted to 
100j.tl with buffer and the degree of metabolism determined by RIA. 
2.34 Purity Determination of [125[} Dynorphin 1-8 
Aliquots of[125I]dynorphin 1-8 (10j.il) were injected onto a C18 reverse phase 
' 
Spherisorb ODS2 HPLC column (25cm x 4mm x 5j.t), and chromatography 
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of the peptide was achieved with a flow rate of 1mllminute, over a gradient 
as follows; 
(0..) 
Time (minutes) 
0 
25 
35 
40 
% Solvent Bin A 
50 
90 
90 
50 
where Solvent A= 0.1% trifluoroacetic acid in distilled water 
and Solvent B = 0.1% trifluoroacetic acid in 50% acetonitrile:50% water. 
A chromatograph of this is illustrated in Figure 2.01 . 
The [125J]dynorphin 1-8 was shown to consist of both the monoiodo and 
diiodo forms, with two highly radioactive peaks being recovered from the 
column with retention times comparable to those of cold monoiodinated and 
diiodoinated dynorphin 1-8. In this mixture, al_percentage of activity was 
also observed to elutEJYfrom the column along with the solvent front, which 
was thought to be iodotyrosine. 
This mixture was therefore chromatographed over the gradient: 
(b) 
Time (minutes) % Solvent B in A 
0 35 
20 65 
25 65 
35 90 
40 35 
Where Solvent A and B are as described above. Radioactive peaks were 
collected, the eluent acetonitrile was blown off in a stream of nitrogen, 
followed by instant freezing in cardice, with the peptide being recovered by 
freeze drying overnight. The monoiodo dynorphin 1-8 was reconstituted in 
distilled water and the purity examined by HPLC. Results of this can be 
seen in Figure 2.02. 
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1000000 Monoiodo dynorphin lw8 Diiodo dynorphin 1-8 
$ 800000 
a 
·s !ado-tyrosine 
tl 600000 
"' ., .., 
c 400000 
" 8 
200000 
0 
0 10 20 30 40 
Time(minutes) 
Fig 2.01 Showing the radioactivity recovered from HPLC separation of 
[125J]dynorphin 1-8 supplied by Penp'insula Laboratories, UK. /' 
0 10 20 30 40 50 
Time(minutes) 
Fig 2.02 Showing a HPLC trace of the radioactivity purity determination of 
the isolated reconstituted monoiodo dynorphin 1-8. 
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2.35 Metabolism of [I25I]Dynorphin 1-8 in Guinea Pig Brain and 
Cerebellum Homogenates. 
Homogenates of guinea pig brain (5701-lg protein per tube) and cerebellum 
(6201J.g protein per tube), were incubated with 421J.l of [125!] dynorphin 1-8 
(10nM final concentration) at 25°C for 30 minutes in the absence or 
presence of peptidase inhibitors. The concentrations of the inhibitors were 
as used in binding assays ie captopril 1001J.M, thiorphan 0.31J.M, bestatin 
301J.M, cFP-AAF-pAB 0.31J.M or 10011M and kelatorphan 301J.M. The 
reactions were terminated by the addition of phosphoric acid to a final 
concentration of 501J.M, then centrifuged at 50 000 x g for 10 minutes. The 
supematant was filtered through a cellulose nitrate membrane filter (pore 
size 0.451J.), before analysis by HPLC. 
2.36 Metabolism of Dynorphin 1-7 and Dynorphin 1-6 in Guinea Pig Brain 
Homogenates. 
In the studies of the metabolism of cold dynorphin 1-7 and dynorphin 1-6, 
the brain homogenate concentration was approximately 3.32 mg protein 
per assay tube. The dynorphin peptide (361J.M) was incubated alongside an 
internal standard, DAMGO (36~!M), and enzyme inhibitors where specified 
in the concentrations described above, for varying lengths of time. The 
reactions were then terminated with phosphoric acid, centrifuged and 
filtered. Filtrates were analysed by HPLC using UV detection at 280nM. 
2.37 Metabolism Studies in Mouse Vas Deferens 
Whole mouse vasa deferentia were chopped into four pieces and placed in 
Krebs solution (without Mg2+). [l25I]dynorphin 1-8 (lOnM) was added, 
along with the peptidase ' inhibitors where appropriate in the 
concentrations described previously. Samples were incubated at 3~C for 
20 minutes, after which time the reaction was terminated by the addition of 
phosphoric acid to a final concentration of 50~!M. This was followed by 
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centrifugation and filtration as described above. 
2.38 HPLC Analysis of [125I]Dynorphin 1-8 Metabolites. 
Filtrate aliquots (25jll) from the metabolism assays above were injected 
onto the ODS2 HPLC column. Separation of the metabolic products was 
achieved over the gradient described in method 2.S ~). 
Fractions (lml) were collected upon passage out of the detector for a 
duration of 50 minutes, and the activity of each fraction determined on a 
gamma counter. The percentages of the unmetabolised [125I]dynorphin 1-8 
and the metabolite [125I] [Leu5]enkephalin were calculated. Peptides were 
identified by comparison with cold iodinated standards, prepared in the 
laboratory. 
2.39 HPLC Analysis of Dynorphin 1-7 and Dynorphin 1-6 Metabolites 
Aliquots (100jll) of the filtrate collected from incubations with guinea pig 
brain homogenate was separated into its metabolic constituents by HPLC. 
Identification of products was made by comparison of retention times with 
standard known peptides. Peak areas were measured and the ratio of 
peptide: internal standard was calculated to determine the levels of 
unmetabolised peptide. 
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2.40 Analysis of results 
2.41 Determination of the Equilibrium Dissociation Constant, Ki 
Competition studies provide a useful means of measuring the affinity of a 
given drug for a radioligand binding site. 
In a radio ligand displacement experiment, the concentration of the receptor 
[Rt] and radioligand concentration, [L], are kept constant while the 
concentration of a competing ligand, [I], is varied. The amount of 
radioligand bound to the receptor [RL], is determined at equilibrium as a 
function of[I] as shown in equation [1]. 
[L][Rt] 
[RL] = [1] 
Kd(1 +[I] /Ki + [L]) 
In this equation [I] is the concentration of free unlabelled competing ligand, 
Ki is the equilibrium dissociation constant for the interaction of [I] with the 
receptor defined as Ki = [R] [I] I [RI] and Kd is the dissociation constant for 
the radioligand. 
The Ki of a competing ligand, [I], can be determined by measuring the 
concentration of that ligand causing a 50% inhibition of the binding of a 
known concentration of radioligand, the ICso. The ICso may be obtained 
from a linear Hill plot, or log-dose response curves. Having determined the 
ICso, the Ki is calculated from the Cheng-Prussof estimation [241], shown 
in equation [2]. 
ICso 
Ki = [2] 
1 + [L]/Kd 
The concentration of free [I] may be difficult to determine experimentally 
therefore it may be approximated to the total concentration of free [I], 
assuming that the amount of [I] bound is low compared to Ki, i.e. ifRt<<Ki. 
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2.42 Saturation Analysis to Determine the Dissociation Constant, the Kd 
and the Total Binding Site Population, the Bmax. 
Saturation analysis data was analysed by two data processing 
programmes, MACFOUNDS and LIGAND. MACFOUNDS was obtained 
from R Barlow (UK) which plots the concentration of bound radioligand 
versus the concentration of free radioligand, resulting in a hyperbola 
saturation curve. The programme is based on the adsorption principles 
described by Langmuir for gas molecules and Michaelis and Menten for 
enzyme and substrate interactions. The quantity of radioligand bound to a 
fixed amount of receptor or other binding protein is described in equation 3 
below. Many authors including Barlow believe that there is no justification 
in the use of linear transformations, including Scatchard and Hill plot 
analysis, with the advent of good curve fitting programmes available to plot 
the quantity of drug bound versus the ligand concentration. 
2.421 Scatchard Plot 
The saturation data was reanalysed by the curve fitting programme 
LIGAND, and Scatchard transformations obtained. The result is a linear 
plot of Bound [radioligand] I Free [radioligand] (fmol/mg/ml) versus Bound 
(fmol/mg protein), with a slope of 1/Kd and the intercept on the abiscissa 
giving the Bmax as shown in Figure 2.03. Comparison of the Bmax and Kd 
values obtained with those determined in Barlows MACFOUNDS 
programme for Macintosh Computers, showed good correlation implying 
either method was suitable to analyse data. 
2.422 Determination of the Dissociation Constant, Kd 
The basis of the theory behind the saturation analyses determination of the 
dissociation constant relies on the receptor concentration [Rt] being 
constant in a given assay and the amount of the radioligand bound to the 
receptor [RL] at equilibrium being a function of the concentration of the free 
ligand [L]. It is assumed that at equilibrium, the reversible interaction is as 
shown in equation [3], in which [R] is the concentration offree receptors and 
the rate of the forward reaction is k+1, and that this is equal to k-1, the rate 
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of reaction in the reverse direction. 
k+l 
[L) + [R] [LR] [3] 
k-1 
The total number of receptors [Rt] = [R] + [RL], therefore it can be stated 
that: 
[Rt-RL] [L] 
Kd= [4] 
[RL] 
[Rt][L] 
ie [RL] = [5) 
Kd+ [L] 
This is an equivelant equation to the Michaelis-Menton equation, and from 
this, it can be seen that when Kd = [L] it follows that [RL] = [Rt]/2 , thus Kd 
is equal to the concentration of the radioligand which occupies 50% of the 
binding sites. 
The Bmax is the maximum number of sites present per unit of tissue for 
the radioligand ie Bmax = [RL] + [R]. The number of receptor sites per 
experiment is given by the saturation graph which is altered to its 
concentration (fmol/mg protein) using a conversion factor which takes into 
account the concentration of the protein in the homogenate as determined 
by the Lowry method [239]. 
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10 .,..... Bmax/Kd 
' 
Slope =-VKd 
Bmax 
~ 0~--------~--------~~----~ 
0 1 2 3 
Bound (fmoVmg protein) 
Figure 2.03 Illustrating a diagramatic representation of a Scatchard 
transformation. 
2.43 Agonist potency and Antagonism 
The fundamental principle of a biological assay is that the interaction of an 
agonist with a receptor induces a biological response. This has an 
advantage over radioligand binding assay since the receptor may be 
examined in its natural functional state. It must be considered though that 
the response may represent a culmination of a complex series of 
biochemical events therefore is not a direct perception of the drug-receptor 
interaction. 
The agonist activity of a drug is usually characterised by the concentration 
required to produce a 50% inhibition of the maximal response in the tissue 
concerned ie ICso. This is usually obtained by observing the effects of 
several concentrations of the drug on the tissue and constructing a log dose 
response curve. 
Assuming a simple bimolecular interaction the binding of the drug to its 
receptor may be described by the Law of Mass Action such that, 
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[DR] [D] 
= [6] 
[Rtl [DJ +Kd 
where [DR] is the amount of drug bound to the receptor, [Rt] is the total 
number of binding sites, [DJ is the drug concentration and Kd is the 
dissociation constant of the drug for the receptor. At maximal response of 
the drug, it has been shown that not all the receptors are necessarily 
occupied [18,242,243]. We assume that the [DR]/[Rt] = [E]/[Emax], that is, 
the proportion of receptors occupied by the agonist is equal to the ratio of 
effect, [E], produced by a given dose of agonist up to a maximal possible 
effect [Emax]. 
In vitro exposure of isolated tissues to low concentrations of irreversible 
antagonists has been shown to produce large parallel rightward shifts in 
dose response curves without the depression of the maximal response 
[18,242]. This therefore suggests there is a significant pool of receptors are 
still available to bind the agonist, that is a receptor reserve. In tissues with 
little or no receptor reserve, the shifts tip over, diverging away from being 
parallel. 
Doseresponse curves for agonists in the presence of competitive · 
antagonists are shifted to the right and equal responses to an agonist in the 
presence or in the absence of an antagonist can only be achieved when the 
same proportion of the receptor population are occupied. 
2.44 The Schild Plot 
If antagonism is competitive, a plot oflog [DR]-1 vs log [A] where [A] is the 
antagonist concentration and [DR] is the dose-ratio, ie the ECso of the 
agonist in the presence of an antagonist divided by the equiactive dose in its 
absenc? . should give a straight line of unity and the intercept on the X 
axis is log Ke. Deviation from a slope of unity is consistent with a system 
involving more than one receptor class. 
A single dose of antagonist can be used to obtain an estimate of the Ke, 
71 
though certain assumptions are made [244,245] : 
[A] 
Ke = 
[DR]-1 
where Ke is the equilibrium constant for the antagonist. 
In all cases we assume; 
(a) the agonist is not taken up by the tissue, 
(b) that sufficient incubation times are allowed, and 
(c) that the antagonists are not toxic to the tissue. 
Chapter Two 
[7] 
Failure to comply to (a) and (b) produce Schild slopes ofless than unity, and 
to comply to (c) produces a slope greater than one. 
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CHAPTER THREE 
CHARACTERISATION OF K·OPIOID BINDING SITES 
Chapter Three 
3.0Aims 
The aim of this chapter was to extend the characterisation ofthe structural 
and environmental requirements for the activation of the K receptor. This 
was hoped to be achieved by the use of selective and non selective ligands. -
Investigations commenced with a thorough study of the binding properties 
of the highly selective Parke;1)avis radioligand [3H]CI977 with the 1C 
receptors in guinea pig brain homogenates. All previously reported studies 
with this radioligand have been performed in Tris/HCl buffer at 25°C 
[57,58,59,60,246]. Tris buffer is thought to induce an artificially increased 
level of high agonist affinity receptor states [24 7], that is, receptors 
· associated with G proteins. Investigations under different incubation 
conditions were therefore performed, to complement these reports. 
Further examination of the 1C receptor continued, with a determination of 
the receptor selectivities of a series of 14-alkoxymorphinal)fr' analogues. 
The affinities of these compounds at each of the opioid receptors was 
obtained by the analysis of their ability to compete with selective 
radioligands in guinea pig brain homogenates. Following this, their 
antagonistic profiles were characterised in isolated tissue preparations. A 
' similar series of compounds, varying only slightly in chemical structure, has 
previously been shown to display quite different pharmacological profiles 
[248], therefore it was thought that these ligands too may illustrate such 
variability. There has been evidence in support of a similar series of 
analogues disclosing 1C subtypes [248], therefore further studies, with newer 
14-alkoxymorphinans were performed to determine if they too possessed 
such a capacity. 
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3.1 Characterisation of the Binding of [3H]CI977 to K Opioid 
Receptors in Guinea Pig Brain and Cerebellum 
3.11 Equilibrium Binding of f3H]Cl977 
Equilibrium binding of [3H]CI977 was performed at 25°C and at 0°C in 
guinea pig brain homogenates (after removal of the cerebellum). Results 
are shown in Figure 3.01. 
At 25°C, the binding of [3H]Cl977 reached equilibrium after 30 minutes, 
whereas at 0°C, equilibrium was not achieved until a period of at least 180 
minutes had elapsed. Similar times had been determined for the equilibrium 
binding of [3H]DAMGO and [3H]DPDPE, performed previously in this 
laboratory [248]. Therefore the incubation times were likewise chosen to be 
30 minutes at 25°C and 4 hours at 0°C. 
3.12 Saturation Analysis of[3H]Cl977 
The saturation analysis of [3H]CI977 was examined in incubations with 
homogenates under various conditions, using the incubation times 
determined above. Results were analysed using MACFOUNDS and 
LIGAND programmes and are recorded below in Table 3.01, with plots 
illustrated in Figures 3.02 and 3.03. 
From Table 3.01, it can be seen that at 0°C, the Kd value of [3H]CI977, 
that is its equilibrium dissociation constant, was 0.6nM, with a Bmax value 
under these conditions of 46.1 fmol/mg protein. Incubation at 25°C 
produced a Kd of 0.4nM similar to that at 0°C, but with a significantly 
increased Bmax value of 79.3 fmol/mg protein. 
Repeating the saturation analysis at 25°C, but in the presence of 100mM 
NaCl plus 50/lM Gpp(NH)p afforded no significant change in affinity. The 
Kd under these conditions being 0. 7nM, but again with a significantly 
reduced Bmax of 43.7 fmol/mg protein when compared to that at 25°C. 
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Incubation of [3H]CI977 with homogenates of guinea pig cerebellum at 
25°C gave a Kd of 0.1nM, and a Bmax of 53.4 fmol/mg protein. This Kd is 
not significantly different to that observed in brain homogenates under the 
same conditions, but is however significantly different that observed at 0°C 
and at 25°C in the presence of sodium and the guanosine nucleotide. This 
suggests that the binding site structure of the binding receptor in both 
tissue preparations at 25°C in Tris/HCl buffer is probably of similar. 
Conditions Bmax Kd(nM) 
(fmol/mg protien) 
25°C 79.30±7.15 0.42±0.12 
0°C 46.07±3.59* 0.56±0.07 
25°C with 100mM NaCl 
and 50J.!M Gpp(NH)p 43.73±6.27* 0.71±0.09 
25°C** 53.41±4.21 0.11±0.01 
Table 3.01 SJ;9w(ng saturation data for the binding of [3H]CI977 in 
homogenates of guinea pig brain (with the cerebellum removed) and 
cerebellum itself. Incubations at 25°C were for 30 minutes, and at 0°C for 
240 minutes. In all cases, n=4. 
* Students t-test determined a significant reduction in Bmax compared to 
that observed in brain homogenates at 25°C in Tris/HCl buffer (pH 7.4), 
with a confidence limit p < 0.05. 
**denotes analysis in guinea pig cerebellum. 
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Figure 3.01 Showing representative plots of total [e], non specific [o] and \ 
specifically [•J bound [3H]CI977 in homogenates of guinea pig brain (after 
removal of the cerebellum), (a) at 25°C, when ligand concentration = 
0.93nM and (b) at 0°C with the ligand concentration= 1.50nM. 
In all cases, the protein concentration was approximately 70 mg/g wet 
tissue, and assays were performed in 1ml of a 1:60 dilution w/v. 
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Figure 3.02 Representative saturation and Scatchard transformations of 
[3H]Cl977 binding in guinea pig brain. Assays were perfo1med in lml of a 
1:60 homogenate w/v, (protein concentration = 70 mg/g wet tissue), (a) at 
0°C (incubation time of 240 minutes) and (b) at 25°C (incubation time of 
30 minutes). Saturation plots illustrate bound radioligand [RL] against free 
radioligand [L], whereas the insert Scatchard transformations illustrate 
bound radioligand versus bound/free radioligand .. 
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Figure 3.03 Representative saturation curves of bound [3H]CI977 at 25°C 
versus free [3H]CI977, with incubation times of 30 minutes, (a) in guinea 
pig brain homogenates with lOOmM NaCI + 50)lM Gpp(NH)p, (b) in guinea 
pig cerebellum homogenates. Inserts represent Scatchard transformations 
of bound versus bound/free radioligand. Assays were performed in lml of 
1:60 dilution w/v, (protein concentration= 70 mg/g wet tissue). 
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3.13 Displacement Studies of[3H]CI977 by Various Ligands 
Displacement of the radioligand [3HJCI977 from binding sites in guinea pig 
. brairi homogenates has been examined. Competing ligands included 
agonists known to exhibit preference for the K receptor, plus selective and 
non selective antagonists. Incubations were carried out at 25°C, 0°C and 
at 25°C in the presence of lOOmM NaCl plus 50!JM Gpp(NH)p. Results are 
recorded in Tables 3.02 and 3.03. 
Displacement of [3HJCI977 (1.03-1.34nM) by unlabelled CI977 at 25°C 
gave an equilibrium inhibition constant, Ki, of 0.25nM, which was 
significantlyincrease~y the inclusion of lOOmM NaCl plus 50!JM Gpp(NH)p 
in the incubation buffer, affording a Ki of 0.74nM. In both cases, the slopes 
of the displacement curves were unity. These Ki values were similar to the 
dissociation constants (Kd values) calculated for the radioligand of 0.42nM 
and 0. 71nM respectively, determined from saturation analyses. In 
contrast, the displacement of [3HJCI977 by unlabelled CI977 at ooc 
afforded a biphasic curve as illustrated in Figure 3.04 which could be 
separated into two components with ICso values of 0.04nM and 5.01nM. 
The ratio of these sites was approximately 45:55% respectively. The 
existence of two sites had not been evident from the saturation data. 
Displacement of [3HJCI977 (1.04-1.60nM) by the selective K agonist PD 
117302 gave a Ki value at 25°C of 1.86nM, which was significantly different 
to that at 0°C of 4.84nM and to that at 25°C in the presence of lOOmM 
NaCl plus 50!JM GppNHp of 3.36nM. In all cases slopes were unity, 
indicating that the ligands were competing at one population of sites only. 
Displacement of the radioligand (1.29-1.51nM) by the K favouring 
ethylketocyclazocine produced Ki values of0.90nM, 2.61nM and 1.78nM for 
incubations at 25°C, 0°C and 25°C with NaCl plus Gpp(NH)n '""~P'"'t.~vely. 
The inhibition constants of the latter two being significantly i)lrreasedfrom 
that at 25°C, all displaying slopes of unity. U69593, the K selective agonist, 
displaced [3HJCI977 (1.12-1.22nM) at 25°C, with a Ki of 2.70nM, this being 
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increased 
significantly ·. . · in incubations at 0°C to 5.37nM and at 25°C with 
NaCl plus Gpp(NH)p to 12.30nM. Slopes, again, were not significantly 
different to unity as illustrated in Figure 3.04. In addition it should be noted 
that the Ki for the displacement at 0°C was also significantly different to 
that at 25°C in the presence of sodium and the guanosine nucleotide. 
The relatively stable dynorphin 1-13, was examined for its capacity to 
displace [3H]CI977 (1.29-l.SOnM). At 25°C, a Ki of 0.32nM was recorded, 
which was significantlyincrea~~dby the inclusion of lOOmM NaCl plus 50J.!M 
Gpp(NH)p, to l.OOnM. Similarly, a significant loss of affinity was illustrated 
by the reduction of the temperature to 0°C, when a Ki of 0.88nM was 
observed. In all cases, slopes were near unity. 
The competitive displacement of [3H]CI977 (1.38-1.48nM) by the K 
selective antagonist nor-BNI gave Ki values of0.40nM and 0.39nM at 25°C 
and 0°C respectively. Furthermore in the presence of lOOmM NaCl plus 
50j.!M Gpp(NH)p, at 25°C, the Ki was calculated as 0.25nM. There are no 
significant differences between any of these three, but all the slopes were 
less than unity, suggesting the competition of the antagonist and the 
radioligand may be occurring at more than one site. Contrastingly, slopes of 
unity were obtained in the displacement of[3H]CI977 (1.19-1.31nM) by the 
universal opioid antagonist naloxone afforded inhibition constants, ie Ki 
values, of 5.18nM at 25°C, 8.83nM at 0°C and 5.58nM at 25°C with NaCl 
plus Gpp(NH)p. A representation of the competition by the two 
antagonists is made in Figure 3.05. 
Following this, the competition of [3H]CI977 (1.12-1.32nM) by the 8 
selective agonist DPDPE and the ll selective DAMGO was examined. At 
ooc neither the 8 selective agonist DPDPE (n=3) 2r the ll selective DAM GO 
(n=3) displaced any [3H]CI977 (1.31-1.82nM), at concentrations in situ, of 
up to 3000nM. This was also so for DPDPE (n=3) at 25°C, but some 
displacement by DAMGO (n=3) was detected at the elevated temperature, 
with a Ki in the range of 1500nM. 
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Ligand Ki(nM) Slope n Conditions 
CI977 0.25±0.04 0.95±0.03 3 25°C 
(a) 0.02±0.01 0.98±0.06 3 0°C 
(b) 1.73±0.41 0.94±0.05 
0.74±0.12* 1.00±0.03 6 25°C with NaCI ± GppNHp 
PD117302 1.86±0.23 1.01±0.03 9 25°C 
4.84±0.86** 1.04±0.01 6 0°C 
3.36±0.62* 1.04±0.02 3 25°C with NaCI ± GppNHp 
EKC 0.90±0.05 0.98±0.02 4 25°C 
2.61±0.41* 0.95±0.03 5 ooc 
1. 78±0.27* 0.97±0.02 5 25°C with NaCI + GppNHp 
U69593 2.70±0.35 0.94±0.04 9 25°C 
5.37±0.78* 0.98±0.04 9 0°C 
12.30±0.85**•*** 1.03±0.03 4 25°C with NaCI + GppNHp 
(l(· \ ~ L I 
Table 3.02 S~jlfg inhibition constants for the displacement of [3H]CI977 by various K selective ligands in 
homogenates of guinea pig brain (in the absence of the cerebellum), where n =number of experimental observations. 
Incubations were performed at 25°C for 30 minutes and at 0°C for 240 minutes. (a) and (b) represent the two Ki 
values determined from the biphasic plot observed in the displacement of[3H]CI977 by CI977 at 0°C. 
* and ** indicate significantly different inhibition constants from that at 25°C, with confidence limits p < 0.05, and 
p < 0.005 respectively. 
***significantly different inhibition constant determined from that at 0°C, with a confidence limit of p < 0.005. 
Ligand Ki(nM) Slope n Conditions 
Nor-BNI 0.40±0.07 0.81±0.07 7 25°C 
0.39±0.07 0.79±0.10 5 0°C 
0.25±0.13 0.83±0.05 5 25°C with NaCl + Gpp(NH)p 
Naloxone 5.18±0. 79 1.00±0.02 4 25°C 
8.83±2.04 1.02±0.02 4 ooc 
5.58±1.12 0.99±0.02 3 25°C with NaCI + Gpp(NH)p 
DPDPE >3000nM NIA 3 25°C 
>3000nM 3 ooc 
DAM GO >1000nM NIA 3 25°C 
>3000nM 3 0°C 
Dynorphin 1-13 0.32±0.02 0.87±0.03 3 25°C 
0.88±0.14* 0.96±0.06 5 0°C 
1.00±0.19* 0.94±0.03 3 25°C with NaCl + Gpp(NH)p 
Table 3.03 Sh~iiig the inhibition constants for the displacement of [3H]CI977 by K selective (norbinaltorphimine) 
and non selective (naloxone) antagonists, aswell as the 11 selective DAMGO and o selective DPDPE in homogenates 
of guinea pig brain (after the removal of the cerebellum), where n = number of experimental observations. 
Incubations at 25°C were for 30 minutes and at 0°C for 240 minutes_ 
* indicates significantly different inhibition constants from that at 25°C, with a confidence limit p < 0.05. 
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· Figure 3.04 Showing a comparison of the competitive displacement of 
specifically bound [3H]CI977 (Points represent means ± S.E.M. when n:., 3). 
in homogenates of guinea pig brain (after removal of the cerebellum) at ooc 
[•], 25°C [o] by (a) CI977, which demonstrates a biphasic curve at 0°C, 
and (b) U69593, which displays monophasic displacements only. 
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Figure 3.05 Showing a comparison of the competitive displacement of 
specifically bound [3H]CI977 (points represent means± S.E.M. when n:;. 3) 
in homogenates of guinea pig brain (after removal of the cerebellum). 
Incubations were performed at 0°C [•], 25°C (o] and 25°C in the presence of 
lOOmM NaCl plus 50J.LM Gpp(NH)p [o] by 
(a) nor-BNI, which afforded shallow displacement slopes, 
and (b) naloxone, which afforded slopes of unity. 
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3.2 Displacement of [3H]Diprenorphine by U69593 and CI977 
3.21 Results 
The competitive displacements of [3H]diprenorphine by the two K selective 
ligands was carried out in homogenates of cerebellar tissue. The results are 
shown in Figure 3.06. 
The displacement of [3H]diprenorphine (0.08-0.21nM) by U69593 afforded 
an inhibition constant, that is a Ki value, of 6.83±1.40nM (n=3). When 
lOOmM NaCl plus 50!lM of the stable GTP analogue, Gpp(NH)p, was 
included in the incubation buffers, the Ki was significantly increased to 
204.67±44.90nM (n=3). In both cases the slopes were shallow and 
significantly different to unity, being 0.72±0.06 and 0.51±0.01 respectively. 
The displacement of [3H]diprenorphine (0.08-0.21nM) was repeated with 
CI977 as the unlabelled competing ligand. This displacement afforded an 
inhibition constant in Tris/HCI buffer of 2.11±0.47nM (n=4), whereas in the 
presence of lOOmM NaCl plus 50!lM Gpp(NH)p, this was increased to 
30.49±7.29nM (n=3) reflecting a much reduced affinity of CI977 for the K 
receptors. The slopes were significantly less than unity being 0.64±0.08 
and 0.47±0.10 respectively, and although this partly relates to the labelling 
of non K receptors by the [3H]diprenorphine, removal of this non displaced \ 
portion still affords shallow slopes extending over greater than two log units. 
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Figure 3.06 Showing the competitive displacement of specifically bound 
[3H]diprenorphine in guinea pig cerebellum homogenates at 25°C [•J and at 
25°C in the presence of lOOmM NaCI plus 50mM Gpp(NH)p [c], by 
(a) U69593 
(b) CI977. 
Points represent means± S.E.M. when n ?-3. 
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3.30 Discussion 
The dissociation constants of the radioligand [3H]CI977 in whole guinea pig 
brain homogenates (after removal of the cerebellum), were determined at 
25°C, 0°C and at 25°C in the presence of 100 mM NaCl plus 50J.!M 
Gpp(NH)p, the combination of which is known to induce low agonist affinity 
receptor binding states [119,120,121,122,249]. Results quoted were 
obtained from analysis of the saturation data by the MACFOUNDS 
programme. However when these results were compared to data 
determined by the LIGAND programme, no significant differences were 
observed. Examination of the binding curves revealed that under each of 
the ~hove described set o~ncubation conditions, the binding of [3H]CI977 X 
was saturable, and was of high affinity and monophasic, ie the ligand was 
bound to a single set of receptors. 
The maximum number of sites in guinea pig brain homogenate was 
determined as 79 fmol/mg protein at 25°C in Tris/HCl buffer (pH 7.4). This 
is similar to that described recently by Boyle and colleagues [58] who 
determined a Bmax of 98.7 fmol/mg protein in the same tissue preparation. 
However, with the inclusion of the stable guanosine nucleotide, Gpp(NH)p 
plus NaCl, the binding site number was significantly reduced by 
approximately one half to 46 fmollmg protein, but with no significant 
change in the affinity of the radioligand for that site. 
The presence of Gpp(NH)p modifies the ratio of receptors away from those 
associated with G proteins towards those which are dissociated. Therefore, 
one explanation for the reduction in the receptor population is that CI977 is 
differentiating high and low affinity receptor states, a feature common with 
the binding of agonists to G protein linked receptors. The coupling of the 
receptor to the G protein induces a favourable conformation of the ligand 
binding site, that is, the binding site is held in such a manner that the ligand 
recognizes it with high affinity. The data would suggest that under the 
binding assay conditions employed, the [3H]CI977 has too low an affinity for 
the induced low agonist affinity state to be recognized and therefore is not 
measured in the binding assay. Thus the Kd value of 46 fmol/mg protein 
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represents labelling of high affinity states only. This preference for coupled 
receptors has also been proposed for other K ligands which demonstrate 
reduced binding when the receptors were held in a uncoupled conformation 
[66,118,122,250]. This uncoupled conformation is therefore acknowledged 
as the low affinity state for agonist binding. A similar high and low agonist 
affinity receptor state equilibrium has been shown for the binding of 
[3H]U69593 in guinea pig cerebellum homogenates at 25°C which afforded 
biphasic curves consisting of a fast association phase linearly dependant on 
its concentration, and an independant slower component [83]. The addition 
ofGpp(NH)p and sodium ions to the buffer promoted the dissociation of the 
receptor-G protein complex, resulting in an equilibrium shift towards the low 
affinity conformation [251] and thus the conversion of the biphasic curve to 
a monophasic curve. 
When saturation analyses were performed at 0°C, the affinity constant 
was again similar to that at 25°C but the Bmax was significantly reduced 
to 46 fmol/mg protein, similar to the measured value at 25°C in the 
presence of NaCl and Gpp(NH)p. It can be proposed, although not proved, 
that the receptors labelled at ooc in the guinea pig brain may be a similar 
population to that labelled after the uncoupling from the G proteins by the _ 
presence of Na+/Gpp(NH)p and from this, that the reduction in the 
temperature of the receptor environment induces the uncoupled receptor 
state. This may explain the findings of Nock et al [78,252] who claimed to 
apparently differentiate sub types of the K receptor at 0°C. These authors 
reported an enhancement of [3H]ethylketocyclazocine binding by reducing 
the temperature from 25°C to 4°C, whereas the binding of[3H]U69593 was 
seen to decrease. Similarly, they observed that the presence of NaCl 
afforded the same effect. The present findings suggest this therefore may 
have been an alteration of the agonist affinity states rather than the 
exposure ofreceptor subtypes. 
The saturation binding of [3H]CI977 in guinea pig cerebellum, demonstrated 
a Kd of O.llnM, which is similar to that found in the brain, but with a 
significantly lower Bmax of 53 fmol/mg protein. Although the guinea pig 
cerebellum is reputed as being a tissue with a high percentage of K 
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receptors [55,253,122], this observation agrees with reports by Boyle and 
coworkers [246] who described saturation analyses in human brain regions 
with [3HJCI977. Their investigations showed that the cerebellum, in 
comparison to other brain regions, possessed the lowest number of 
[3H]Cl977 binding sites with a Bmax of 21 fmol/mg protein [246]. It is 
therefore obvious that although the percentage of K receptors in the guinea 
pig cerebellum is higher than in the brain [253], the overall total number of 
opioid receptors is significantly less than in the guinea pig brain weight for 
weight. The realisation that the Kd determined in the guinea pig cerebellum 
is identical to that quoted in literature for the affinity in human brain [58], 
illustrates some similarity in the properties of the K receptors in these two 
tissues. 
On the other hand, previous investigations have suggested that the K 
receptors in the cerebellum may not necessarily be that same as in other 
tissues. Itzak and Pasternak [124] showed in the cerebellum that the 
inclusion ofNaCl with Gpp(NH)p had much less effect on K binding than on 
IJ. and o binding [124], affording a 60% preservation of 
[3H]ethylketocyclazocine binding in the absence and presence of DADLE 
and DAM GO, which led to a proposal that K receptors in this tissue may not 
be coupled to adenylate cyclase. In each case, NaCl or Gpp(NH)p on its 
own had no effect at all on the binding of [3H]ethylketocyclazocine. These 
results contrasted with effects in other tissues such as rat brain in which 
the presence of NaCl alone reduced [3H]ethylketocyclazocine specific 
binding by more than 50% and Gpp(NH)p alone by 30%. This however was 
thought to be a result from the higher concentration of o and I! receptors in 
this tissue which are believed to be more sensitive to the uncoupling of the 
receptors from G proteins. The lack of selectivity of 
[3H]ethylketocyclazocine means that this reduction in binding was not 
necessarily a reduction in K binding, rather a reduction in the affinity for the 
higher populous of!J. and o receptors . 
The recently cloned K receptor from mouse brain has been shown to be of a 
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comparable structure to receptors known to be associated with signal 
transduction via G protein coupling [53]. Such receptors are characterised 
by the distinctive seven transmembrane hydrophobic sections. 
Furthermore, the cloned receptor displays inhibitory coupling to adenylate 
cyclase, which agrees with the previously described pharmacological 
observations, which showed that guanine nucleotides such as Gpp(NH)p 
decrease the affinity of the benzomorphinans for the K receptor [122,55]. 
Although the possibility of the presence of receptor subtypes still remains, 
with each subtype displaying a different degree of association with such 
second messenger systems, it is more likely however that the observations 
by Itzak and Pasternak [124] are merely an artifact of the methodology, 
that is, the result of the use of non selective ligands. 
Parallel results of the effects of temperature and the inclusion of 
Gpp(NH)p/Na+ were obtained from the competition experiments of 
[3H]CI977 with unlabelled CI977. A Ki of 0.25nM was determined at 25°C 
agreeing with the observations by Boyle and coworkers [58] who calculated 
a Ki of0.19nM at the same temperature. Accordingly, a slope of unity was 
obtained in our study which agreed with the [3H]CI977 displacement by 
various ligands determined in these preliminary investigations [58]. In the 
present studies, no change was observed in the affinity of CI977 for its 
binding site when the displacement was repeated at 0°C, but a three fold 
reduction in affinity was however recorded at 25°C in the presence ofNaCl 
plus Gpp(NH)p. Furthermore, the slope at 0°C was shallow, implying the 
radioligand was being displaced from different, distinct sites. 
Once again, this raises the possibility that the radioligand is binding to 
subtypes of the K receptor, for which [3H]CI977 has different affinities, 
hence two displacement curves are seen. However the monophasic 
Scatchard analyses suggest this is unlikely. The saturation analyses 
demonstrated that the affinity of the ligand for the receptor under all 
conditions did not vary, it was merely the number of sites that change. 
Boyle and colleagues [58] described [3H]CI977 as a ligand which binds with 
high affinity to a single population of non interacting sites, but these 
investigations were only at 25°C in Tris buffer, that is, in a forced high 
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affinity receptor population, this observation agreeing with the present data 
under the same conditions. 
The shallow slope at 0°C may indicate therefore, that a fluctuation of the 
receptors between high and low agonist affinity binding states still exists, 
unlike that at 25°C with NaCl and Gpp(NH)p in which the receptors might 
be expected to be held in the uncoupled conformation by the non 
hydrolysable guanine nucleotide. The biphasic displacement curve is 
therefore a consequence. The specific binding in all the saturation analyses 
was in the region of 85% therefore it is highly unlikely that [3HJCI977 is 
binding to an non opioid site. 
The displacement of [3H]CI977 at 25°C by the K preferring agonists PD 
117302 and U69593 produced Ki values for the competing ligands of 1.9nM 
and 2. 7nM respectively. These figures being comparable with those 
published previously [58]. Additionally/these ligands, -plus 
ethylketocyclazocin0xhibited a significant reduction in their affinity for 
the [3H]CI977 labelled site upon the addition of NaCl plus Gpp(NH)p 
varying from two fold for ethylketocyclazocine to five fold for U69593, all 
' displaying a two fold reduction in affinity in incubations at 0°C. This implies 
that U69593 is more susceptible to the reduction in the high affinity 
receptor population than PD 117302 and ethylketocyclazocine agreeing 
with previous reports [78,124,252]. In all cases slopes were unity, implying 
these compounds were competing with [3H]CI977 at one population of sites. 
Furthermore, these observations were reflected in the effect of sodium on 
the binding of ethylketocyclazocine and the benzomorphinans [122], which 
afford far weaker shifts than the selective agonists such as U69593 or the 
dynorphin peptides. 
As expected, the antagonists nor-BNI and naloxone did not discriminate 
between the different incubation conditions, the affinity of naloxone at 25°C 
being identical to that described previously [58]. This lack of differentiation 
of binding under different buffer conditions is consistent with the reported 
inability of antagonists to discriminate high and low affinity receptor states 
[122]. Unlike the naloxone displacement of [3H]CI977 which afforded 
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slopes of unity under all conditions, the K selective nor-BNI produced 
shallow displacement curves in each case. This provides evidence in favour 
of these two highly potent K selective ligands, CI977 and nor-BNI, 
competing at two distinct sites, ie receptor subtypes. 
In an attempt to try and explain the different sensitivities to NaCl plus 
Gpp(NH)p observed in the displacements above, the competition of the non 
selective antagonist [3H]diprenorphine, by two K selective ligands U69593 
and CI977 in the guinea pig cerebellum, a tissue known to contain a large 
percentage of K receptors [55,122,253], was performed. Incubations were 
conducted at 25°C in Tris buffer, and with the addition of 100mM NaCl plus 
50J.!M Gpp(NH)p, to enhance the segregation of the G protein complexed 
receptors from their associated G proteins. 
Results showed that CI977 possessed higher affinity for the 
[3H]diprenorphine labelled binding sites than U69593 agreeing with 
previous claims [58] that CI977 was one of the most potent K ligands to 
date. The further addition of 100mM sodium plus 50J.!M of the stable 
guanosine nucleotide, afforded large reductions in the affinity of these K 
-
selective ligands. In-both buffer systems, very shallow displacement slopes 
were observed though this was in agreement with similar observations 
made in analyses performed in HEPES buffer in the presence of Mg2+ 
reported by Wood and Traynor [24 7] for studies in the same tissue 
preparation and with the same radio ligand. 
In fact, CI977 exhibited a 14 fold decrease in its affinity for the antagonist 
labelled receptor whereas U69593 demonstrated a 30 fold decrease. That 
is, the displacement of [3H]diprenorphine by U69593 is more sensitive to 
the reduction of high affinity receptor sites than CI977. This observation 
agrees with the data shown above for the displacement of [3H]CI977 by 
these two ligands in which U69593 showed a significantly higher sensitivity 
to the reduction in high affinity binding sites than any other agonist 
examined, reflecting previous similar claims [78,122,124,252]. It must be 
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remembered that the assays in Tds/HCl buffer are induced into a non 
physiological environment as described previously [247], that is, they 
proceed in the presence of non biologically elevated level of high agonist 
affinity binding sites. The lower affinities observed by the inclusion of 
Gpp(NH)p and sodium ions may therefore be a truer representation of the 
physiological situation, and hence CI977 binds with greater affinity to the K 
receptor population compared to U69593. The fact that U69593 has a 
higher dghtward shift provides further evidence for its lack of recognition of 
low affinity sites, whereas it would appear that the CI977 binds to G protein 
dissociated receptor forms. However, the binding assays do not measure 
activation, only the ligand binding to the receptor, therefore [3H]CI977 is I 
not necessarily activating the receptor in its capacity as an agonist, it may 
merely be binding in the manner associated with antagonists. The higher 
sensitivity of U69593 to the effects of Na/Gpp(NH)p does not contradict 
the previously published similar Bmax values for CI977 and U69593, since 
the authors used normal Tds/HCl buffer in which the equilibdum is towards 
that of high affinity and did not discuss the use of other buffers. 
However, the shallow slopes observed in each case suggest that these 
selective ligands are displacing the antagonist from more than one site, 
agreeing with binding profiles for [3H]diprenorphine reported previously in 
the same tissue, as well as rat brain and guinea pig brain [247]. It must 
also be pointed out, that in the displacement by both ligands, approximately 
20% of the [3H]diprenorphine binding is not displacable. However, this 
antagonist is not selective for the K receptor, therefore this population of 
receptors, insensitive to the selective agonist displacement, may represent 
the ~ and 8 receptors present in the tissue. The high population of K 
receptors in the cerebellum has been reported to contribute to a 84% 
predominance [253], however this has also been contradicted by the 
determination of the much lower 35% K population [55]. Even accounting 
for this, shallow slopes are obtained which suggests that the unlabelled 
ligands are distinguishing K subtypes [36,24 7]. Previous investigations 
exposed a population of sites which did not have high affinity for~. 8 or K 
ligands, whereas the K insensitive DADLE did displace this population to 
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some degree [36]. Additionally, the peptide dynorphin 1-17 could only 
displace 50% of this population, previously described by Pfeiffer et al [36], 
therefore the possibility of heterogeneity was strongly considered [247]. 
This was emphasised in buffer conditions shown to induce low affinity 
receptors, in which the binding sites may represent a functional state, an 
example of this being the displacement of [3H]CI977 by nor-BNI, in which 
shallow slopes suggest that more than one receptor population was 
involved, this not being eliminated in the presence of Gpp(NH)p and NaCl. 
The different populations of K binding sites observed here are therefore quite 
probably illustrating heterogeneity and not high and low affinity receptor 
states as in other cases above. 
There have been numerous attempts to characterise K subtypes. The 
general conscensus is in favour of two main groups of subtypes, originally 
differentiated by their DAD LE sensitivity [35,83]. The classification is now 
based on their sensitivity to U69593, the U69593 sensitive binding site 
being termed K 1 and the non U69593 sensitive binding K sites, being K2 
[78,252,254]. Both sites bind ethylketocyclazocine in the presence of 
DADLE and either DAMGO or bremazocine [75,78,79,80,87,252]. 
Other researchers have provided evidence for additional subtypes such as 
K3 [42,86] to which the ligand Na!BzoH binds with high affinity. NalBzoH, 
naloxone benzoylhydrazone, is a novel mixed agonist/antagonist, exerting its 
antagonism at l!p J-!2, o and K1 receptors whereas it appears to be an 
agonist, capable of precipitating analgesia, at the K3 receptor population. 
Extensive reports by Rothman and colleagues [66,87] have presented 
evidence in support of four separable K receptor subtypes. Studies have 
identified K1a and K1b sites, both of which are recognized by U69593, but are 
not differentiated by nor-BNI, and two other sites, given the nomenclature 
K2a and K2b, which exhibit a much lower affinity for U69593, and which 
possess quite different affinities for the selective antagonist [41,66,87,255]. 
Thus nor-BNI displays Kd values at K2a of0.6nM and at K2b of 128nM [87]. 
Furthermore, U69593 is thought to bind weakly to K2a but not at all to K2b, 
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and ligand profile studies suggest K2a has high affinity for the endogenous 
peptides such as dynorphin 1-8 and the benzomorphans, such as 
bremazocine and ethylketocyclazocine, and tifluadom. 
It may be of importance to point out that Rothman and coworkers used 
quite different blocking agents such as cycloFOXY, BIT and FIT [87] in 
these studies, compared to the antagonists used by other groups. These 
compounds are irreversible and designed to remove one population of sites 
fully. If some sites remain active however, these would appear as potential 
contaminants of the site under investigation. Indeed, no other groups to 
date have yet fully agreed with their observations when approaching this 
problem with other blocking methods. Therefore although these results 
explain a lot of atypical data, they must be taken with a "pinch of salt". 
Consideration must be given to the fact that perhaps the observed different · -' 
results only as a direct effect ofthese unusual blocking methods. 
Unfortunately, no clear details have been described for the effects of 
Gpp(NH)p on the K 1 and K2 subtypes, farless the subclasses within these 
groups. Although it has been pointed out previously that U69593 and 
CI977 recognize a similar number of binding sites in guinea pig brain [58], 
this suggests that CI977 is not binding to K2 sites if the high insensitivity of 
U69593 for this receptor population is to be believed. 
Furthermore, the guinea pig cerebellum has been shown previously to 
consist of a predominating K 1 population, with few K2 receptors [81], 
therefore the shallow slopes imply that this is not a single population, and 
that perhaps these studies are reflecting the separation of the group into 
K1a and K 1b· It may be that the higher population of K 1 receptors in this 
tissue compared to that in other tissues, allow the subdivisions of the K 1 
receptor which may not necessarily have been possible in lower 
populations. However, it cannot be estimated whether this would be the K1a 
and K1b as described by Rothman and colleagues [66,87], or that described 
by Clark et al [ 41]. 
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Alternatively, the shallow slope may result from the initial high affinity 
binding to the K 1 receptors, with the lower selectivity for the K2 site being 
demonstrated as the concentration of the agonist increased. Furthermore, 
U69593 has been proposed to have weak affinity for the K 2a site, therefore 
such a site must too be considered. Likewise the shallow displacement 
slope demonstrated by the CI977 competition with [3H]diprenorphine, is 
worthy of a similar consideration. A great deal of work is still required 
before the true nature of the U69593 and CI977 binding sites is fully 
characterised, and whether they have similar affinities for the same 
subtypes or whether they bind to different sites is as yet unknown. 
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3.31 Conclusions 
Scatchard transformation data suggests that [3H]CI977 binds to one 
receptor population only in the guinea pig brain, however this was not 
confirmed in the displacement of [3H]CI977 by the antagonist nor-BNI in 
which a shallow displacement curve was observed. Nor-BNI is thought to 
possess some selectivity for the JC1 receptor population [42], and has 
previously been shown to discriminate JC28 and JC2b, therefore the subdivision 
of this receptor group in this tissue may be exemplified. 
U69593 is thought to demonstrate K 1 selectivity, but there has been 
proposals in~erature in favour of subtypes lying within this classification. 
Guinea pig cerebellum has been suggested to possess a predominately 1e1 
receptor population [81], but the shallow displacement of [3H]diprenorphine 
by U69593 implies that subdivisions within this group are being illustrated 
by these ligands. The existence of more than one CI977 receptor in the 
cerebellum was also evidenced in a similar manner. However, whether 
these two ligands are illustrating the same or different receptor subtypes 
has yet to be confirmed. 
The results suggest that in both the brain and the guinea pig cerebellum, 
CI977 is capable of exposing 1C receptor subtypes as well as illustrating 
preference for the G protein complexed, so called agonist high affinity 
receptor states. Although producing a similar profile, U69593 is however, 
more sensitive to the reduction in the high agonist affinity site population 
than CI977. 
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3.4 Selectivity of 14-Alkoxymorphinans 
3.41 Introduction 
A series of 14-alkoxymorphinans has been synthesised by the workers of 
Professor Helmut Schmidhammer, at the University of Innsbruck in 
Austria. There have been suggestions [248] that such compounds can 
differentiate 1C opioid receptors. Thus the pharmacological properties and 
opioid receptor selectivity of a series of these compounds were analysed in 
radioligand binding assays and isolated tissue bioassays. This series of 
compounds 9-re'Shown below. The codes used are those derived from the 
name of the originating chemist; 
HS332= N-(cyclopropylmethy!)-3-hydroxy-4,14-dimethyloxymorphinan-6-
one, 
HS341= N -( cyclopropylmethy!)-3-hydroxy-4, methoxy-14-
ethoxymorphinan-6-one. 
HS357= N-(cyclopropylmethy!)-3-hydroxy-4, methoxy-14-
hydroxymorphinan-6-one. 
HS365= N-(cyclopropylmethyl)-3-hydroxy-4, butoxy-14-methoxy-
morphinan-6-one 
HS367= N-(allyl)-3-hydroxy-4,14-dimethyloxymorphinan-6-one 
HS332 
HS341 
HS357 
HS365 
HS367 
HO 
RI 
0 
Rl = OCH3 R2 = OCH3 
Rl = OCH3 R2 = OCH2CH3 
Rl = OCH3 R2 =OH 
Rl = OC4H9 R2 = OCH3 
R1 = OCH3 R2 = OCH3 
N--R3 
R3= Cyclopropylmethyl 
R3 = Cyclopropylmethyl 
R3 = Cyclopropylmethyl 
R3 = Cyclopropylmethyl 
R3 = CH2CH=CH2 
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3.42 Results 
3.421 Isolated Tissue Bioassays 
The ability of each of the selected compounds to antagonise various opioid 
ligands was determined in the mouse vas deferens. Each of the 
alkoxymorphinan derivatives was examined for agonist potency, but none 
exhibited any activity up to 10 JlM. 
The K opioid receptor selective ligand CI977, afforded an ICso in mouse 
vasa deferentia of 7 .50nM. Antagonism of this ligand by the 
alkoxymorphinans afforded an equilibrium constant (Ke) for HS332 of 
368.0nM and for HS341 of 233.3nM, in each case Schild slopes were unity. 
Single dose analyses produced a HS357 equilibrium constant of 242.9nM at 
the CI977 site in mouse vas deferens and a HS365 Ke of 174.2nM. 
Contrastingly, the antagonist HS367 afforded a Ke of 4.67nM, the results 
being shown in Table 3.04. 
Determination of the o receptor affinity of the series of 14-
alkoxymorphinans was obtained from their ability to antagonise DPDPE. 
In the mouse vas deferens, the concentration of DPDPE required to inhibit 
the electrically induced contractions of the tissue by 50%, that is the ICso, 
was determined as 8.14nM. Antagonism by HS332 afforded a Ke value of 
315.7nM similar to that for HS341 which was determined as 106.3nM. 
Contrastingly, the affinity of the other three analogues for the o site was 
much weaker, in the order HS367 (Ke = 2272nM), > HS357 (Ke = 8922nM) 
> HS365 ( Ke >10 OOOnM). 
To complete the series, the affinity of the alkoxymorphinans for 11 receptors 
was investigated by determining the antagonism of the inhibition of mouse 
vasa deferentia contractions produced by the peptide, DAMGO. In these 
tissues, DAMGO afforded an ICso of 16.8nM. Results varied between 3nM 
and 100nM. The equilibrium constants calculated for HS332, HS341 and 
HS367 were all less than 10nM, while in contrast HS357 afforded a Ke of 
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93.8nM and HS365 a Ke of 24.9nM. The receptor selectivity ratios for the 
various compounds were calculated and are shown in Table 3.05. 
HS332 showed highest affinity for the 11 receptor, with a selectivity ratio of 
56 fold preference over o receptors and of 65 fold preference over K 
receptors. There was however little selectivity between o and K sites. The 
14-alkoxymorphinan HS341, afforded a similar selectivity profile. Changes 
were observed with HS357, which afforded a 95 fold preference for the 11 
receptors over o receptors but only a 2.6 preference for 11 over K receptors. 
Additionally, therefore a high selectivity for the K receptor when compared 
too sites was observed with a o/K selectivity ratio of37 fold. 
The lack of affinity of HS365 for the o receptor meant that high selectivity 
forK and 11 over o receptors were recorded, with a 1000 fold preference for 11 
sites over o and 60 fold for K over 8 receptors. However, the compound 
therefore also had also higher affinity for the 11 receptor over the K receptor 
by 7 times. Similarly, the poor affinity of HS367 foro sites meant that the 
preference for 11 over 8 was 500 fold and for K over o was 486, such that no 
difference was observed between the affinity for the 11 receptor and that for 
the K receptor. 
100 
Agonist ICso (nM) Ke(nM) 
. 
HS332 HS341 HS357 HS365 HS367 
CI977 7.50±1.40 368.0±53.2** 233.3±107.3* 242.9±36.6 174.2±37.3 4.67±0.13 
DPDPE 8.14±0.63 315.7±84.2 106.3±8.6 8922±110 >10 000 2272±237.5 
DAM GO 14.81±1.50 5.62±0.56 2.92±0.48 93.8±16.2 24.9±3.1 4.60±1.20 
Table 3.04 ~the ICso (nM) values of three selective opioid agonists and the determined affinity constants (Ke 
(nM)) for the 14-alkoxymorphinans HS332, HS341, HS357, HS365 and HS367 in the mouse vas deferens. The 
affinities for the K receptor were determined against CI977, for the o receptor against DPDPE and for the fl receptor 
against DAMGO. 
n=15 for each of the ICso determinations, and n=3 for each affinity constant determination (where n= the number of 
experimental observations), except* where n=4 and** where n=10. 
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HS332 HS341 HS357 HS365 HS367 
0/J.i 56 36 95 1000 500 
KIJ.i 65 80 2.6 7 0.99 
0/K 0.86 0.46 36.7 >60 486.5 
Table 3.05 Showing the receptor selectivity ratios for the five antagonists 
examined in mouse vas deferens. Results were made over at least three 
experimental observations as described in Table 3.04. 
Further investigations with the alkoxymorphinan HS332, illustrated in 
Table 3.06, showed a Ke value of 450.6nM in the mouse vas deferens 
determined against dynorphin 1-13, similar to that (368nM) determined 
against CI977. Likewise, antagonism of the K selective ligand U69593 
afforded a HS332 Ke value of 354.20nM. A significant decrease in the 
receptor affinity of this antagonist was however observed against the K 
preferring ethylketocyclazocine (Students t-test, p < 0.05), with a Ke of 
910.3nM. In each of these cases, the Schild slopes were unity. 
For comparison, studies were also performed for HS332 in guinea pig 
myenteric plexus (Table 3.06). An equilibrium constant of 97 .50nM was 
determined against the K selective U69593, this being significantly different 
from that determined against CI977 of 284.54nM (p < 0.05), both of which 
were accompanied by Schild slopes of unity. A futher reduction in the 
affinity of HS332 was determined against tifluadom (p < 0.005), when a Ke 
of lOOOnM was calculated. 
The non peptide, K preferring ethylketocyclazocine, was examined which 
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afforded an ICso of 0.13nM ~ the guinea pig myenteric plexus and a 
significantly higher HS332 et/\ ''6f 3.95nM (p < 0.005). For comparison, 
naloxone antagonism of ethylketocyclazocine was examined which afforded 
an unexpected equilibrium constant of 2. 78nM calculated by Schild analysis 
as illustrated in Figure 3.07. 
103 
Mouse vas deferens Guinea pig myenteric plexus 
Ligand IC50 (nM) Ke (nM) n IC50 (nM) Ke(nM) n p 
CI977 7.90±1. 74 368.02±53.28" 10 0.09±0.02 284.5±50.~1" 7 Not Sign. /} 
20.¥±3.40 \ Ethylketocyclazocine 910)'4±148.Jl9""' 4 0.13±0.02 3.95±1.58* 8 < 0.005 
Ethylketocyclazocine** Not tested 0.04±0.01 2.78±0.56 5 
91.~18.'¥ 0 U69593 354)0±89.59" 6 2.20±0.42 97.~0±14. 77 6 < 0.05 
Tifluadom Not tested 0.17±0.02 100v±24~1" 3 
69.7ft17.!JZ" 
'; Dynorphin 1-13 45~6±52;35 6 Not tested 
Table 3.06 Showing ICso values for various K ligands in the mouse vas deferens and guinea pig myenteric plexus 
preparations and the resulting HS332 Ke values, where n = the number of experimental observations and P is the 
probability of significant difference between the affinity constants determined in the two tissues obtained from the 
Students t-test. In all Schild analyses, slopes were unity. 
*denotes Ke values determined by a single dose analysis 
** denotes a naloxone Ke value determined by Schild analysis 
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Figure 3.07 (a) Sh_9W!ng the dose-response curves for the inhibition of 
electrically induced contractions of guinea pig myenteric plexus longitudinal 
muscle by ethylketocyclazocine in the absence [•] and presence of lOnM 
[a], 30nM [•] and lOOnM [o] naloxone. Error bars represent SEM from five 
experimental observations. 
(b) A representative Schild plot for the above antagonism. 
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Ligand IC50 (nM) Ke(nM) Schild plot slope n 
Cl977 7.50±1.40 223.30±107 .30 0.99±0.01 4 
N ormorphine* 870.33±126.81 1.84±0.48 S.D. 4 
Ethylketocyclazocine* 20.60±3.40 8.19±1.24 S.D. 4. 
DAM GO 10.91±1.66 2.92±0.48 S.D. 3 
DPDPE 3.01±0.08 106.3±8.6 S.D. 3 
Table 3.07 Showing ICso values and HS341 Ke values of various ligands in 
mouse vas deferens. 
n= the number of experimental observations 
S.D.= single dose method used to determine Ke value 
*results for these compounds were obtained from reference [248]. 
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3.422 Displacement Binding Assays 
The inhibition constants, described as Ki values, for the 14-
alkoxymorphinans in guinea pig brain homogenates (after removal of the 
cerebellum) against the selective radioligands [3H]U69593 (K), [3H]DPDPE 
(8) and [3HJDAMGO (!l) at 25°C, are recorded in Table 3.08. A sample 
graph illustrating the competitive displacement of each radioligand by 
HS357 is illustrated in Figure 3.08. 
The inhibition constants of the antagonist HS357 were found to be 23nM, 
336nM and 54nM at K, 8 and ll receptor sites respectively. HS365 and 
HS367 showed similar affinity for JC sites (13nM and ~5nM respectively), 
though both had higher affinity for ll receptors (11 and 7nM respectively) 
/ 
and a ~eaker affinity for 8 receptors (42nM and 25nM respectively). Indeed 
each of the five compounds examined had similar 8 affinity except HS357 
which had a 10 fold weaker affinity. HS357 also had weakest affinity 
(54nM) of all the compounds tested for the ll receptor, with the others all 
having affinity < 10nM. The affinity of each compound for the JC receptor 
varied from 4.2nM (for HS332) to 26nM (for HS367). 
The receptor selectivity ratios were calculated and are recorded in Table 
3.09. Of the compounds examined, the highest selectivity for ll over 8 was 
seen with HS357, the highest ll over JC selectivity with HS341 and the 
highest 8 over JC with HS357. On the whole, the compounds were generally 
not selective, although out of the selies, HS357 demonstrates the highest 
selectivity across the three receptor populations. 
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Assay Site Ki(nM) 
HS332 HS341 HS357 HS365 HS367 
K 4.18±0.60 5.46±0.54 23.00±5.24 13.01±1.87 25.38±3.65 
0 13.8±3.72 21.4±1.58 335.94±78.35 42.00±4.18 25.60±5.85 
ll 6.15±1.62 1.42±0.26 54.35±8.28 10.93±1.94 7.29±0.55 
Table 3.08 Showing the displacement of three radioligands [3H]U69593 (1.57-2.51nM), [3HJDPDPE (2.09-2.86nM) 
and [3H]DAMGO (2.59-3.26nM) by the antagonists HS357, HS365 and HS367. Data for HS332 and HS341 was 
obtained from reference [248], in which the concentrations of the radioligands were [3H]U69593 (1.95±0.13nM), 
[3H]DPDPE (2.01±0.16nM) and [3H]DAMGO (1.84±0.12nM). The number of experimental observations> 3 in each 
case . 
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HS332 HS341 HS357 HS365 HS367 
0/Jl 2.2 1.5 6.3 3.8 3.4 
KIJl 0.7 4.0 0.42 1.2 3.4 
OIK 3.19 3.78 14.61 3.23 1.01 
Table 3.09 Showing the receptor selectivity ratios for the five antagonists 
examined in guinea pig brain homogenates (after removal of the 
cerebellum). Ratios for HS332 and HS341 were obtained from reference 
[248] and in all cases, results were made over at least three experimental 
observations. 
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Figure 3.08 Showng the competitive displacement of specifically bound 
[3H]U69593 (1.57-2.51nM) [•],[3H]DPDPE (2.09-2.86nM) [•] and 
[3H]DAMGO (2.59-3.26nM) (o] by HS357 in guinea pig brain homogenates 
(after removal of the cerebellum). Error bars represent SEM from three 
experimental observations. 
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3.43 Discussion 
3.431 Isolated Tissue Bioassays 
The~evelopment of selective ligands for each of the opioid receptors has led 
to the synthesis of compounds structurally based on morphine, 
characterised as 14-alkoxymorphinans. The name morphinan is used to 
describe those derivatives of morphine that lack a furan bridge and possess 
a BID ring fusion which may be either cis (morphinans) or trans 
(isomorphinans). The morphinan nucleus possesses three chiral centres at 
C9, C13 arid C14, two of which are constrained (C9 and C13) by the 
piperidine bridge. Morphinan-6-one, lacking a substituent on the aromatic 
A ring, has showed considerable antinociceptive activity in the order of 
three times that of morphine [256], the activity residing only in the (-)-
enantiomorphs, that is, compounds configurationally related to morphine. 
The alteration of effects produced by variation of N-substituents have been 
known for many decades [256]. Early studies demonstrated that the 
extension of the N-alkyl chain was of no biological advantage, in fact the 
inclusion of an allyl moiety produced compounds which were antagonists 
[257]. Subsequently (- )-3-hydroxy-N-cyclopropylmethylmorphinan proved 
) 
to be a powerful morphine antagonist. 
Like morphine, most analgesically active morphinans contain an oxygen 
function, usually a hydroxyl, in position C3. The presence of 3-0H or 3-0Ac 
invariably leads to a significant enhancement of opiate activity, whereas 3-
0Me, at best, affords only a moderate increase [258,259]. The insertion of a 
hydroxyl group into the C14 position of morphinelike structures affords 
compounds which are potent antagonists often with weak analgesic actions. 
In the morphinan series, 14-0H substituted analogues can be good 
analgesics with high potencies, as well as having prolonged activity relative 
to morphine. This pharmacology contrasts with 14-H analogues bearing 
antagonistic N substituents which are good analgesics but are only weak 
antagonists [260]. 
The alkoxymorphinans used in this study showed no agonist activity in 
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either the mouse vas deferens or the guinea pig myenteric plexus. 
Examination of the affinity of the alkoxymorphinan HS332 in the mouse 
vas deferens afforded similar Ke values using a variety of IC agonists, of 
approximately 400nM (against CI977, dynorphin 1-13 and U69593) with · 
the exception of ethylketocyclazocine which afforded a HS332 Ke of 
900nM, this demonstrating a significant reduction in the affinity of the 14-
alkoxymorphinan for the IC receptor defined by ethylketocyclazocine 
(Students t-test, p< 0.05). Contrastingly, in the guinea pig myenteric plexus 
the Ke values varied over a wide range, with the highest affinity recorded 
using ethylketocyclazocine (4nM) and the lowest affinity with tifluadom 
(1000nM). 
Differences between the two tissues were also seen when comparing the IC 
agonist potencies, with potencies varying up to 90 fold i for the same 
agonist as in the case of CI977. Such differences in the potency of the 
agonists agree with previous observations by Cox and Chavkin [243]. They 
hypothesised that this effect was a consequence of the presence of much 
higher receptor populations in the plexus as opposed to the mouse tissue, 
therefore the agonists appeared to ~a higher potency~he different Ke 
values of the antagonists determined against ethylketocylclazocine and 
U69593 in the two tissues is not however so easily explained and raises the 
possibility of receptor differences in these two preparations. Sub types are 
most readily demonstrated in Scatchard transformations of saturation data 
in which biphasic plots generate more than one Kd value, these values 
exemplifying more than one receptor site to which the radioligand binds. 
However, the ability of an antagonist to reduce the actions of any agonist at 
a particular receptor, affords a Ke value (equilibrium constant), and this 
value is specific for that particular interaction. ThereforE) if an antagonist 
binds to more than one receptor population, these separate receptors may 
display different Ke values and therefore can be characterised. Additionally, 
once characterised, different agonists can be examined and the receptors 
through which they interact assessed. 
These observations therefore suggest that these two tissues may be 
capable of displaying IC heterogeneity [261], and comparison of the 
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interactions of various ligands in the two preparations can further the 
understanding of such a phenomenon. The work complements the 
observations by Davis and colleagues [262] who have shown differential 
sensitivity of U69593 and bremazocine in the mouse vas deferens to 
quadazocine antagonism, with the agonism of U69593 being far more 
sensitive. Such observations were not paralleled in the guinea pig 
myenteric plexus in which both agonists were antagonised to a similar 
degree. This is in contrast to the data observed with HS332 in which a 
similar antagonism was obtained in the mouse vas deferens but receptor 
populations of different sensitivities were determined in the guinea pig 
myenteric plexus. This cannot be explained by interactions with the J..L or o 
sites which had been blocked prior to these observations, therefore the 
authors described this as a difference in the K receptor complement 
between the two tissues. 
There has been much discussion about the discrimination of K receptor 
subtypes, and it has been suggested that U69593 binds with higher affinity 
to the so-called K 1 subtype than K2 [55,79,84,255]. The higher affinity of 
HS332 for the U69593 receptor in the guinea pig myenteric plexus 
compared to that in the mouse vas deferens (p < 0.05), contrasting with 
similar Ke values in both preparations using CI977, supports the 
suggestion of the presence of two different receptor populations which are 
unveiled by this antagonist. However, this contrasts with the reports by 
Davis et a! [262] who observed the opposite effect, with receptor differences 
in the mouse vas deferens but not in the guinea pig myenteric plexus. !fit 
were to be hypothesised from previous evidence that U69593 preferentially 
acts via K 1 receptors, then it would appear that in the guinea pig myenteric 
plexus, the K 1 site is predominately present. This suggests that either there 
is no K1 population in the mouse vas deferens or that the other K sites are 
present in a much higher concentrationLt_hat the K 1 interactions are 
masked. This also suggests that CI977 does not display such a selectivity 
for the K 1 receptors. 
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Furthermore, highly contrasting results were obtained for the HS332 
antagonism of the inhibition of tissue contractions by ethylketocyclazocine, 
with a Ke value being determined in the mouse vas deferens of 910nM 
whereas in the guinea pig myenteric plexus the Ke was 4nM. Previous 
reports of the HS332 antagonism [afforded an equilibrium constant in the ?; 
mouse vas deferens of 146nM and in guinea pig myenteric plexus of 3.9nM 
[248]. These figures were however obtained from a single antagonist dose, 
whereas the presently reported Ke value of 910nM in the uasa deferentia 
was obtained from Schild analysis, with a slope of unity. The Schild 
analysis ought to be more accurate, being calculated from three antagonist 
doses, therefore the old data will be disregarded with caution. j 
For comparison, the naloxone antagonism of ethylketocyclazocine was 
examined in the guinea pig myenteric plexus. An unexpected equilibrium 
constant of 2.78nM was afforded, this value being associated with the 
antagonism at iJ- receptors. A Schild slope of unity suggested there was no 
cross reactivity with K receptors. Tissues from different batches of guinea 
pig of the same strain were examined which confirmed this observation. 
Ethylketocyclazocine has always been considered as a K agonist, exhibiting 
antagonism at the iJ- receptor [111]. However, a recent publication [263] 
utilising the advent of selective antagonists for separate opioid receptors in 
the guinea pig myenteric plexus, have shown that ethylketocyclazocine 
afforded iJ- agonism agreeing with the present observations. The authors 
blocked K receptors with 20nM nor-BNI and calculated the rightward shift 
in the dose-response curve. The tissue preparations were washed, then 
reincubated with the same dose of nor-BNI plus lOOnM of the iJ- selective 
antagonist CTAP. A further two fold shift was observed in the dose-
response curve implying that ethylketocyclazocine displays some agonist 
interactions via the iJ- receptor in the guinea pig myenteric plexusL 
It can therefore b~ypothesised that in our strain of guinea pig, 
ethylketocyclazocine exerts agonism preferentially via iJ- receptors in the 
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myenteric plexus. It is not clear from these studies however, the reason 
behind this. It can be suggested that perhaps this strain of guinea pig are 
exhibiting an abnormally high level of 11 receptors, or a lack of a population 
of K receptors sensitive to ethylketocyclazocine agonism. It is possible that 
this is merely a result of naloxone being /.!-preferring and 
ethylketocyclazocine being only two fold selective for the 1C receptor [54,55], 
hence the competition at 11 receptors is exposed this not necessarily being a 
true representation of the ethylketocyclazocine activity. The original 
investigations into the receptor selectivity of nor-BNI afforded Ke values 
against morphine (11), U50 488 (K) and ethylketocyclazocine of 12nM, 
0.16nM and 0.41nM respectively [25]. Therefore against this highly K-
selective antagonist, ethylketocyclazocine affords an affinity constant at 
the outer limits of selective 1C receptor interactions, therefore implying that 
it possesses the capacity to compete at both 11 and K receptors but is 
relatively unselective and that its interactions reflects the selectivity of the 
/ 
antagonist rather than its own. 
In the mouse vas deferens, a tissue endowed with /.!, 8 and 1C receptors, the 
affinity of HS332 has been shown to be similar at 8 sitesys-Jor'K sites 
[248], whereas the affinity for the /.! receptor is nearly 50 fold higher, with a 
Ke of 5.6nM. The antagonism of ethylketocyclazocine by HS332 is 
therefore unlikely to be occurring via the 11 receptors in the vasa deferentia. 
Although the affinity is significantly weaker for this site, similar to that 
observed in the guinea pig myenteric plexus for the antagonism of 
tifluadom, it is possible that this still reflects a K receptor interaction, 
however 8 receptor antagonism cannot be ruled out since HS332 affinity for 
both K and 8 receptors is similar. Once again however, this raises the 
possibility of K receptor subtypes for which these two, less selective 
agonists have less affinity compared to that of the newer CI977 and 
U69593. Ethylketocyclazocine has been shown to possess a weaker 
affinity for the hypothesised K3 subtype [74] but there has been no further 
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support for this suggestion. 
In contrast, antagonism of ethylketocyclazocine by HS341 in the mouse 
vas deferens affords a Ke closer to that for J.! interactions rather than K or o 
values, again supporting the idea of J.! receptor agonism by 
ethylketocyclazocine in a different tissue preparation. However, the Ke 
value is slightly higher than the Ke value determined against the J.! selective 
DAMGO therefore may represent a mixture of actions. This differs from 
previous investigations which did not show any discrimination between the 
antagonism at the ethylketocyclazocine sites by HS341 in mouse vas 
deferens compared to that in the guinea pig myenteric plexus, although they 
observed such differences with HS332 [248]. This was proposed by the 
authors to result from ethylketocyclazocine acting at a combination of 
receptor sites. 
Each of the five antagonists displayed highest affinity for the J.! receptor. 
The equilibrium constant ofHS332 at the K receptor was similar to that at 
the o receptor, both affording Ke values of approximately 350nM .. HS341 
displayed a similar profile. Contrastingly, a quite different antagonist profile 
was seen with HS357. The affinity ofHS357 for the K receptor was similar·j 
to that of HS332 and HS341, but the ability of HS357 to antagonise the 
elec~ally-induced contractions of mouse vas deferens at o and J.! receptors 
was considerably less, with Ke values of 8922nM and 94nM respectively. 
Similar findings at J.! and K were seen with HS365 but a negligible affinity for 
the o receptor, at which a Ke value was outwith 10 J.!M. In contrast, HS367 
had higher affinity at the K receptor at which an equilibrium constant of 
4.7nM was determined similar to the Ke of 4.6nM observed at the J.! 
receptor, though weak at the o receptor with a Ke of2272nM. 
When the affinities for each receptor in turn are examined, it can be seen 
that the at the K receptor, characterised with CI977, the order of affinity is 
HS367 »HS365 > HS341 = HS357 > HS332. However, with the exception 
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of HS367, the other four antagonists exhibit generally similar affinities, in 
the range of 200-300nM. By examination of the structural differences 
between these compounds, it can therefore be professed that replacing the X 7./ 
~
cyclopropylmethyl group in HS332 to the non cyclic structure, -CH2-
CH=CH2 affording HS367, enhances the affinity of the compound 80 fold at 
the 1C receptor. This contrasts with naloxone and naltrexone which afford 
similar affinities for 1C receptors [264]. No significant enhancement in the 
potency was observed by the conversion of the 14-methoxy to an -ethoxy 
residue, and likewise little effect was observed by the replacement of this 
group with -OH. Extension of the 4-methox.y carbon chain in HS332 by 
three carbons, affording HS365, did however double the affinity at the 1C 
receptor. 
Comparison of the affinities of the 14-alkoxymorphinans at the 8 receptor, 
characterised with DPDPE, produced a much different picture, the order of 
potency in this case being HS341 > HS332 »>HS367 >> HS357 > HS365, 
ranging from 100-10 OOOnM. Re-examination of the chemical structures of 
these antagonists shows that the conversion of the 14-methoxy to a 14-
ethoxy doubles affinity for the 8 receptor. The removal of a carbon from 
this position however, produces a 28 fold decrease in the receptor affinity, 
suggesting the necessity of a carbon chain at this position. Furthermore, 
the replacement of the cyclopropylmethyl group in HS332 with the -CH2-
CH=CH2 in HS367, afforded a 7 fold reduction in affinity for the 8 receptor. 
Increasing the size of the group in the 4 position, i.e. substituting the 
methoxy group on the A ring with 4-butoxy, abolished all affinity for the 8 
receptor, as evidenced by HS365 suggesting steric constraint in this 
position. 
The order of affinity for the 11 receptor was HS341 > HS367 = HS332 > 
HS365 >>HS357, ranging from 2.9-94nM. Analysis of these observations, 
by the consideration of their chemical structures, shows that the 
replacement of the cyclopropylmethyl group with -CH2-CH=CH2 has no 
effect at all on J.l receptor affinity, therefore this portion of the molecule is 
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probably not a determining group in the binding to the Jl site. However, 
alteration of the group in the 14 position does alter the affinity of the 
receptor for these compounds. Addition of one more carbon atom to the 
methyl in this position, affords a slight increase in the affinity, as evidenced 
with HS341, however the removal of the methyl, leaving a hydroxyl residue 
in this position affords a 20 fold reduction in affinity. This suggests that 
either function in position 14 plays an important role in Jl receptor affinity 
for these analogues and that an extended residue may be more favoured. 
Replacement of the 4-methoxy with a butoxy group was also accompanied 
by a reduction in the Jl affinity, and taking into account the size of this side 
chain it can be hypothesised that this conversion again affords a reduction 
in the binding by the bulkiness of the substitution occluding the molecule 
from the binding site, though not to the same extent as the 8 receptor 
affinity. 
Overall therefore, in the mouse vas deferens, the affinity of these analogues 
for the K site is considerably enhanced by the substitution of the N-
cyclopropylmethyl, with N-allyl. This however reduces 8 binding, but has no 
effect on Jl binding. Extension of the carbon chain at the 14 position 
enhances 8 and 11 binding, but has little effect on K receptor affinity, whereas 
removal of carbon from this position significantly reduces 8 and Jl receptor 
affinity, having no affect on K binding (Figure 3.09). 
Important 
constraint here 
at the o receptor 
Constituent in this position 
controls K affinity, with 
some control of o effects 
o and Jl receptor requires carbon 
0 in this position 
Figure 3.09 Showing the major modifications in the 14-alkoxymorphinans 
and the consequence for the affinity and/or selectivity in the mouse vas 
deferens. 
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Figure 3.10 Showing correlation graphs oflog Ke against log Ki, for values 
determined in mouse vas deferens and guinea pig brain at (a) o receptors, 
(b) K receptors, and (c) Jl receptors. 
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3.432 Comparison of the Affinities of 14-Al/wxymorphinans in Different 
Tissues 
The affinities of antagonists determined in binding assays should be close to 
affinity from functional bioassays [265]. Discrepancies between the 
receptor affinities for the series of 14-alkoxymorphinans in guinea pig brain 
and mouse vas deferens were however observed (Figure 3.10). 
Comparison of the Ki and Ke values (Figure 3.10) shows correlation only 
between the brain homogenate and the mouse vas deferens at the 11 
receptor. At the K receptor, Ke values determined in the mouse vas 
deferens show far lower affinities for the K site compared to the 
corresponding Ki values determined in the guinea pig brain. For example, 
examination of the structure activity relationships of these compounds 
showed that in the mouse vas deferens, the presence of a -CH2-CH=CH2 
group, as opposed to a cyclopropylmethyl group attached to the nitrogen 
increased the K receptor affinity by approximately 80 fold, whereas in the 
guinea pig brain a 6 fold reduction was observed by this conversion. An 
extension in the carbon chain length at the 4-alkoxy position, also resulted 
in a significant increase in affinity in the vasa deferentia, whereas in the 
guinea pig brain a 3 fold reduction in the affinity was seen. 
It may therefore be hypothesised that [3H]U69593 is binding to a different 
site in the brain compared to that characterised with CI977 in the mouse 
vas deferens and hence such discrepancies result. As discussed above, 
recent studies with U69593 have shown an increased sensitivity to 
quadazocine antagonism [262] in the mouse vas deferens, compared to the 
guinea pig myenteric plexus. It can therefore be hypothesised that the 
higher affinity of these 14-alkoxymorphinans for [3H]U69593 sites in the 
guinea pig brain, as opposed to the lesser affinity for the CI977 I U69593 
sites in the mouse vas deferens, reflects a difference in the K receptor 
populations between the two tissues, which can be distinguished by these 
antagonists. The 3 fold potentiation in the HS341 antagonism seen in the 
guinea pig myenteric plexus when studying the inhibition of U69593 
activity as opposed to that ofCI977, may also indicate heterogeneity. 
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Marked differences were also seen in the 8 receptor affinities of the HS 
compounds. Thus there is a lack of affinity for the 8 receptor in the mouse 
vas deferens, compared to that in the guinea pig brain. This can also be 
proposed to result from different populations ofreceptors in the two tissues. 
A recent report in the literature [266] has suggested the existence of a 
single o receptor subtype in mouse vas deferens. Use of the selective 
antagonists 7-benzylidenenaltrexone (BNTX) and 5' -naltrindole 
isothiocyanate for 81 and 82 respectively, indicated evidence for mouse vas 
deferens consisting of a uniquely 82 population of sites. If the presence of 
subtypes is accepted, then the new HS alkoxymorphinan antagonists are 
distinguishing 8 subtypes, since their affinity for the mouse vas deferens 
DPDPE sites is much less than that for the guinea pig brain DPDPE sites. 
Furthermore if claims of a o2 receptor population in the mouse vas deferens 
are accepted, the 14-alkoxymorphinans demonstrate selectivity for a o1 
receptor population, as exemplified in the brain. 
Variations in the antagonist affinities between the brain and the vas 
deferens were also observed in earlier studies [248] with a similar group of 
analogues which was explained at the time to result from the differences 
created by the use of different buffer systems in the two assays. The 
induction of an artificially increased level of high affinity sites by the Tris 
buffer, was thought to produce such inctiscrepancies [267]. However, this 
would not be the case if the compounds are pure antagonists since they 
should recognize receptors in both the G protein-coupled and uncoupled 
states equally well. This could suggest that the compounds act as agonists 
in the brain, this property being absent in the vas deferens. Thus the 
analyses in isolated tissues would afford the affinity data for receptors in 
low affinity states, lying to the right of the affinity as measured in low ionic 
strength buffers in which highly coupled receptors are present. This would 
be the case for all compounds at the o and K receptors, except possibly the 
N-allyl derivative, similar to other compounds with N-cyclopropylmethyl 
groups such as diprenorphine and ethylketocyclazocine which are known to 
have partial agonism. However using this arg~efuent, all these 14-
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alkoxymorphinans are therefore antagonists at the ll receptor since the 
isolated tissue Ke values con·elate with the radioligand binding Ki values. 
Whatever the explanation, it therefore cannot be ruled out that the 
comparison of the results obtained from studies in the brain and the isolated 
tissues could provide models for the demonstration of both K and 8 
heterogeneity. 
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3.44 Conclusions 
A novel series of 14-alkoxymorphinans have been examined in a variety of 
tissues known to possess opioid receptors, namely the guinea pig brain, 
guinea pig myenteric plexus and the mouse vas deferens. 
No agonism was observed with any of these compounds in the mouse vas 
deferens or the guinea pig myenteric plexus, examined up to 10J.1M. 
Differences in the antagonism of a selection of K receptor agonists was 
observed between the two isolated tissue preparations suggesting the 
occurence of different receptor populations. Simil~r profiles were 
determined for the antagonism of the J.l receptor in the mouse vas deferens 
and guinea pig brain homogenates, but significant differences in the 
affinities of the selected 14-alkoxymorphinans for the K and o sites were 
noted, which may indicate heterogeneity. Furthermore, 
ethylketocyclazocine demonstrated an apparent agonism via J.l receptors in 
the myenteric plexus from the guinea pig in this study, agreeing with recent 
reports [263]. 
The results demonstrate that the structural requirements for antagonism 
at each of the opioid receptors varies considerably. More importantly to the 
present investigations, the affinity for various receptor populations varies 
between both tissues and species. These compounds therefore provide 
evidence in support of the possible existence of receptor subtypes or at 
least variable receptor populations in different tissues. Furthermore, the 
utilisation of different tissue preparations to investigate such receptor 
subpopulations allows a further insight into opioid receptor multiplicity. 
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AN INVESTIGATION OF SOME ENDOGENOUS K OPIOID 
PEPTIDES 
Chapter Four 
4.0 Introduction 
There have been several reports which suggest that the dynorphin peptides 
interact with 1C opioid receptors, and that this series ofpeptides may be the 
endogenous ligands involved in JC receptor activation [ 18,19,37]. The 
properties of the endogenous dynorphin family are not completely 
understood, although it has been suggested that the larger members display 
JC selectivity, with a proposed cross-over point to~~~ selectivity between the 
smaller dynorphin 1-6 and dynorphin 1-7 [38,47]. Dynorphin 1-8 has been 
considered to possess some selectivity for the 1C receptor. Additionally, the 
conversion of dynorphin 1-8 into [Leu5]enkephalin, a highly potent peptide 
possessing ll and 11 activity, has been hypothesised as one of its biological 
roles [110,261]. The production of this enkephalin is therefore of interest in 
any investigation of the endogenous role of the dynorphin peptides. 
Characterisation of the specificity and actions of dynorphin 1-8 has proved 
inconclusive in the past. At concentrations required to saturate 1C binding, 
dynorphin 1-8 does not exhibit K selectivity therefore Jl and 11 binding needs 
to be suppressed [38,268,269]. The classic opioid antagonist naloxone has 
slightly weaker interactions, but similar affinities with 1C and 11 receptors, · 
compared to its affinity for the Jl receptor [270], this therefore also reducing 
the extent of the understanding of 1C receptor properties [44]. In addition, 
the incomplete stabilisation of dynorphin peptides in several biological 
systems has hindered characterisation [268,269]. Reducing the 
temperature, in an attempt to reduce protease activity, also reduces total 
binding, possibly as a result of modification of the peptide conformation 
itself[268]. 
Previous reports, such as that of Chavkin and Goldstein [ 4 7] describes the 
selectivity of the small dynorphin peptides in guinea pig myenteric plexus, 
though the stability of the peptide is not considered. Corbett and coworkers 
[38] have published the most fundamental summary to date. In this work, 
a series of dynorphin peptides were studied for their ability to inhibit the 
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contractions of four isolated tissue preparations in the presence of a 
cocktail of protease inhibitors. Furthermore, the binding properties of these 
peptides was determined in guinea pig brain. 
In an attempt to further these studies, the receptor selectivity of dynorphin 
1-8 in guinea pig brain homogenates using highly selective ligands, which 
were not available at the time of these original investigations, has been 
determined. Assays were performed at 25°C in the absence and presence of 
peptidase inhibitor cocktail (100j.J.M captopril, 30j.J.M bestatin and 0.3j.J.M 
thiorphan), plus the further addition of 0.3j.J.M of the endopeptidase 
E.C.3.4.24.15. inhibitor, cFP-AAF-pAB, (cFP-AAF-ABz, N-[1(R,S)-carboxy-
3-phenylpropyl]-Ala-Ala-Phe-p-aminobenzoate), and at 0°C in an attempt 
to increase peptide stability [268,269,271]. 
4.1 Receptor Selectivity of Dynorphin 1-8 in Guinea Pig Brain 
Homogenates 
4.11 Equilibrium Binding of Selective Opioid Receptor Radioligands 
The equilibrium binding of [3H]DAMGO and [3H]DPDPE was examined at 
0°C in homogenates of guinea pig brain. Equilibrium was reached a little 
faster for [3H]DPDPE than for [3H]DAMGO, with the equilibrium time of 
[3H]DAMGO (2.28nM) being 175 minutes and that of [3H]DPDPE (0.80nM) 
being 220 minutes (Figure 4.01) however the specific binding of [3H]DPDPE 
was much lower than [3H]DAMGO. Binding of [3H]CI977 at 0°C has been 
discussed in the previous chapter, and reaches equilibrium after 
approximately 180 minutes. 
The binding of these ligands has previously been characterised at 25°C in 
this laboratory along with that of [3H]U69593 [248]. At this temperature, 
equilibrium was reached within 30 minutes in all cases. 
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Figure 4.01 S~wing representative plots of the total [ll, non specific li:J] and 
specific binding [•] at 0°C in guinea pig brain homogenates against time for 
(a) [3H]DAMGO (2.28nM) , and 
(b) [3H]DPDPE (0.8nM). 
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4.12 Radioligand Displacement Studies by Dynorphin 1-8 in Guinea Pig 
Brain Homogenates 
--Displacement studies of the a selective, 11 selective and the 11: selective 
radioligands by dynorphin 1-8 were performed in homogenates of guinea pig 
brain (prepared after the removal of the cerebellum) at 25°C and at 0°C. 
The aim of these experiments was to determine the affinity of this 
prodynorphin derived peptide for each opioid receptor site. Results are 
shown in Table 4.01. The equilibrium inhibition constants, ie Ki values, 
were derived using the Cheng-Prusoff equation [241]. 
At 25°C, dynorphin 1-8 displaced the a opioid receptor ligand [3H]DPDPE 
(0.88-1.1lnM), affording a Ki of 4.59nM, and a slope of unity, indicating that 
the two ligands are recognizing one population of sites only. A significant 
increase in the potency of the peptide was observed following preincubation 
of the homogenate with the inhibitor cocktail (captopril 100J.!.M, bestatin 
30J.!.M and thiorphan 0.3J.!.M), affording an inhibition constant of2.23nM. No 
further significant change was seen on the additional inclusion of 0.3J.!.M of 
the E.C.3.4.24.15. inhibitor cFP-AAF-pAB with the inhibitor cocktail. In 
both cases, slopes of unity were observed. The displacement of [3H]DPDPE 
by dynorphin 1-8 at ooc was not significantly different from any of the 
incubations at 25°C, with a Ki of2.48nM and a slope of 1.0. 
The displacement of the 11 selective [3H]DAMGO (1.37-1.93nM) by the 
endogenous opioid peptide dynorphin 1-8, afforded a Ki of 18.07nM with a 
slope of 0.88. A significant enhancement of the affinity of dynorphin 1-8 as 
illustrated by an inhibition constant of 4.40nM, was obtained following the 
inclusion of and preincubation with the inhibitor cocktail. Likewise the 
preincubation of the homogenate with the inhibitor cocktail plus 0.3J.!.M of 
cFP-AAF-pAB gave a further significant increase in the affinity (Ki of 
1.64nM). In both experiments with peptidase inhibition, the slope was not 
significantly different to unity. 
Four hour incubations at 0°C produced an inhibition constant of 2.91nM for 
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the displacement of[3H]DAMGO by dynorphin 1-8, accompanied by a slope 
of unity. This inhibition constant was significantly different to that 
determined at 25°C in the absence of inhibitors, but is similar to the Ki 
obtained in the presence of the peptidase inhibitor cocktail. 
The displacement of the K selective [3H]U69593 (1.60-2.36nM) by 
dynorphin 1-8 in guinea pig brain homogenates at 25°C produced an 
inhibition constant, Ki, of 40.09nM and a slope of 0.85. When repeated in 
the presence of the inhibitor cocktail the affinity was significantly 
enhanced, affording a Ki of 1.74nM, and a slope of unity was obtained. No 
significant potentiation of the dynorphin 1-8 was observed by the further 
addition of0.3l!M of the E.C.3.4.24.15. inhibitor to the inhibitor cocktail. 
Previous investigations in this laboratory have implicated a very poor 
binding capacity of [3H]U69593 at ooc [248], therefore for studies at this 
temperature [3H]CI977 was used. In the absence of the inhibitor cocktail, 
displacement of[3H]CI977 (1.56-1.91nM) by dynorphin 1-8 afforded a Ki of 
1.94nM with a slope of 0.85. No significant change was detected by the 
inclusion of the inhibitor cocktail. 
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Radio ligand Ki(nM) Slope n Incubation 
[3HJDPDPE 4.59±0.73 0.99±0.01 3 25°C 
[3HJDPDPE with 
inhibitor cocktail 2.23±0.42* 0.97±0.01 4 25°C 
[3HJDPDPE with inhibitor cocktail 
~nd 0.31lM cFP-AAF-pAB 1.21±0.07* 0.96±0.01 4 25°C 
[3HJDPDPE 2.48±0.64 0.96±0.02 3 0°C 
[3HJDAMGO 18.07±3.77 0.88±0.01 3 25°C 
[3HJDAMGO with 
inhibitor cocktail 4.40±1.03* 0.98±0.03 5 25°C 
[3HJDAMGO with inhibitor cocktail 
and 0.31lM cFP-AAF-pAB 1.64±0.32** 0.98±0.01 3 25°C 
[3HJDAMGO 2.91±0.60* 0.93±0.02 4 0°C 
[3HJU69593 40.09±8.98 0.85±0.02 4 25°C 
[3HJU69593 with 
inhibitor cocktail 1. 74±0.40** 0.95±0.05 5 25°C 
[3HJU69593 with inhibitor cocktail 
. and 0.31lM cFP-AAF-pAB 0.52±0.16** 0.94±0.05 3 25°C 
[3HJCI977 2.04±0.32 0.85±0.08 3 0°C 
[3HJCI977 with 
inhibitor cocktail 4.13±0.97 0.86±0.11 3 0°C 
Table 4.01 Showing the inhibition constants (determined from Kd values 
from reference [272] for studies with [3H]DPDPE, [3H]DAMGO and 
[3H]U69593. [3H]CI977 Kd values were calculated in chapter three) 
determined for the dynorphin 1-8 displacement of various selective tritiated 
ligands in guinea pig brain homogenates. lncubations at 25°C and at 0°C 
were for 30 and 240 minutes respectively. 
* and ** indicate a significant difference from the Ki determined with the 
same radioligand at 25°C in Tris/HCl buffer with a confidence limit p < 0.05 
and p < 0.005 respectively. 
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4.13 Discussion 
The results indicate that at 25°C in Tris/HCl buffer (pH 7.4), dynorphin 1-8 
expressed its highest affinity for the o receptor followed by the ~ sites at 
which its affinity was 3 fold less, as indicated by the appropriate Ki values 
of 5nM (o) to 18nM (~). The K receptor affinity of dynorphin 1-8 was much 
less affording a Ki of 40nM under the same incubation conditions. Such 
findings agree with the previous observations [38] which showed that 
dynorphin 1-8 was capable of competing at all three receptor types but 
suggests this endogenous peptide of the "K preferring" dynorphin family has 
its lowest affinity for the K receptor. 
The presence of the inhibitor cocktail, consisting of 100~M captopril, 30~M 
bestatin and 0.3~M thiorphan, significantly potentiated the affinity at each 
receptor (p < 0.05, Students t-test). This suggests that dynorphin 1-8 was 
being stabilised to some degree, the enhancement in the affinity being 2 fold 
at the o receptor site, 4 fold at the ~ site whereas enhancement at K opioid 
receptors was 25 fold. The inhibition constants were very similar at the 
three receptors under these conditions ranging from 1.74nM at the 1C 
receptor to 4.40nM at the ~ sites. A similar effect was recorded by the 
-----preincubation of the homogenate with the cocktail plus 0.3~M of the 
E.C.3.4.24.15. inhibitor, cFP-AAF-pAB, however the affinity was again 
significantly increased at each receptor site, when compared to that with 
the cocktail alone. The increase in the affinity for each receptor resulting 
from the inclusion of these four inhibitors compared to that in their absence 
is 4 fold at the o receptor, 11 fold for the ~ receptor but 77 fold at the 1C 
receptor. 
These results confirm the high instability of dynorphin 1-8 in crude brain 
homogenates [38,65,268,273]. The inclusion of selective inhibitors of 
peptidases, previously shown to hydrolyse this octapeptide, can potentiate 
its affinity for receptors, most probably as a consequence of peptide 
stabilisation [38]. However, the degree of this stabilisation is not 
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determinable; by these studies. Furthermore, the proposed selectivity of 
-------
dynorphin 1-8 for the 1C receptor [47,274] is not evidenced in this tissue 
preparation, although as shown above, when stabilised the affinity for the 1C 
receptors is most enhanced compared to the changes in activity at J.l and a 
receptors. 
The competitive displacement of the selective radioligands by dynorphin 1-8 
was also performed at 0°C to investigate the possible stabilisation of the 
peptide by a reduction in the peptidase activity. The inhibition constants 
determined from these displacements were not significantly different to 
those obtained at 25°C in the presence of the inhibitor cocktail which 
suggests that dynorphin 1-8 is being offered a similar degree of protection 
by lowering the temperature. However, under these conditions, the peptide 
exhibited no selectivity between the three opioid receptor populations, the 
Ki values being determined at approximately 2nM in each case. Again 
though, when compared to affinities at 25°C in the absence of any inhibitors 
the greatest increase in affinity following the stabilisation offered by the 
reduction in temperature was at the 1C receptor. 
These results at 0°C are similar to the observations made by Corbett et al 
[38] who reported the displacement ofradioligands by dynorphin 1-8. They 
observed Ki values at each of the receptors between 1.34-4.99nM in the 
order 1C > J.1 > a receptor affinity. This suggests that there are no real 
discrepancies between the two sets of data, and slight variations can 
possibly be attributed to the use of selective ligands in this study whereas 
Corbett and eo-workers used [3H]bremazocine to characterise the 1C 
receptor after J.l and a suppression, and [3H]DADLE to label the a sites. It 
can therefore be reasoned that the slight differences observed between 
these two investigations merely result from the use of different ligands, 
rather than the identification of different selectivity profiles. 
In conclusion, dynorphin 1-8 is capable of displacing highly selective 
radioligands from each of the opioid receptors with relatively high potency 
at 25°C. This can be enhanced by the inclusion of peptidase inhibitors or by 
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the reduction of the incubation temperature to 0°C, which can be 
postulated to result from a degree of stabilisation of the peptide. However 
no selectivity for K sites was seen although following stabilisation, the 
improvement in affinity at the K sites was much greater. 
4.2 Isolated Tissue Bioassays 
4.21 Introduction 
Dynorphin 1-8 has been proposed as an endogenous ligand for the K 
receptor [47,274], but the extent of its selectivity at the receptor has never 
been fully established. The results from the radioligand displacement 
assays indicate that dynorphin 1-8 has the potential to compete at the K 
receptor with relatively high affinity. However, the octapeptide did not 
appear to bind with any degree of selectively for the K receptors in 
preference over Jl and o receptor sites. Opioids have been shown to inhibit 
the longitudinal muscle contractions produced by the electrically induced 
release of noradrenaline in the mouse vas deferens [275,276,277], whereas 
in guinea pig myenteric plexus, the muscle preparation contracts as a 
response to acetylcholine release [278,279]. Isolated tissue bioassays were 
therefore proposed as a method to further clarify these observations. 
Schild analysis was performed with three antagonists, two of relatively poor 
selectivity (naloxone and HS341) and one of high K selectivity (nor-BNI). 
4.22 Determination of Naloxone Antagonist Equilibrium Constants (Ke) in 
Mouse Vas Deferens 
The ability of naloxone to inhibit the depression of the electrically induced 
contractions produced by several opioids in mouse vasa deferentia was 
investigated and results are shown in Tables 4.02 and 4.03. 
The o selective agonist DPDPE, and the Jl selective DAMGO afforded !Cso 
values of 2.90nM and 31.10nM respectively. The naloxone antagonism of 
these ligands afforded an equilibrium constant at the 
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o receptor of 15.48nM and at the 1.1 receptor of 2. 71nM. Schild plot slopes of 
unity were obtained in each case. 
The selective 1C agonist U69593 expressed an IC50 of 30.02nM, with a 
naloxone Ke of 14.88nM (Table 4.02) being calculated from its antagonism 
as illustrated in Figure 4.03. This Ke value has been shown previously to 
reflect interactions of the antagonist with 1C receptors [17]. Similarly, a 
naloxone Ke of 11.28nM was calculated from the antagonism of the highly 
stable, 1C receptor preferring peptide dynorphin 1-13, which afforded an IC5o L 
ofl6nM in these tissues (Figure 4.04). This contrasted with dynorphin 1-8, 
which produced an IC5o of 32.70nM and a naloxone Ke of 4.23nM, (Figure 
4.05). The Schild plot slopes for both were unity. 
The effect of tissue preincubation with the inhibitor cocktail, consisting of 
bestatin 301.1M, tbiorphan 0.31.1M and captopril 301.1M, was examined with 
the stable o and 1.1 ligands. In treated tissues, the IC5o value for DPDPE 
was not significantly different to that determined prior to the addition of the 
cocktail, being 3.31nM and 2.91nM respectively. Furthermore, the 
naloxone equilibrium constant was unchanged by the inclusion of the 
cocktail, being determined as 16.24nM. Studies with DAMGO afforded an 
ICso of 44.70nM1 in tissues preincubated with the inhibitor cocktail similar 
to that of 40.20nM1 in its absence. Likewise there was no alteration in the 
naloxone Ke value being 1.94nM in the presence of the inhibitor cocktail. 
Additionally, the IO>o of the unstable [Leu5]enkephalin, in the absence of 
any inhibitors, was determined as 14.20nM, this being potentiated by the 
presence of the inhibitor cocktail to 2.50nM (p< 0.005, Students t-test). 
The naloxone Ke value determined against [Leu5]enkephalin after peptidase 
inhibition was 23.30nM. 
' NB. In these cases, the ICso values differed from earlier experiments, 
resulting from the peptides being supplied by a different manufacturer. 
Examination of the peptides by HPLC confirmed the identity of the 
peptides, therefore it is suggested that such discrepancies result from 
inaccuracies in the levels of salt and H 20 in the samples. 
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The inhibition of the electrically induced contractions of mouse vas deferens 
by dynorphin 1-8, produced an ICso in the absence of inhibitors of 116.0nMl 
(see footnote on previous page). When the tissue was preincubated with 
the inhibitor cocktail for 30 minutes prior to and during the dose-response 
determination, a significant increase in the potency of dynorphin 1-8 was 
observed (p< 0.005, Students t-test), affording an ICso of 41.20nM (Figure 
4.02). Moreover, a significant reduction in the affinity (p<0.005) of naloxone 
was observed, illustrated in the Ke value being converted from 4.23nM to 
14.64nM, as illustrated in Figure 4.06. 
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Agonist ICso{nM) naloxone Ke (nM) Schild slope n 
U69593 30.02±7.37 14.88±2.95 0.96±0.02 4 
DPDPE 2.90±0.27 15.48±3.36 0.97±0.01 6 
DAM GO 31.10±5.00 2.71±0.38 0.96±0.01 4 
Dynorphin 1-8 32.70±2.12 4.23±0.62 0.99±0.01 7 
Dynorphin 1-13 16.03±4.24 11.28±3.10 0.96±0.02 7 
Table 4.02 (Showing)Ieso and naloxone Ke values for various agonists in the inhibition of the electrically induced 
contractions of mouse vas deferens determined from dose-response data. 
,... n =number of experimental observations (..:> 
... 
Agonist (a) ICso (nM) (b) ICso (nM) (b) naloxone Ke (nM) n 
DPDPE 2.91±0.34 3.31±0.41 16.24±1.90 4 
DAM GO 40.20±4.41 44.70±7.90 1.94±0.32* 5 
Dynorphin 1-8 116.00±13.10 41.20±7.80 14.64±2.15 16 
[Leu5]enkephalin 14.20±3.60 2.50±0.10 23.30±1.60 4 
Table 4.03 Showing ICso and naloxone Ke values (determined by the single dose analysis method using 100nM 
naloxone, except* which used 30nM) for various agonists (a) in the absence and (b) in the presence of the inhibitor 
cocktail (preincubated for 30 minutes), for the inhibition of the electrically induced contractions of mouse vas 
deferens determined from dose-response data. 
The inhibitor cocktail consisted ofbestatin 30~M. captopril 30~M and thiorphan 0.3~M. 
n = the number of experimental observations. 
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Figure 4.02 Showing traces of the inhibition of electrically induced 
contractions of mouse vas deferens by 
(a) dynorphin 1-8 (shown in nM), and 
(b) dynorphin 1-8 following a 30 minute preincubation of the tissue with the 
inhibitor cocktail (captopril30f!M, bestatin 30!-!M and thiorphan 0.3f!M). 
w.o. signifies wash out of peptide from the tissue by overflow. 
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Figure 4.03 (a) Sh~ng the dose-response curves of the inhibition of 
electrically induced contractions of mouse vas deferens by U69593 in the 
absence [ll] and presence of30nM [c], lOOnM [•] and 300nM [o] naloxone. 
Error bars represent SEM from 4 experimental observations. 
(b) A representative Schild plot for the above antagonism. 
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Figure 4.04 (a) Sh~ng the dose-response curves of the inhibition of 
electrically induced contractions of mouse vas deferens by dynorphin 1-13 
in the absence [•] and presence of 30nM [o], 100nM [e] and 300nM [o] 
naloxone. Error bars represent SEM from 7 experimental observations. 
(b) A representative Schild plot for the above antagonism. 
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Figure 4.05 (a) Sho~i£g the dose-response curves of the inhibition of 
electrically induced contractions of mouse vas deferens by dynorphin 1-8 in 
the absence [Ill] and presence of lOnM [o], 30nM [e] and 100nM [o] naloxone. 
Error bars represent SEM from 7 experimental observations. 
(b) A representative Schild plot for the above antagonism. 
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Figure 4.06 Showing dose-response curves of the inhibition of electrically 
induced contractions of mouse vas deferens in the presence [o) of the 
inhibitor cocktail (captopril 30)lM, bestatin 30)lM, thiorphan 0.3)lM), by 
dynorphin 1-8 plus single dose antagonism by 100nM [c) naloxone. 
Error bars represent SEM from 16 experimental observations. 
Also illustrated is a control in the absence of peptidase inhibition [•]. 
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4.23 Determination of Nor-BNI Antagonist Equilibrium Constants (Ke) in 
Mouse Vas Deferens 
The antagonism by the K selective nor-BNI on the depression of the 
electrically1nduced contractions produced by a series of opioids was 
investigated in the absence and presence of various enzyme inhibitors. 
Results are shown in Tables 4.04 and 4.05. 
The K selective U69593, o selective DPDPE and ll selective DAMGO had 
potencies (ICso) of 91.21nM, 2.90nM and 31.10nM respectively. 
Antagonism by nor-BNI afforded equilibrium constants of 0.06nM at the K 
receptor, at the o receptor of 17.03nM and at the ll receptor 9.10nM 
(\ 
against the three afore mentioned ligands, thus confirming the K selectivity 
ofnor-BNL In all cases slopes ofSchild plots were unity. 
The inhibition of contractions in mouse vas deferens by dynorphin 1-13 
gave an ICso of 49.18nM, with antagonism of this peptide by nor-BNI 
producing a Ke of 0.02nM, in line with its antagonism of U69593. In the 
same way, the ICso for dynorphin 1-8 was 116.00nM and a nor-BNI Ke of 
0.05nM was observed, as shown in Figure 4.07. Dynorphin 1-6 was far less 
potent, demonstrated in its ICso of 1919.4nM with a nor-BNI Ke of 0.50nM 
being calculated from the antagonism of this peptide. 
Various combinations of inhibitors were added 30 minutes prior to the 
agonist dose-response analysis and nor-BNI Ke values were calculated. In 
the presence of the inhibitor cocktail (captopril 30!lM, bestatin 30!lM and 
thiorphan 0.3!lM), the potency was similar and the receptor selectivity of 
U69593 was unaltered, the ICso being determined as 212.0nM, and likewise 
the nor-BNI Ke was calculated as 0.05nM. The potency of dynorphin 1-8 
was significantly increased (p<0.005) giving an ICso of 41.2nM, as shown in 
Table 4.05 with the nor-BNI equilibrium constant being significantly 
reduced to 17.20nM (p<0.005), shown in Figure 4.08. 
An increase in the affinity of the antagonist to give a Ke of 4.74nM was 
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observed on the addition of0.3J.1M of the E.C.3.4.24.15. inhibitor, cFP-AAF-
pAB with the cocktail, this value being significantly different to both the Ke 
determined in the absence and presence of the inhibitor cocktail (p< 0.005 
in both cases). No further change was observed however in the ICso, which 
was calculated as 66.30nM (Figure 4.08). A similar effect was observed by 
the addition of the mixed inhibitor kelatorphan (30J.1M) with the inhibitor 
cocktail, in place of cFP-AAF-pAB which afforded a nor-BNI Ke of 5.44nM. 
However, under these conditions, dynorphin 1-8 had an ICso of 8.0nM, this 
being a significant potentiation of the peptide (p< 0.005) from that of 
41.2nM in the presence of the cocktail, or from 66nM in the presence of the 
cocktail plus the selective inhibitor ofE.C.3.4.24.15 .. 
Dynorphin 1-6 was also examined for its efficacy in the mouse vas deferens. 
The ICso (78.3nM) reflected a pronounced potentiation of the peptide's 
ability to inhibit the electrically induced contractions of the mouse vas 
deferens following the inclusion of the inhibitor cocktail. Furthermore the 
affinity of the antagonist, nor-BNI, was reduced by the addition of the 
cocktail, with the equilibrium constant being converted from 0.5nM in its 
absence to 36.4nM with the peptidase inhibitors (Tables 4.04, 4.05). 
4.24 Determination of HS341 Antagonist Equilibrium Constants (Ke) in 
Mouse Vas Deferens 
The alkoxymorphinan HS341 has been characterised (see previous 
chapter) and has been shown to have affinities in the order of Jl (Ke 2.9nM) 
> li (Ke 106nM) > K (Ke 233nM). Results are shown in Table 4.06. 
An ICso of 13.1nM was calculated for dynorphin 1-8 in the absence of any 
peptidase inhibition which was significantly potentiated to 4.6nM after 
preincubation with the inhibitor cocktail (p< 0.05, Student t-test). The 
affinity of HS341 was also significantly increased (p< 0.005) by the 
presence of the peptidase inhibitors from 422.5nM in their absence to 
30.2nM (Figure 4.09). Further addition of 0.3JlM of the E.C.3.4.24.15. 
inhibitor, c-FP-AAF-pAB, alongside the cocktail did not however potentiate 
the dynorphin 1-8 reflected in the ICso of 4.7nM, and similarly no change 
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was observed in the affinity of HS341 against the peptide which was 
determined as 36nM under these conditions. Thus in the absence of 
inhibitors, dynorphin 1-8 appears to be acting via K receptors, and in the 
presence of inhibitors via a mixed receptor population. 
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Agonist ICso (nM) nor-BNI Ke (nM) Schild slope n 
U69593 91.21±18.41 0.06±0.02 0.99±0.01 6 
DPDPE 2.90±0.27 17.03±3.31 0.99±0.00 6 
DAM GO 31.10±5.00 9.10±1.70 0.96±0.02 5 
Dynorphin 1-8 116.00±13.10 0.05±0.01 0.94±0.02 5 
Dynorphin 1-13 49.18±12.90 0.02±0.01 0.99±0.01 4 
Dynorphin 1-6 1919.40±417 .90 0.50±0.09 S.D. 4 
Table 4.04 Sho~g ICso and nor-BNI Ke values for various agonists in the inhibition of the electrically induced 
contractions of mouse vas deferens determined from dose-response data. 
S.D. indicates the single dose method was used to calculate the Ke values, using l.OnM nor-BNI. 
n =number of experimental observations 
Agonist lC5o(nM) nor-BNI Ke (nM) [nor-BNI] nM n 
U69593 212.00±44.70 0.05±0.02 (l.OnM) 8 
Dynorphin 1-8 41.20±7.80 17 .20±3.40 (lOOnM) 6 
Dynorphin 1-8 plus 
0.3~M cFP-AAF-pAB 66.30±11.20 4.74±0.55 (lOnMl 8 
Dynorphin 1-8 plus 30~M kelatorphan 8.00±1.90 5.44±1.50 (lOnM) 4 
Dynorphin 1-6 78.30±8.80 36.38±6.03 (l.OnM) 4 
Table 4.05 Showing IC5o and nor-BNI Ke values (determined by the single antagonist dose method, with antagonist 
concentrations as shown) for various agonists for the inhibition of the el~ctrically induced contractions of mouse vas 
deferens,after preincubation of tissues with the inhibitor cocktail (bestatin 30~M,captopril 30J.!M and thiorphan 
0.3~M). Results were determined from dose- response data. 
n =the number of experimental observations. 
Ligand ICso (nM) Ke(nM) Schild plot slope n 
CI977 7.50±1.40 223.30±107.30 0.99±0.01 4 
DAM GO 10.91±1.66 2.92±0.48 S.D. 3 
DPDPE 3.01±0.08 106.3±8.6 S.D. 3 
Dynorphin 1-8 13.06±0.22* 422 .51±85 .23 0.99±0.01 3 
Dynorphin 1-8 plus 
the inhibitor cocktail 4.60±1.90* 30.20±3.50 S.D. 4 
Dynorphin 1-8 plus 
the inhibitor cocktail 
and 0.3J-lM cFP-AAF-pAB 4.70±0.70* 36.00±12. 70 S.D. 4 
Table 4.06 Showing ICso values and HS341 Ke values of various ligands in mouse vas deferens where n = the 
number of experimental observations. The inhibitor cocktail consisted of 30J.,lM bestatin, 30jlM captopril and 0.3J.,lM 
thiorphan, preincubated with the tissue for 30 minutes prior to the dose-response determination. 
S.D.= indicates the single dose method was used to determine Ke value. 
*signifies ICso values obtained from the same tissues, illustrating the potentiation of dynorphin 1-8 by the 
peptidase inhibitors 
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Figure 4.07 (a) Showing the dose-response curve of the inhibition of 
electrically induced contractions of mouse vas deferens by dynorphin 1-8 in 
the absence [1] and presence of 0.3nM [o], l.OnM [•] and 3.0nM [cl nor-BNI. 
Error bars represent SEM obtained from 5 experimental observations_ 
(b) A representative Schild plot for the above antagonism. 
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Figure 4.08 Showing the dose-response curve of the inhibition of electrically 
induced contractions of mouse vas deferens by dynorphin 1-8 in the 
presence [•J of the inhibitor cocktail (captopril 30!lM, bestatin 30!lM, 
thiorphan 0.3!lM) and (a) single dose antagonism by 100nM [o] nor-BNI, and 
(b) with the cocktail and 0.3!lM cFP-AAF-pAB [•], and single dose 
antagonism by lOnM nor-BNI [c ]. Error bars represent SEM obtained 
from 6 and 8 experimental observations for (a) and (b) respectively. 
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Figure 4.09 (a) Showing the dose-response curves for the inhibition of 
electrically induced contractions of mouse vas deferens by dynorphin 1-8 in 
the absence [•] and presence of 1000nM [o] , 3000nM [W] and 10 OOOnM [o] 
HS341. Error bars represent SEM obtained from 4 experimental 
observations. 
(b) a representative Schild plot for the above antagonism. 
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4.25 Determination of Naloxone Antagonist Equilibrium Constants (Ke) in 
Guinea Pig Myenteric Plexus 
[Leu5]enkephalin, [Met5]enkephalin, plus some of their carboxy terminal 
extended peptides, were examined for their ability to inhibit the electrically 
induced contractions of guinea pig myenteric plexus-longitudinal muscle. 
The absence of apparently functional li receptors in this tissue preparation 
allowed a direct investigation of the structural requirements for the 
activation: of K receptors in preference to the J..L receptor population. The 
results are illustrated in Tables 4.07 and 4.08. 
The prodynorphin-derived peptides, [Leu5]enkephalin and [Leu5]enkephalin-
Arrf', afforded ICso values of 464.8nM and 783.4nM and antagonism by 
naloxone afforded Ke values of 2.95nM and 4.27nM respectively, these 
being in the range known to reflect interactions at the J..L receptor sites [17]. 
The extended peptide [Leu5]enkephalin-Arrf'·Arg7 was however shown to be 
more potent in the inhibition of the electrically induced contractions of this 
tissue than the shorter analogues, with an ICso of 83.5nM. Additionally, the 
naloxone equilibrium constant was determined as 16.68nM, reflecting K 
receptor interactions [17]. Preincubation of this tissue preparation with 
the inhibitor cocktail significantly increased the potency of the 
heptapeptide (p< 0.005), affording an ICso of 3.03nM. Likewise, a 
significant increase (p< 0.005) in the affinity of the antagonist naloxone was 
reflected in the equilibrium constant of 6.83nM. This value is midway 
between the range thought to indicate J..l and K receptor interactions. 
Dynorphin 1-8 was the most potent agonist in this series of peptides 
examined, exhibiting an ICso of 38.35nM and antagonism afforded a 
naloxone Ke of 11.39nM, as shown in Figure 4.10. In all cases the Schild 
plot slope was unity. 
Three proenkephalin products containing [Met5]enkephalin as their carboxy 
terminus pentapeptide, were studied in the guinea pig myenteric plexus 
preparation (Table 4.08). [Met5]enkephalin itself produced an ICso of 
228.4nM and antagonism by naloxone affording a J..l like equilibrium 
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constant of 1.74nM. The two extended peptides, [Met5]enkephalin-Arg6-
Giy7-LeuB and [Met5]enkephalin-Arg6-Phe7, had similar potencies to 
[Met5]enkephalin itself, with ICso values being calculated as 174.4nM and 
405.2nM respectively. Furthermore, the naloxone Ke values determined 
against these agonists were also similar, being 2.17nM for 
[Met5]enkephalin-Arg6-Giy7-LeuB and 4.92nM for [Met5]enkephalin-Arg6-
Phe7, both of these being in the range associated with and illustrated by 
stable selective J.l agonists. 
When the tissues were preincubated with the inhibitor cocktail, the potency 
of both [Met5]enkephalin-Arg6-Giy7-LeuB and [Met5]enkephalin-Arg6-Phe7 
was significantly improved (p< 0.005), affording ICso values of 16.00nM and 
117 .4nM respectively. However, only in the studies with [Met5]enkephalin-
Arg6-Phe7 was there any change in the naloxone Ke by the inclusion of 
these peptidase inhibitors, under these conditions being determined as 
10. 70nM (p< 0.005). This value resembles antagonism at the 1C rather than 
the 1.1. receptor. In all cases Schild plot slopes were of unity. 
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Agonist ICso (nM) naloxone Ke (nM) Schild slope n 
[Leu5]enkephalin 464.85±77.56 2.95±0.41 1.00±0.01 6 
[Leu5]enkephalin-Arg6 783.42±153.68 4.27±0.68 0.99±0.01 8 
[Leu5]enkephalin-Arg6-Arg7 83.50±17.61 * 16.68±1.12** 0.98±0.02 6 
[Leu5]enkephalin-Arg6-Arg 7, 
with the inhibitor cocktail 3.03±0.58* 6.83±1.11** S.D. 6 
[Leu5]enkephalin-Arg6-Arg 7-nes 38.35±8.58 11.39±2.45 1.00±0.01 5 
Table 4.07 Showing ICso and naloxone Ke values for various prodynorphin derived pep tides on the inhibition of the 
electrically induced contractions of guinea pig myenteric plexus. In specified cases, experiments were assessed in 
the presence of the inhibitor cocktail (bestatin 30J1M,captopril30J1M and thiorphan 0.3J1M). 
S.D. indicates the single dose method was used to calculate the Ke values. 
n = the number of experimental observations. 
• and** are significantly different, determined by Students t-test with a confidence limit, p< 0.005 
.... ------------------------------------
Agonist ICso (nM) naloxone Ke (nM) Schild slope n 
[Met5]enkephalin 228.43±28.93 1.74±0.20 0.98±0.02 6 
[Met5]enkephalin-Arg6-Gly 7-Le uS 174.43±45.88* 2.17±0.43 0.97±0.02 5 
[Met5]enkephalin-Arg6-Gly7-Leu s 
with the inhibitor cocktail 16.00±4.89* 1.42±0.16 ~.D. (30nM naloxone) 3 
[Met5]enkephalin-Arg6-Phe 7 405.20±52.21 ** 4.92±0.50<*> 1.00±0.02 8 
[Met5]enkephalin-Arg6. Phe 7 
with the inhibitor cocktail 117.44±13.96 ** 10. 70±1.65<*> 1.00±0.01 6 
Table 4.08 Showing ICso and naloxone Ke values for the potency of various proenkephalin derived peptides on the 
inhibition of the electrically induced contractions of guinea pig myenteric plexus. In specified cases, experiments 
were assessed in the presence of the inhibitor cocktail (bestatin 30J.tM,captopril30J.tM and thiorphan 0.3JlM). 
S.D. indicates the single dose method was used to calculate the Ke values, with concentration used in brackets. 
n = the number of experimental observations. 
• , ** and <*>all represent values which are significantly different, determined by Students t-test with a confidence 
limit, p< 0.005 
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Figure 4.10 (a) Showing the dose-response curve of the inhibition of 
electrically induced contractions of guinea pig myenteric plexus longitudinal 
muscle by dynorphin 1-8 in the absence [•] and presence of lOOnM [Cl], 
300nM [ •] and lOOOnM [o] naloxone. Error bars represent SEM obtained 
from 5 experimental observations. 
(b) A representative Schild plot for the above antagonism. 
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4.3 Discussion 
In an attempt to clarify some of the biochemical binding data, the 
pharmacology of dynorphin 1-8 was examined in two isolated tissue 
preparations. The determination of antagonist equilibrium constants, the 
Ke values, obtained from the competition of different agonists with 
previously characterised antagonists, allows the identification of the 
participating receptor therefore the receptors involved in the inhibition of 
electrically induced contractions produced by dynorphin 1-8 should be 
identifiable. The use of various peptidase inhibitors, in an attempt to 
stabilise the peptide was investigated, with a view to the determination of 
the full potential of the peptide. 
r--\...--
In addition to this, a study of some related prodynorphin and proenkephalin 
peptides has been performed. It must be recalled at this point however, 
that studies in isolated tissues depend on the activation of a receptor, 
contrasting with investigations by displacement binding assays in which 
only the receptor's affinity for a ligand is determined with no measure of 
activation. Therefore, the results between these two assays need not 
njj!cessarily be comparable. 
The two most suitable peripheral tissues to observe the interactions of the 
selected opioid peptides with their preferred receptors, were the mouse vas 
deferens (containing 11. o and 1C sites [17,123]) and the guinea pig myenteric 
plexus (containing 11 and 1C receptors [18]). 
4.31 Naloxone Antagonism in the Mouse Vas Deferens 
Stable selective compounds were assayed to characterise the naloxone Ke 
values at each opioid receptor in the mouse vas deferens. The 1C selective 
U69593 and the o selective DPDPE both afforded naloxone Ke values of 
approximately 15nM, whereas the 11 selective DAMGO produced a naloxone 
Ke of 3nM. Additionally, the highly stable dynorphin 1-13 afforded a 
naloxone Ke of llnM and when stabilised with the inhibitor cocktail, 
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[Leu5]enkephalin gave a Ke of 23nM. All of these values were consistent 
with previously reported data for naloxone antagonism in similar bioassays 
[17]. 
A naloxone Ke of 4nM was determined from the antagonism of the 
dynorphin 1-8 depression of electrically induced contractions in the mouse 
vas deferens. This suggests that the antagonism is most probably 
occurring at the J.L receptor when the values obtained from the antagonism 
of the known selective ligands are considered. This deduction agrees with 
the data derived from the radioligand displacement assays suggesting that 
in these two tissues, the brain and the vas deferens, dynorphin 1-8 exhibits 
little affinity for the 11: receptor compared to other sites therefore 
contradicting its proposed 11: selectivity [. 18,47]. The Ke value however 
lies slightly outwith the region reflecting J.L antagonism, but the affinity does 
not correlate with that associated with 11: and 8 interactions. Such an 
equilibrium constant would normally indicate the antagonism to be effected 
at more than one receptor population, hence the combination of two Ke 
values. This however was not thought to be the case, since a Schild slope of 
unity was determined. This indicates that the peptide was only being 
antagonised at one site, therefore suggesting a lack of 11: opioid receptor 
participation in the effects of dynorphin 1-8. 
Tissue pretreatment with the inhibitor cocktail, consisting of 30J.LM 
bestatin, 30J.LM captopril and 0.3J.LM thiorphan, afforded a potentiation of 
dynorphin 1-8 which was reflected in an improved potency (ICso). 
Furthermore, naloxone antagonism now afforded an equilibrium constant of 
14.6nM, clearly within the range associated with !d8 interactions. This may 
therefore agree with the displacement studies which indicate that dynorphin 
1-8 binds preferentially at the 8 site in the absence of enzyme inhibitors. 
The potency and antagonism by naloxone of the stable ligands DPDPE and 
DAMGO with similarly treated tissues were unaffected by the presence of 
the inhibitors. These observations with dynorphin 1-8 therefore result from 
a stabilisation of the peptide and are not merely an arbitrary effect 
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produced in the presence of the inhibitors. Such increases in the potency of 
the peptide agree with McKnight et al [65] and Corbett and eo-workers [38]. 
Such observations however do not extend the characterisation of dynorphin 
1-8 much further than that obtained from the guinea pig brain 
displacement assays. If anything, these results confuse the issue further, 
therefore an alternative approach is necessary. Problems are created in 
receptor identification due to a lack of distinction by naloxone between the K 
and 8 receptors. Additionally the mouse vas deferens has been described by 
several authors [243,280] to possess a predominating 8 receptor population 
therefore complications arise when studying ligands of relative 
unselectivity. Such a domination may falsely exhibit a receptor affinity for ' 
ligands that do not possess high selectivity for one site only as a result of its 
overpowering presence. 
Thus, in the mouse vas deferens, a preference of dynorphin 1-8 for the Jl 
receptor is evidenced in the absence of the inhibitor cocktail with naloxone 
antagonism but for the K/8 receptors in the presence ofthe inhibitors. This 
contrasts with the reputed selectivity in guinea pig myenteric plexus 
[281,283] which demonstrates that dynorphin 1-8 acts at K receptors 
without peptidase inhibition, and mainly Jl interactions in the presence of 
the cocktail. 
More recently it has been claimed that different subtypes of K opioid 
receptors are expressed in guinea pig myenteric plexus as opposed to the 
mouse vas deferens [262]. Therefore it must be questioned whether the 
differencies observed are a result of the K receptor population in the guinea 
pig myenteric plexus having a much greater affinity for dynorphin 1-8 than 
the K population in the mouse vas deferens. However, the findings could be 
the result of a much lower K receptor reserve [243] in the mouse vas 
deferens than in the guinea pig myenteric plexus, therefore allowing 8 
interactions in the mouse vas deferens to occur. 
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In an attempt to rectifY these complications, antagonism of dynorphin 1-8 
was determined using the highly K selective nor-BNI. This allows an 
identification of any K receptor interactions by dynorphin 1-8 in the mouse 
vas deferens separate to those at the o receptor. 
4.32 Nor-BNI Antagonism in the Mouse vas Deferens 
Inhibition of the electrically induced contractions of the mouse vas deferens 
by highly potent selective agonists was antagonised by nor-BNI, affording 
equilibrium constants of 9.1nM at the J.l. receptor, 17.0nM at the o receptor 
and 0.06nM at the K sites. Thus exemplifYing the high K selectivity of nor-
BNI and confirming previous reports of a nor-BNI Ke value of 0.05nM 
against the selective U50488 in the mouse vas deferens [61]. These 
authors reported nor-BNI equilibrium constants at J.l. sites against DAMGO 
and at o sites competing with DPDPE of25nM and 15nM respectively [61]. 
In the present studies, a nor-BNI Ke value of 0.02nM was determined 
against dynorphin 1-13 receptor activation in the vasa deferentia, thus 
confirming the K selectivity of this peptide. The antagonism of dynorphin 1-
8 afforded a nor-BNI Ke value of 0.05nM and a Schild slope of unity, 
suggesting that dynorphin 1-8 is displaying selectivity for the 'K receptors in 
this tissue in contrast with the naloxone data (p 156) and shows the 
difficulty of using naloxone as an antagonist for the characterisation of the 
K receptor. One of the main aims of the present studies was to investigate 
the activity of dynorphin 1-8, and to determine whether its presence in 
biological systems was as an intermediate in the release of the potent 
[Leu5]enkephalin [110,261]. [Leu5]enkephalin has previously been shown 
to possess little affinity for the K receptor, with a Ki greater than 8000nM 
[38], therefore this is not the peptide antagonised by nor-BNI under these 
conditions. The result therefore suggests that dynorphin 1-8 can act 
selectively at K receptors, at least in the mouse vas deferens, supporting 
the view that dynorphin 1-8 is probably one of the smallest endogenous 
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ligands displaying a preference for the K receptor [47,282]. Furthermore, 
this is evidence against the view that perhaps its role is primarily as an 
intermediate in the production of [Leu5]enkephalin [110,261], rather than 
as an active compound itself. 
The inhibitor cocktail (captopril 30J.LM, bestatin 30J.LM and thiorphan 
0.3J.LM) was preincubated with mouse vasa deferentia and the nor-BNI Ke 
against dynorphin 1-8 determined as 17.2nM, this value lying within the 
range associated with J.L'o interactions. When U69593 was examined in the 
vas deferens following preincubation with the inhibitor cocktail, no change in 
the nor-BNI Ke value was observed against this agonist. Consequently, 
this change in the equilibrium constant determined against dynorphin 1-8 
results from the stabilisation effects of the peptidase inhibitors on the 
peptide and not as a direct result ofthe inhibitors on the tissue. 
When this observation is combined with the results obtained from the 
naloxone antagonism under the same conditions (which indicated an 
interaction at K or o receptors, but not at 11 receptors), it can be concluded 
that dynorphin 1-8 under these conditions is acting at the o receptor in this 
tissue. This is hardly surprising when the activities of the cocktail of 
enzyme inhibitors are analysed. The main cleavage points protected by the 
cocktail are Tyrl-Gly2, Gly3-Phe4 and Arrf'-Arg7 by bestatin, thiorphan and Y 
captopril respectively. The hydrolysis of the Leu5-Arg6 bond in dynorphin 1-
8 is however well documented [125,128,131,133,134]. No protection of this 
bond is offered by the inhibitor cocktail, therefore it can be hypothesised 
that the o receptor antagonism displayed by both naloxone and nor-BNI 
occurs by the antagonism of the product of hydrolysis at this point, namely 
[Leu5]enkephalin, and not by the antagonism of the added dynorphin 1-8 
itself. This is confirmed by the fact that dynorphin 1-8, when unprotected, 
acts preferentially at K receptors as evidenced by the nor-BNI Ke value. 
The most favoured opinion in the literature is that hydrolysis to afford 
[Leu5]enkephalin is effected by the endopeptidase E.C.3.4.24.15. 
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[131,198,202]. The preincubation of the mouse vas deferens with the 
inhibitor cocktail plus 0.3j.!M of the E.C.3.4.24.15. inhibitor, cFP-AAF-pAB, 
to protect the Leu5-Arg6 bond [202,281,283], produced a nor-BNI Ke value 
against dynorphin 1-8 of 5nM, reduced from 17nM in the presence of the 
cocktail alone. This is again suggestive of o receptor involvement, but with 
the possible contamination by some K receptor actions which may result 
from the protection of the Leu5-Arg6 bond. Due to inadequate availability of 
this inhibitor, the Ke value was determined by the single dose method, 
therefore a Schild slope was not obtained. If it were to be assumed that this 
value represented a combination of mainly o plus some K receptor 
antagonism blocking the activity of [Leu5]enkephalin and dynorphin 1-8 
respectively, the evidence suggests that the main activity of the added 
peptide still procedes via the o receptors. This implies that the 0 
predominating active peptide in the presence of these inhibitors is still 
· [Leu5]enkephalin. The findings are confirmed with the inhibitor cocktail 
plus 30j.!M of the mixed inhibitor kelatorphan [229,284,285], affording a 
similar nor-BNI Ke against dynorphin 1-8 of 5nM. ·This inhibitor however 
increased the potency of the peptide, this being reflected in the alteration of 
the ICso from 66nM in its absence (inhibitor cocktail alone) to 8nM, 
implying that it offers greater protection from hydrolysis than the 
E.C.3.4.24.15. inhibitor, cFP-AAF-pAB. 
The nor-BNI antagonism of dynorphin 1-8 in the mouse vas deferens, 
therefore illustrates K activity in the absence of inhibitors but J.llo activity in 
the presence of the inhibitor cocktail and with the further inclusion of0.3j.!M 
of the E.C.3.4.24.15. inhibitor or 30j.!M kelatorphan, although some K 
activity may be proceeding in these two latter cases. Previous studies in 
this laboratory in guinea pig myenteric plexus tackled the same question 
[281,283] and demonstrated that in the absence of any peptidase inhibition, 
dynorphin 1-8 acted with selectivity at the 1C receptor exemplified by a nor-
BNI value of 0.17nM. A loss of selectivity was observed by the inclusion of 
the inhibitor cocktail but K selectivity was regained by the further inclusion 
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of0.3JlM of the E.C.3.4.24.15. inhibitor, cFP-AAF-pAB [243]. 
Therefore taken together with the naloxone antagonism data, the results 
show that dynorphin 1-8 displays 1C activity in both of these isolated tissues, 
but that the inclusion of the inhibitor cocktail reduces the selectivity. It can 
be proposed that these inhibitors allow the release of [Leu5]enkephalin and 
stabilise it to the extent that it becomes the predominately active peptide in 
these tissues. The release of the pentapeptide can be reduced to some 
extent by the inclusion of the selective inhibitor of the Leu5-Arg6 bond 
hydrolysing endopeptidase E.C.3.4.24.15. 
Dynorphin 1-6 is thought to possess little 1C receptor affinity [38,47], this 
having been proposed to result from the lack of the basic amino acid pair at 
its carboxy terminal, thought to be a requirement for 1C receptor activation 
[48,286]. Therefore, a brief study of the receptor selectivity of this peptide 
utilising the highly selective nor-BNI was performed in the mouse vas 
deferens. A nor-BNI Ke of 0.5nM was observed suggesting that this 
peptide was probably acting at more than one receptor site including some 
1C receptor interaction. This value suggests that dynorphin 1-6 is relatively 
unselective, apparently illustrating both 1C and ll/Jl · 'agonism. Although it 
must be recalled that there will be differences between the two tissues, this 
result agrees broadly with previous data reported in guinea pig brain 
homogenates which showed this peptide to possess similar affinities for the 
I> and Jl receptors, but with weaker affinity for the 1C receptor [38]. 
Preincubation of the mouse vas deferens with the inhibitor cocktail 
potentiated the activity of dynorphin 1-6 more than 20 fold, and the affinity 
of nor-BNI was significantly decreased, affording a Ke of 36nM. This 
suggests that the presence of these inhibitors completely abolishes any 
determinable affinity dynorphin 1-6 may have displayed at the 1C receptor. 
The antagonism of dynorphin 1-6 by naloxone was discussed more than a 
decade ago when a Ke of 4nM was reported in guinea pig myenteric plexus 
[47], but this did not assess the I> affinity of this peptide since a functional I> 
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receptor population is not present in this tissue preparation. However, in 
guinea pig brain homogenates, the affinity of dynorphin 1-6 has been shown 
to be similar at J.1 and o receptors [286]. The antagonism of selective ligands 
suggested that nor-BNI showed least affinity for the o receptor with a Ke of 
approximately 20nM, and taking into account the high population of o 
receptors in this tissue, it can be suggested that dynorphin 1-6 is acting at 
the o receptor in the presence of the inhibitor cocktail. However, further 
evidence is required to support this suggestion. 
4.33 HS341 Antagonism in the Mouse vas Deferens 
Studies of dynorphin 1-8 discussed above, indicate that full stabilisation of 
the octapeptide by the preincubation of the tissue and inclusion in the organ 
bath of various protease inhibitoryis not possible but its activity can be 
potentiated to a certain extent. This however was thought to be misleading, 
since the activity of its stabilised metabolites was exhibited rather than 
that of dynorphin 1-8 itself. To confirm this, studies were performed with 
the 14-alkoxymorphinan, HS341, shown in the previous chapter to 
antagonise ligands at each of the opioid receptors in the mouse vas 
deferens. 
The antagonism of dynorphin 1-8 by HS341 afforded a Ke of 423nM, and a 
Schild slope of unity, which agrees with the data obtained from nor-BNI 
antagonism suggesting that dynorphin 1-8 selectively activates 1C receptors 
in the mouse vas deferens in the absence of any peptidase inhibitors. By 
contrast, preincubation of the tissues with the inhibitor cocktail and with 
the cocktail plus 0.3J.1M cFP-AAF-pAB (the site directed inhibitor of 
E.C.3.4.24.15.), both increased the potency of dynorphin 1-8, reflected in the 
ICso values, as well as the antagonism by HS341 affording equilibrium 
constants in the range of 35nM. Although this is a slightly higher affinity 
than the HS341 Ke value obtained against the selective DPDPE, it is 
probable that these Ke values illustrate t{t<eceptor interactions since J.1 
interactions would afford a Ke of 3nM. This agrees with the nor-BNI data 
obtained above, which suggested that the antagonism in the presence of 
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these inhibitors was of[Leu5]enkephalin which was produced from the Leu5. 
Art" hydrolysis, and not actually of dynorphin 1-8. 
4.34 Naloxone Antagonism in Guinea Pig Myenteric Plexus 
4.341 Naloxone Antagonism of Prodynorphin Derived Pep tides 
A series of small dynorphin peptides were examined in the guinea pig 
myenteric plexus to investigate their receptor preferences. The guinea pig 
myenteric plexus possesses a greater 1C and ll receptor reserve than the 
mouse vas deferens, therefore ought to present a clearer picture of receptor 
activation [243]. The lack of a functional o receptor in this tissue [17] 
means that naloxone antagonism may identify the 1C selectivity of these 
peptides without the complications observed in the mouse vas deferens. It 
must be taken into account though, that the full selectivity profile of the 
peptides will not be possible due to the absence of the o receptor. 
The smaller [Leu5]enkephalin containing peptides, that is [Leu5]enkephalin 
itself and dynorphin 1-6, were relatively weak agonists in the myenteric 
plexus, reflected in ICso values near to 500nM. The potency of 
[Leu5]enkephalin was 20 fold less than in the mouse vas deferens, therefore 
taking into consideration the 10 fold o selectivity of the pentapeptide in 
preference to the 11 receptors, reported in brain tissue [38], this weaker 
potency can be suggested to result from [Leu5]enkephalin interacting with 
its less favoured 11 site in the plexus [17]. Naloxone antagonism of 
[Leu5]enkephalin and dynorphin 1-6 afforded equilibrium constants of 
2.9nM and 4.3nM. The latter value is on the high side of the range 
associated with 11 receptor but both analyses were accompanied by Schild 
slopes of unity implying these peptides were activating a single receptor 
population. 
Such observations confirm those previously published in favour of 
dynorphin peptides smaller than seven amino acids lacking 1C affinity 
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[38,47]. The heptapeptide dynorphin 1-7, and similarly dynorphin 1-8 itself 
are increasingly more potent, with ICso values of 83.5nM and 38.4nM 
respectively. The naloxone antagonism of dynorphin 1-7 determined in the 
guinea pig myenteric plexus is in the "K range" being 17nM agreeing with 
that determined in single dose Ke determination of 15nM by Chavkin et al 
[47]. Similarly, the naloxone Ke of dynorphin 1-8 was calculated as 11.3nM 
which agrees with previous reports by James et al [274] who calculated a 
Ke of 15nM using the single dose method [244,245], confirming the proposed 
K activity of this octapeptide [38,274]. These two peptides were shown to 
be interacting solely with the K receptors, as exemplified by Schild slopes of 
unity. 
Preincubation of the guinea pig myenteric plexus with the inhibitor cocktail 
consisting of 30J.!M bestatin, 30J.!M captopril and 0.3J.!M thiorphan, afforded 
a significant increase in the potency of dynorphin 1-7, and a conversion in 
the naloxone equilibrium constant from 16. 7nM to a "mixed" KIJ.! value of 
6.8nM. When the activity of the inhibitors are once again considered, the 
Leu5-Arg6 bond is seen to be unprotected. Taking into account the weak 
but still Jl preferring activity of [Leu5]enkephalin, it seems reasonable to 
propose that such an affinity value is not wholly a result of the antagonism 
ofdynorphin 1-7 but in fact the antagonism of at least one metabolite also. 
The combination of two interacting receptors has been proposed previously 
by James and eo-workers [274] who performed a similar experiment in 
guinea pig myenteric plexus with dynorphin 1-8, when they preincubated 
the tissue with their peptidase inhibitor cocktail [65]. They reported a 
naloxone Ke of8nM determined by the single dose method, agreeing with our 
studies which they proposed to be due to partial de~tion ofdynorphin 1-
8 to either the Jl selective [Leu5]enkephalin or dynorphin 1-6 [47]. Since 
this value was determined by the single dose method, the extent of the 
receptor and metabolite interactions is not obvious since Schild slopes were 
not obtained. However, Schild analysis of the naloxone antagonism of 
dynorphin 1-8 in the presence of the inhibitor cocktail has been performed 
[283] showed greater Jl activity than the studies of James et a! [65], giving 
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a Ke value of 3.0nM but with a significantly shallow slope, confirming the 
proposed antagonism of more than one peptide. 
Results therefore confirm that for 1C receptor activation, the seven amino 
acid structure is required [37,47], whereas the smaller peptides, namely 
dynorphin 1-6 and the pentapeptide [Leu5]enkephalin, have preference for 
the Jl receptor in the guinea pig myenteric plexus. Structure-activity 
relationship studies [47] have shown that the Arg7 pays the greatest 
contribution to potency, but it is also the second member of a basic pair. 
Such pairs are often cleavage signals for enzymic attack therefore it could 
be hypothesised that this basic pair is the signalling system for the 
biologically important release of[Leu5]enkephalin from dynorphin 1-8. 
4.342 Naloxone Antagonism of Proenkephalin Derived Products 
The activities of the proenkephalin derived [Met5]enkephalin, 
[Met5]enkephalin-Arg6-Gly7-Leu8 and [Met5]enkephalin-Arg6-Phe7 were 
analysed in guinea pig myenteric plexus to determine whether they 
possessed any affinity for the K receptor. Such a study was performed to 
investigate whether 1C receptor activity was dependent on the peptide 
structural size, or the actual chemical composition of the amino acid 
sequence. The potency of [Met5]enkephalin was not significantly different 
to the extended peptides, [Met5]enkephalin-Arg6-Giy7.Leu8 and 
[Met5]enkephalin-Arg6-Phe7, all of which demonstrated ICso values of 
approximately 300nM. [Met5]enkephalin and [Met5]enkephalin-Arg-Gly-
Leu afforded "Jllike" naloxone equilibrium constants with Schild slopes of 
unity, demonstrating no activity at the 1C sites in this tissue preparation. A 
Ke was determined against [Met5]enkephalin-Arg6-Phe7 of 5nM with a 
Schild slope of unity. It is likely that this is indicative of Jl receptor 
activation. 
Preincubation of the tissue with the inhibitor cocktail (30J.1M bestatin, 
30J.1M captopril and 0.3JlM thiorphan) increased the potency of 
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[Met5]enkephalin-Arg6-Gly7-LeuB 11 fold. However, there was no change in 
the receptor selectivity of the peptide, with a naloxone Ke value of 1.4nM 
being calculated which suggests the antagonism was still proceeding at Jl 
receptors. Contrastingly, the l();o of [Met5]enkephalin-Arg6-Phe7 was only 
potentiated 4 fold by the pretreatment of the guinea pig myenteric plexus 
with the inhibitor cocktail, however the naloxone Ke value wasmsreasedto 
llnM. The Schild slope of unity determined from three increasing 
antagonist doses, implies that the peptide was active solely at the 11: 
receptor under these conditions. 
Binding assay data published in the early eighties for [Met5]enkephalin, 
[Met5]enkephalin-Arg6-Gly7-LeuB and [Met5]enkephalin-Arg6-Phe~ [48,286] 
suggested that these three peptides showed no selectivity for K receptors in 
guinea pig brain membranes. All of them however displayed higher affinity 
at I> and J..l receptors which was proposed to result from the lack of a basic 
pair of amino acids in the carboxy terminal, which has been implicated to be 
essential forK activity [47]. Thus [Met5]enkephalin-Arg6-Arg7 was 15 fold 
more potent at the 11: receptor than the nonapeptide [Met5]enkephalin-Arg6-
Gly7·LeuB·Lys9, therefore showing selectivity was not wholly a size. 
dependant issue. The pentapeptide, [Met5]enkephalin itself, was relatively 
selective for the o receptor, but extension of the peptide abolishes this 
selectivity. The only proenkephalin derived peptide acting via K receptors in 
the guinea pig myenteric plexus was [Met5]enkephalin-Arg6-Phe7 after 
tissue preincubation with, and in the presence of, the inhibitor cocktail, this 
preference having been implicated in guinea pig brain homogenates 
described above [48]. It must always be recalled though, that we are 
comparing studies in the periphery with studies in the brain therefore this 
comparison is not completely ideal. 
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4.35 Conclusions 
Antagonism of dynorphin 1-8 by nor-BNI in the mouse vas deferens and by 
naloxone in the guinea pig myenteric plexus confirmed the proposed K 
preference of dynorphin 1-8. Pretreatment of these tissues with the 
inhibitor cocktail followed by the determination of antagonist affinity 
constants concluded that the antagonism is proceeding predominately at 
the o site. The o preferring peptide [Leu5]enkephalin, is known to be a 
product of dynorphin 1-8 [125,128,131,133,134,198,202] resulting from the 
Leu5-Arg6 cleavage, therefore it can be proposed that the o affinity of the 
peptide under these conditions is demonstrating the affinity of 
[Leu5]enkephalin and not dynorphin 1-8. 
When a selective inhibitor of endopeptidase E.C.3.4.24.15., a possible 
candidate for the Leu5-Arg6 hydrolysis [131,198,202], was included 
alongside the inhibitor cocktail, some but not full protection of this cleavage 
is effected, with the o preferring metabolite still being formed. This probably 
indicates the involvement of other enzymes in the cleavage ofthe Leu5-Arg6 
bond. Candidates include endo-oligopeptidase A [213,214], endopeptidase 
E.C.3.4.24.16. [135,226] and Pz-peptidase [209], but no evidence has been 
obtained in support of this. Previous investigations in guinea pig myenteric 
plexus, demonstrated complete 1C selectivity with the same inhibitor 
combination, which suggests a different complement or variable 
concentrations of active enzymes between the two tissues [ 243]. 
Investigation of the series of small prodynorphin peptides in guinea pig 
myenteric plexus showed that [Leu5]enkephalin and dynorphin 1-6 
displayed Jl preference, whereas dynorphin 1-7 and dynorphin 1-8 showed K 
selectivity. Characterisation of the smaller proenkephalin products in the 
guinea pig myenteric plexus, showed that [Met5]enkephalin, 
[Met5]enkephalin-Arg6-Giy7-Leu8 and [Met5]enkephalin-Arg6-Phe7 all 
displayed Jl preference. Following tissue pretreatment with the inhibitor 
cocktail, [Met5]enkephalin-Arg6-Phe7 uniquely displayed 1C opioid receptor 
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preference. 
Results confirm previous suggestions that dynorphin 1-8 may be K 
selective, and that it is readily converted into the o preferring 
[Leu5]enkephalin. It is as yet unknown whether this is a biological 
conversion or merely a degredation product, though this may depend on the 
receptor populations in the viscinity. 
The proenkephalin derived opioid peptides possess less affinity than the 
prodynorphin derived peptides, and this may be partially due to the absence 
of a pair of basic amino acids at their C-terminus. 
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4.4 Metabolism Studies 
4.41lntroduction 
The attempt to characterise the selectivity of dynorphin 1-8 in various 
tissues by competitive binding and isolated tissue bioassays was not wholly 
satisfactory. There was much evidence implying that dynorphin 1-8 was 
subject to considerable enzymic hydrolysis even after pretreatment of the 
tissue preparations with high levels of peptidase inhibitors. However, the 
methods used were not suitable to determine the extent of this instability. 
To further understand the role and receptor selectivity of dynorphin 1-8 and 
to try and explain the results reported above, a quantification of its 
stabilisation under the the specified enzyme inhibitor conditions must be 
established. The release of [Leu5]enkephalin, a proposed product of the 
endopeptidase E.C.3.4.24.15. [200] resulting from the hydrolysis of the 
Leu5-Arg6 bond of dynorphin 1-8, was also determined. Such a cleavage can 
be considered to be a specific release of an active opioid rather than a 
degrfclation of dynorphin 1-8 [200,212,213], but this proposal is as yet 
unconfirmed. 
4.5 Results 
4.51 Determination of Dynorphin 1-8 Metabolism in Guinea Pig Brain 
Homogenates at 25"C by Radioimmunoassay (RIA) 
Dynorphin 1-8 (10.0nM) was incubated with guinea pig brain homogenate 
(1ml of 1:60 w/v dilution) for 30 mins. A 12% recovery of immunoreactive 
dynorphin 1-8 was determined as a percentage of the control recovery in 
which cold dynorphin 1-8 was added after the addition of phosphoric acid. 
When unlabelled dynorphin 1-8 was incubated in the homogenate alongside 
the inhibitor cocktail (captopril 100~-tM, bestatin 30~-tM and thiorphan 
0.3~-tM) the quantity of immunoreactive dynorphin 1-8 was not significantly 
altered, the recovery being 18%. 
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In contrast, in the presence of the inhibitor cocktail plus 0.3!lM of the 
E.C.3.4.24.15. inhibitor, cFP-AAF-pAB, the quantity of cold dynorphin 1-8 
recovered was determined as 120% of the control. Results were not 
particularly reproducible, therefore questioning the efficiency of this 
method. Additionally, little could be established about the metabolites in the 
reaction, in particular [Leu5]enkephalin. Therefore direct metabolism of 
dynorphin 1-8 was investigated. 
4.52 [125J]Dynorphin 1-8 Metabolism in Guinea Pig Brain Homogenate at 
25"C. 
Metabolism of [125I]dynorphin 1-8 (10nM) was followed in incubations with 
500!11 homogenised guinea pig brain (1.12mg protein/m!), after removal of 
the cerebellum, at 25°C for 30 minutes. [125I][Leu5]enkephalin was 
identified as the radioactive peak eo-eluting with standard cold iodinated 
[Leu5]enkephalin, 29 mins after sample injection. The liberation of this, 
along with the recovery of unmetabolised [125I]dynorphin 1-8 is shown in 
Figure 4.11. 
The recovery of the [125I]dynorphin 1-8 after incubation in 0.5ml Tris/HCl 
buffer (pH7.4) alone was 89.37±0.95% with 3.49±0.33% eluted at the 
determined retention time for [125I][Leu5] enkephalin (n=5). In the presence 
of 0.5ml of homogenate, only 8.26±3.42% of the [125I]dynorphin 1-8 was 
recovered intact, but 14.81±2.62% of the radioactivity eo-eluted with the 
iodinated [Leu5]enkephalin standard (n=5). The recovery of [125I]dynorphin 
1-8 (11.40±2.98%) was not enhanced by the preincubation of the 
homogenate with the inhibitor cocktail (captopril 10011M, bestatin 30!lM 
and thiorphan 0.3!lM). This inhibitor combination however, significantly 
increased the level of production of [LeuS]enkephalin (p< 0.005, Students t-
test), with 48.93±4.85% of the radioactivity recovered as such (n=4). 
When the homogenate was preincubated in the presence of both the 
inhibitor cocktail and 0.3!lM of the E.C.3.4.24.15. inhibitor, cFP-AAF-pAB, 
a significant increase in the recovery of [125I]dynorphin 1-8, to 
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24.87±2.68%, was observed (p< 0.005). At the same time, a decrease in the 
production of iodinated [Leu5]enkephalin to 28.82±4.25% was seen (n=6). 
When the homogenate was preincubated with 100!lM cFP-AAF-pAB in 
addition to the inhibitor cocktail, the recovery of dynorphin 1-8 significantly 
increased further to 40.74±5.40% (p< 0.05), with a reduction (Students t-
test p< 0.005) in the [125I][Leu5]enkephalin to 16.89±1.28% (n=6). 
Preincubation of the homogenate with the inhibitor cocktail plus 301!M of 
the mixed inhibitor kelatorphan, afforded a recovery of 25.34±4.00% of 
[125I]dynorphin 1-8 unmetabolised, similar to the recoveries associated with 
the incubations performed in the presence of 0.3!lM of cFP-AAF-pAB with 
the cocktail. Likewise, the liberation of 30.75±6.17% of radioactivity as 
[125I][Leu5]enkephalin (n=6) in the incubations with the cocktail plus 30!lM 
kelatorphan was similar to that determined with cFP-AAF-pAB instead of 
the kelatorphan. 
4.53 [125J]Dynorphin 1-8 Metabolism in Guinea Pig Brain Homogenate at 
ooc. 
Incubation of [125I]dynorphin 1-8 in guinea pig brain homogenate was 
carried out at 0°C for 240 mins, this being the time used in ligand binding 
assays at 0°C. In all cases, the number of experimental observations, n=3. 
Results are illustrated in Figure 4.12. 
Incubation of the radioligand in Tris/HCl buffer (pH7.4), afforded a 
[125I]dynorphin 1-8 recovery of 91.01±1.92%, with 7.52±1.22% of the 
radioactivity being identified as [Leu5]enkephalin. In the presence of 0.5ml 
of guinea pig brain homogenate, a 240 mins incubation yielded only 
5.72±3.12% of the radioactivity in the form of [125I]dynorphin 1-8 and 
14.87±5.63% as [Leu5]enkephalin. When the homogenate was 
preincubated with the inhibitor cocktail, the recovery of [125I]dynorphin 1-8 
was unchanged (11.36±3.92%), but with a significant increase (p< 0.05) in 
the recovery of iodinated [Leu5] enkephalin to 25.11±3.42%. 
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No significant increase in the recovery of [125J]dynorphin 1-8 (17 .32±6. 7 6%) 
was determined when 0.3J.LM of the E.C.3.4.24.15. inhibitor cFP-AAF-pAB 
was added alongside the inhibitor cocktail and likewise the [125I][Leu5] 
enkephalin level remained as 24.99±1.72%. The addition of 100J.LM cFP-
AAF-pAB to the same system, resulted however in significant protection 
(p< 0.005) of the octapeptide, with 24.41±1.53% of the radioactivity being 
identified as [125I]dynorphin 1-8. This was accompanied by a reduction (p< 
0.005) of the radioactivity at the same retention time as [125I][Leu5] 
enkephalin to 13.85±1.85%. 
4.54 [I25J]Dynorphin 1-8 Metabolism in Guinea Pig Cerebellum 
Homogenate at 25"C 
[125I]dynorphin 1-8 was incubated in homogenates of guinea pig cerebellum, 
at similar protein concentrations to the brain, at 25°C for 30 minutes. 
Results are shown in Figure 4.13. 
The incubation of [125I]dynorphin 1-8 in Tris/HCl buffer (pH7.4) afforded a 
recovery of 89.37±0.95% of the radioactivity as [125I]dynorphin 1-8 and 
3.49±0.33% at the same retention time as iodinated [Leu5] enkephalin 
(n=5). When incubated with 0.5ml of the homogenate, 25.56±7.53% of the 
radioactivity was determined as [l25I]dynorphin 1-8 and 11.82±4.23% eo-
eluted with [Leu5]enkephalin (n=4). The recoveries of these two peptides 
were unchanged by preincubation of the homogenate with the inhibitor 
cocktail when 16. 77±5.80% of the radioactivity was determined as 
[125I]dynorphin 1-8 and 13.66±2.82% as [125J][Leu5]enkephalin (n=3). 
A significant increase in the recovery of both [125I]dynorphin 1-8 (p< 0.005) 
and [125I][Leu5]enkephalin (p< 0.005) was observed after the further 
addition of 0.3J.LM of cFP-AAF-pAB with the inhibitor cocktail from that 
with the cocktail alone, when 34.41±6.89% of the former and 24.10±2.69% 
of the latter was determined (n=4). The increase in the concentration of 
cFP-AAF-pAB to 100J.LM afforded a further increase in protection of the 
[125I]dynorphin 1-8 (p< 0.005), with 55.05±3.74% of the radioactivity 
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present as the unmetabolised peptide. However, no real change was 
detennined in the levels of[125I][Leu5]enkephalin, the recovery of which was 
23.80±0.72% (n=3). 
The addition of30!!M of the mixed enzyme inhibitor, kelatorphan, along with 
the inhibitor cocktail, afforded a 42.70±7.14% recovery of [125I]dynorphin 1-
8 and a 24.01±5.20% recovery as [125IJ[Leu5] enkephalin. 
4.55 Dynorphin 1-7 Metabolism in Guinea Pig Brain Homogenates at 25 "C 
Dynorphin 1-7 (36!!M) was incubated at 25°C for time periods between zero 
and 20 minutes with homogenates of guinea pig brain minus the cerebellum, 
using 3.32mg protein per assay. Results are illustrated in Figure 4.14. In 
all cases n=4. Labelled analogues were not available so higher 
concentrations of peptide was added to allow visibility on the HPLC. 
Likewise, the protein concentration was raised accordingly. 
At 25°C the levels of dynorphin 1-7 dropped rapidly from 100% to 
65.28±2.23% in 2 minutes, to 32.08±4.47% after a 5 minute incubation 
time and to 21.88±6.37% after 10 minutes, affording a t112 of 3.5±1.2 
minutes. When the homogenate was preincubated with the inhibitor 
cocktail (captopril 100!!M, bestatin 30!!M and thiorphan 0.3!!M) for 30 
minutes prior to and during the incubation with dynorphin 1-7, a decrease in 
the rate of degr,dation was observed. A recovery of 77.43±5.66% 
unmetabolised dynorphin 1-7 was detennined after a 5 minute incubation, 
where only 32.08±4.4 7% remained after the same time in its absence. 
After 10 minutes, in the presence of the inhibitor cocktail, there was still 
50.98±11.07% of the peptide remained unhydrolysed, 34.06±6.90% was 
observed after 20 minutes and 13.32±0.54% after 30 minutes. A half life, 
t 112 , of 10.5±2.8 minutes was therefore calculated. 
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4.56 Metabolism of Dynorphin 1-7 in Guinea Pig Brain Homogenates at ooc 
The metabolism of dynorphin 1-7 (32!lM) at 0°C was studied over a 150 
minute period in homogenates of guinea pig brain (3.32mg of protein per 
assay). Loss of the peptide proceeded at a slower rate than at 25°C. 
Results are illustrated in Figure 4.15. In all cases n=4. Thus after a 30 
minute incubation in the homogenate, 31.51±5.48% of the dynorphin 1-7 
was recovered unmetabolised (t112 22.5±3.5 minutes). This contrasts with 
that of 90.76±10.23% recovered in the presence of the inhibitor cocktail. 
Without the inhibitor cocktail the recovery dropped to 11.75±2.94% after 60 
minutes, levelling out to 9.50±2.80% after 120 minutes and 9.89±2.47% 
after 150 minutes. 
The inclusion of the inhibitor cocktail facilitated a degree of protection, with 
a recovery of 39.34±4.50% unmetabolised peptide after 60 minutes, 
13.32±0.37% after 120 minutes and 9.67±1.39% after 150 minutes (t112 
55.0±3.0 minutes). 
4.57 Possible Release of [Leus]enkephalin from Dynorphin 1-7 
There is some evidence for the possible transient presence of [Leu5] 
enkephalin during the metabolism of dynorphin 1-7 at 0°C. Results of this 
are shown in Figure 4.16. In all cases n=3. 
In the absence of the inhibitor cocktail, after a 30 minute incubation in the 
homogenate, 28.17±9.25% of the dynorphin 1-7 had been converted to a 
peak which eo-eluted with standard [Leu5] enkephalin. In the presence of 
the inhibitor cocktail, the recovery after the same time period was only 
3.01±0.85%. 
After a 60 minute incubation, 4.33±0.61% of the dynorphin 1-7 was 
recovered as [Leu5]enkephalin in the presence of the inhibitor cocktail, 
whereas 9.08±2.73% was detected in its absence. Levels drop off quite 
noticeably by 120 minutes when negligible amounts result with or without 
the cocktail. 
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4.58 Metabolism of Dynorphin 1-6 in Guinea Pig Brain Homogenates at 
250C 
The metabolism of dynorphin 1-6 was investigated in homogenates of 
guinea pig brain in the absence and presence of the inhibitor cocktail in a 
similar manner to that with dynorphin 1-7. Results illustrated in Figure 
4.17. In all cases n=4. 
As with dynorphin 1-7, in the absence of the inhibitor cocktail the levels of 
the peptide decreased rapidly, with only 57.48±6.22% recovered after 2 
minutes, 34.54±2.74% after 5 minutes and 14.81±3.62% after 10 minutes 
affording a halflife, t 112 , 3.2±0.9 minutes. The peptide was protected by the 
inhibitor cocktail to a greater extent than dynorphin 1-7. No metabolism 
was detected after 2 minutes, the recovery being 101.53±0. 73%, and 
83.06±1.86% of the dynorphin 1-6 was still present after 5 minutes. The 
slow decline in dynorphin 1-6 levels continued with a recovery of 
76.03±4.38% after 10 minutes and 62.83±3.56% and 43.40±3.57% after 20 
and 30 minutes respectively with a halflife, t 112 , of 25±2.5 minutes. 
4.59 Metabolism of Dynorphin 1-6 in Guinea Pig Brain Homogenates at ooc 
The metabolism profile of dynorphin 1-6 at ooc was determined, and results 
are shown in Figure 4.18. In all cases n=4. 
Dynorphin 1-6 did not appear to be stabilised by the inclusion of the 
inhibitor cocktail in the incubation, with the losses of peptide being similar 
irrespective of its presence. After 30 minutes in the absence of the inhibitor 
cocktail, 91.16±7.33% of the peptide was recovered, compared to 
92.20±5.59% in its presence. Similarly, after 60 minutes, 68.74±0.78% was 
recovered when the cocktail was added, 58.36±1.68% without. This pattern 
was unchanged after 120 minutes, when the recoveries of dynorphin 1-6 
were 30.99±4.49% and 31.16±4.73% in the presence and absence of the 
inhibitor cocktail respectively. Finally, after a 150 minute incubation the 
recovery with the inhibitor cocktail was 24.56±3.19% and without the 
cocktail was 18.38±4.73%, these not being significantly different. The half 
lifes of the peptide were determined to be 90±2.0 minutes in the absence of 
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the inhibtor cocktail and 85±2.0 minutes in its presence. 
There was no evidence at either 0°C or 25°C for the release of any product 
eluting from the HPLC with standard [Leu5] enkephalin. If any was 
liberated, it was either below the level of detection of the laboratory HPLC 
system or too transient to be seen. 
4. 60 Metabolism of [125I]Dynorphin 1-8 in Mouse vas Deferens at 25 "C 
Metabolism of [125I]dynorphin 1-8 was studied in mouse vas deferens at 
25°C. Incubations were for 20 minutes, and results are illustrated in Figure 
4.19. In all cases n=3. 
Of the total radioactivity added, 85. 73±0.15% was recovered as 
[125J]dynorphin 1-8 when no tissue was present in the incubation, and 
3.38±0.25% was shown to elute at the same retention time as 
[Leu5]enkephalin. When a single vas deferens was incubated in 0.5ml of 
Krebs solution with [125I]dynorphin 1-8 (10nM), a recovery of 4.40±0.63% 
[125I]dynorphin 1-8 and 15.08±0.75% [125J][Leu5] enkephalin was observed 
after the 20 minute contact time. No protection of the peptide was offered 
by the preincubation of the tissue with the inhibitor cocktail with a recovery 
of 5.37±0.48% of the radioactivity being identified as [125J]dynorphin 1-8, 
but a significant increase in production and protection of the peptide, 
determined as [125I][Leu5] enkephalin (p< 0.005), to 48.34±3.97% was 
observed. 
The addition of0.3J.1M of the E.C.3.4.24.15. inhibitor cFP-AAF-pAB with the 
inhibitor cocktail however offered significant protection to [125I]dynorphin 1-
8 (p< 0.005), resulting in a recovery of 40.32±2.40% unmetabolised. 
Alongside, a drop in the production of [125I][Leu5] enkephalin to 
27.19±1.22% was observed (p< 0.005). 
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Figure 4.11 Showing a bar chart of the percentage radioactivity recoveries after the metabolism of [125I]dynorphin 
1-8 in guinea pig brain homogenate (without the cerebellum) at 25°C. Filled bars represent [125I]dynorphin 1-8 and 
open bars represent [125I][Leu5]enkephalin. 1=tris buffer only (no tissue), 2=homogenate only, 3=homogenate + the 
inhibitor cocktail, 4= homogenate with the inhibitor cocktail plus 0.3J.1M cFP-AAF-pAB, 5=homogenate + the 
inhibitor cocktail plus 100J.1M cFP-AAF-pAB and 6=inhibitor cocktail plus 30J.1M kelatorphan. 
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Figure 4.12 Sho~ing a bar chart of the percentage radioactivity recoveries after the metabolism of [125I]dynorphin 
1-8 in guinea pig brain, (with the cerebellum removed) at 0°C. Filled bars repreilent [125I]dynorphin 1-8 and open 
bars represent [l25I][Leu5]enkephalin. 1=tris buffer only (no tissue), 2=homogenate only, 3=homogenate with the 
inhibitor cocktail, 4= homogenate with the inhibitor cocktail plus 0.3J.1M cFP-AAF-pAB and 5=homogenate with the 
inhibitor cocktail plus 100J.1McFP-AAF-pAB. 
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Figure 4.13 Showing a bar chart of the percentage radioactivity recoveries after the metabolism of [I25I]dynorphin 
1-8 in guinea pig cerebellum at 25°C. Filled bars represent [125I]dynorphin 1-8 and open bars represent 
[I25I][Leu5]enkephalin. l=tris buffer only (no tissue), 2=homogenate only, 3=homogenate in the presence of the 
inhibitor cocktail, 4= homogenate with the inhibitor cocktail plus 0.3).1M cFP-AAF-pAB, 5=homogenate with the 
inhibitor cocktail with lOO).lMcFP-AAF-pAB and 6=homogenate with the inhibitor cocktail plus 30).1M kelatorphan. 
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Figure 4.14 A time course of dynorphin 1-7 metabolism in guinea pig brain 
homogenate at 25°C, showing recoveries in the absence of inhibitors [•] and 
in the presence of the inhibitor cocktail [a], where error bars represent SEM 
from 4 experimental observations. 
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Figure 4.15 A time course of dynorphin 1-7 metabolism in guinea pig brain 
homogenate at 0°C, showing recoveries from incubations in the absence of 
inhibitors [•] and in the presence of the inhibitor cocktail [c ], where error 
bars represent SEM from 4 experimental observations. 
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Figure 4.16 The degree of [Leu5]enkephalin production from dynorphin 1-7 
during the metabolism at 0°C for varying lengths of time, expressed as the 
percentage of radioactivity coeluting with standard iodinated 
[Leu5]enkephalin, where error bars represent SEM from 3 experimental 
observations. 
The release of[Leu5] enkephalin is illustrated in the absence of inhibitors [o] 
and the release in the presence of the inhibitor cocktail [•]. 
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Figure 4.17 Showing a time course of dynorphin 1-6 metabolism in guinea 
pig brain homogenate at 25°C, showing results from incubations in the 
absence of inhibitors [a] and in the presence of the inhibitor cocktail [• ], 
where error bars represent SEM from 4 experimental observations. 
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Figure 4.18 A time course of dynorphin 1-6 metabolism in guinea pig brain 
homogenate at 0°C, showing recoveries from incubations in the absence of 
inhibitors [o] and in the presence of the inhibitor cocktail [•], where error 
bars represent SEM from 4 experimental observations. 
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Figure 4.19 Sho~g a bar chart of the percentage radioactivity recoveries after the metabolism of [125I]dynorphin 
I ,- / 
1-8 in mouse vas deferens at 25°C. Filled bars represent [125I]dynorphin 1-8 and open bars represent 
[125I][Leu5]enkephalin. l=tris buffer only (no tissue), 2=tissue only, 3=tissue + the inhibitor cocktail and 4= tissue + 
inhibitor cocktail plus 0.3~M cFP-AAF -pAB. 
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4. 7 Discussion 
4.71 [125J]Dynorphin 1-8 Metabolism in Guinea Pig Brain Homogenate at 
25"C 
Iodinated dynorphin 1-8 was incubated in guinea pig brain homogenates 
(after removal of the cerebellum) under the same conditions used previously 
in the radioligand displacement assays, namely, at 25°C for 30 minutes. 
The recoverable [l25I]dynorphin 1-8, and its metabolite 
[125I][Leu5]enkephalin, were isolated by fraction collection following HPLC 
separation. The peptides were quantified by the determination of 
radioactivity present in each fraction, and identified by comparison of their 
retention times on the column with those of standard cold iodinated 
peptides. An absence of the homogenate acted as a control, with 90% of the 
[125J]dynorphin 1-8 being recoverable, and a 3% conversion to 
[125J][Leu5]enkephalin. 
Mter a 30 minute incubation at 25°C only 8% of the radioactivity was 
recovered as unmetabolised [125J]dynorphin 1-8, whereas 15% of the 
radioactivity was identified as iodinated [Leu5]enkephalin. This rapid 
metabolism agrees with previous reports [268,269], in which no more than 
2% of the original dynorphin 1-8 concentration could be recovered after a 20 
minute incubation with a similar tissue preparation. When such 
observations are considered, some of the data from the radioligand binding 
assays in which the competition of dynorphin 1-8 at the 1C receptor 
proceeded with lower affinity than at the other two receptors can be partly 
explained, as a result not so much as a lack of selectivity of dynorphin 1-8 
for this receptor population, but rather as a consequence of only very low 
levels of this peptide remaining in the homogenate at the end of the 
incubation time. The resulting shallow displacement slope can be 
hypothesised to be an interference in the competition of [3H]U69593 by 
various metabolites, most probably dynorphin 1-7 or 1-6 due to the lack of1e 
affinity of the other dynorphin 1-8 fragments. Fragments smaller than this 
have been shown to possess no affinity for the 1C receptor [38,47]. 
Alternatively, it could be a consequence of the dynorphin 1-8 breaking down 
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at such a high rate, that it is unstable even when bound to the receptor and 
therefore a point of equilibrium cannot be reached. Furthermore, it must be 
considered that the highest affinity of dynorphin 1-8, displayed for the 1i 
receptor in guinea pig brain homogenates, may result from the competition 
of the higher levels of the 1i prefering metabolite, [Leu5]enkephalin, rather 
than dynorphin 1-8 itself. 
It can also be proposed that the displacement of [3H]DAMGO from the ll 
. site occurs_in_ a _sinril~r Il1anner !0 that observed at the 1i sites resulting 
from the competition by [Leu5]enkephalin (or other small active metabolite) 
and not wholly dynorphin 1-8. However, the resulting shallow slope 
accompanying radioligand displacement from 11 receptors, suggests that 
more than one metabolite is involved. Although it may be that both 
dynorphin 1-8 and [Leu5]enkephalin are involved, as in all cases, the lack of 
information about the complete spectrum of metabolites present, in 
particular dynorphin 1-6 and 1-7which have been shown to be active in the 
same log scale as dynorphin 1-8 and [Leu5]enkephalin, means that other 
peptides may also play a significant role at this receptor. 
Incubations of [125I]dynorphin 1-8 in homogenates of guinea pig brain 
preincubated with and in the presence of the inhibitor cocktail (30jlM 
bestatin, 100~-LM captopril and 0.3jlM thiorphan) afforded a large increase in 
the conversion to [Leu5]enkephalin to 50%, but with little or no effect on the 
dynorphin 1-8 recovery. This high percentage of radioactivity recovered as 
[Leu5]enkephalin is hardly surprising when the protection offered by the 
inhibitor cocktail is considered. The three bonds protected by the peptidase 
inhibitors making up the cocktail, are TyrLGly2, Gly3-Phe4 and Argf>-Arg7, \ 
therefore any [Leu5]enkephalin formed would be somewhat protected, but 
the hydrolysis point which is responsible for its release, ie the Leu5-Arg/3 
bond, is not. In other words, [Leu5]enkephalin ought to be formed as readily 
as in the absence of any peptidase inhibitors, assuming they do not 
interfere with peptide binding, reflected in the lack of overall protection of 
the dynorphin 1-8, but the pentapeptide once formed is protected from 
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further metabolism by the cocktail. This increased level of 
[Leu5]enkephalin present in the homogenate explains the potentiation of 
the displacement of selective radioligands at o and Jl receptors, discussed in 
the previous chapter. Additionally, endopeptidase E.C.3.4.24.15., one of the 
enzymes thought to facilitate the Leu5-Arg6 cleavage, has been shown to 
protect the enkephalin once formed by holding it in its active site [287], 
therefore this too may enhance its stabilisation beyond that offered by the 
inhibitor cocktail. 
The lack of protection of dynorphin 1-8 by the peptidase inhibitors does not 
however offer any explanation why the competition at the K receptor was 
significantly increased by the addition of the cocktail in the binding assays. 
This potentiation was accompanied by an increase in the displacement 
slope to unity, therefore implying that only one species was now competing 
with the [3H]U69593. It may be that the stabilisation offered by the 
cocktail to the pep tides may protect the receptor bound form of dynorphin 
1-8 and therefore improve the activity as a result of the peptide being less 
accessible to hydrolysing enzymes. 
Preincubation of the homogenate with the inhibitor cocktail plus 0.3J.!M 
cFP-AAF-pAB, a selective inhibitor designed to block the actions of the 
endopeptidase E.C.3.4.24.15., afforded an increase in the recovery of the 
octapeptide to 25%, accompanied by a reduction in [Leu5]enkephalin to 
28%. This concentration of inhibitor cFP-AAF-pAB, has previously been 
shown to fully inhibit the partially purified endopeptidase, E.C.3.4.24.15. 
[202]. It is obvious from these metabolism studies that cleavage of the 
Leu5-Arg6 is still taking place, suggesting either the inhibitor is less active 
than reported, or that other enzymes are present in the guinea pig brain 
homogenate which catalyse the same cleavage. 
To examine this, the concentration of the E.C.3.4.24.15. inhibitor added 
alongside the inhibitor cocktail (100J.!M captopril, 30J.!M bestatin and 0.3J.!M 
thiorphan) was increased 300 fold to lOOJ.!M in situ. This afforded a greater 
protection of dynorphin 1-8, with 41% being recovered, and a reduction in its 
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conversion to [Leu5]enkephalin, with 16% determined as this product. The 
fact that the hydrolysis of the Leu5-Arg6 bond was not fully prevented by 
such a high excess of the inhibitor provides evidence in favour of the 
involvement of other enzymes. 
Orlowski et al [198,202] have claimed that the Leu5-Arg6 hydrolysis is 
exclusive to E.C.3.4.24.15., by showing full protection of dynorphin 1-8 after 
inhibition of the partially purified enzyme, whereas Toffelotto and colleagues 
[235] have provided evidence to the contrary, claiming endo-oligopeptidase 
A is responsible for this cleavage, demonstrated by the use of a selective 
antibody to the enzyme. The properties of these two enzymes, 
E.C.3.4.24.15. and endo-oligopeptidase A, are quite similar therefore it has 
been hypothesised they are one and the same [181,223,237,288]. However 
there has been evidence to the contrary for example E.C.3.4.24.15. has 
been shown to contain a Zn2+ ion whereas endo-oligopeptidase A has not 
[224,235]. The findings here favour the presence of more than one enzyme 
in guinea pig brain with the capacity to hydrolyse Leu5-Arg6, since the 
inhibition ofE.C.3.4.24.15. does not prevent the cleavage of this bond. This 
does not however automatically mean that the enzyme is endo-
oligopeptidase A, since several other enzymes having been shown to 
perform the same hydrolysis including Pz-peptidase [288] and 
endopeptidase E.C.3.4.24.16. [128,228]. The lack of availability of selective 
antibodies and likewise selective inhibitors for these other proposed 
peptidases has haulted such investigations. Cloning and sequencing of 
these enzymes, and further pharmacological studies is as yet incomplete 
but is required to determine whether any of these enzymes are related, or 
whether they are different but all perform this cleavage, varying in their 
distribution. 
Addition of 0.31lM cFP-AAF-pAB to the inhibitor cocktail did increase the 
affinity at each receptor site, although only at the 11 and the K sites was this 
significant. Integration of the metabolism data with that of the radioligand 
displacements shows that under these inhibitor conditions, the significantly 
increased affinity at the 11: receptor can be hypothesised to result from the 
displacement of [3H]U69593 by the increased level of stabilised dynorphin 
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1-8, and the slope of unity implies there was no interference by any other 
fragment. Slopes of unity were also recorded for the displacement of 
[3H]DPDPE and [3H]DAMGO, but these may result from a smaller peptide 
fragment, most likely [Leu5]enkephalin or possibly dynorphin 1-6. Although 
the higher concentration of cFP-AAF-pAB was not examined in radioligand 
displacement assays, it is evident from the examination of the metabolism 
performed with this concentration of E.C.3.4.24.15. inhibitor that such 
bioassays would have been unlikely to reveal further selectivity )< 
~
determinations. Thus the increased potency at Jl and o cannot be ruled out 
as a dynorphin 1-8 action, since its selectivity is not fully characterised 
here. 
The inclusion of 30J.1M kelatorphan with the inhibitor cocktail afforded a 
similar protection of [125I]dynorphin 1-8 to that obtained by the inclusion of 
0.3JlM cFP-AAF-pAB. Kelatorphan, first synthesised in the mid eighties 
[285], has been shown to be a potent inhibitor of both E.C.3.4.24.11., which 
cleaves the Gly3-Phe4 bond in enkephalins, and aminopeptidase, the 
enzyme which is responsible for the cleavage of the Tyr1-Gly2 bond [229]. 
Kelatorphan alone has been shown to /!!:ore potent at inducing 
antinociceptive effects [229,284] in vivo than the combination ofthiorphan 
and bestatin, the two selective inhibitors of the afore\nentioned enzymes. 
l. 
It was claimed therefore to be the first complete inhibitor of enkephalin 
metabolism [289]. The above results show however that although \.· 
kelatorphan may be highly potent in the protection of enkephalin, a 
similarly high stabilisation of dynorphin 1-8 is not offered, the protection not 
exceeding that observed with the selective site directed cFP-AAF-pAB. 
However, the potency of the peptide in the inhibition of electrically induced 
contractions in the mouse vas deferens was shown to be greater after 
tissue pretreatment with the inhibitor cocktail plus kelatorphan, than the 
cocktail plus cFP-AAF-pAB. Again it must be recalled though, that the 
comparison of tissues is not fully satisfactory, since the receptor and 
enzyme compliments may vary, but it can be considered that kelatorphan 
is providing some protection to the Leu5-Arg6 bond and that this protection 
may be greater than that offered by cFP-AAF-pAB in the mouse vas 
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deferens, as exemplified in the bioassay, but not so in the brain 
homogenates as shown in the metabolism studies. 
4.72 [125J]Dynorphin 1-8 Metabolism in Guinea Pig Brain Homogenate at 
ooc 
The metabolism of dynorphin 1-8 in guinea pig brain homogenates was 
performed at 0°C, and the incubation time increased to 240 minutes to 
mirror the conditions studied in the radioligand binding assays. Even at this 
temperature, in the absence of any inhibitors the recoverable dynorphin 1-8 
was less than 10% after incubation with the homogenate, with 15% of the 
radioactivity being identified as [Leu5]enkephalin. This was the same as 
determined at 25°C under the same tissue conditions. 
Preincubation of the homogenate with the inhibitor cocktail (lOO!lM 
captopril, 30!lM bestatin, 0.3!lM thiorphan), did not offer any protection to 
dynorphin 1-8 at all, whereas the recovery of [LeuS]enkephalin rose to 25%, 
this being significantly less than the conversion determined at 25°C with 
the same inhibitor cocktail. Further inclusion of0.3!lM of the E.C.3.4.24.15. 
inhibitor along with the cocktail increased the recoverable dynorphin 1-8 to 
17%, but there was no change in the recovery of [LeuS]enkephalin whereas 
increasing the cFP-AAF-pAB concentration to 10011M afforded a dynorphin 
1-8 recovery of 24% of the total incubated, with a reduction of 
[Leu5]enkephalin to 14%. For both these peptides, the recoveries were less 
than those determined at 25°C with the same inhibitors. Therefore these 
figures show that over the time period required to reach equilibrium binding 
of the radioligands, the reduction of the incubation temperature does not 
offer additional protection to the peptide dynorphin 1-8, compared to that 
offered at 25°C for the shorter incubation period. In fact the presence of the 
peptidase inhibitors does less to enhance the stabilisation of the peptide, 
than at 25°C. Such a lack of protection may be proposed to be a result of 
the peptidase inhibitors being conformationally altered in such a manner 
that they lose some activity at the reduced temperature, whereas the 
enzymes are still actively metabolising the peptide. 
190 
Chapter Four "' · 
This data contrasts strongly with previous investigations which described 
similar peptidase inhibitor actions on the stabilisation of [3H]dynorphin 1-8 
in guinea pig brain homogenates at 0°C [268,269]. The inclusion of 30J.1M 
bestatin saw the release of the major metabolite to be dynorphin 1-6 
whereas in the absence, the main products had been the carboxy terminal 
fractions. In contrast to the present data, the presence of 300J.1M captopril 
in addition to 30J.!M bestatin, afforded a recovery of 80% of dynorphin 1-8 
after a 150 minute incubation [268,269], this being far greater than the 
recoveries observed in the present study. Although the concentration of the 
captopril was 3 fold higher, it had not been expected that such a difference-
would have been created. It may be that the degredation of dynorphin 1-8 is 
(/ 
not directly proportional to time, and that a lag period may be occurring. 
In the present studies, the displacement of[3H]DAMGO and [3H]DPDPE at 
0°C by dynorphin 1-8 afforded similar affinities to those in the presence of 
the inhibitor cocktail at 25°C. This implies that the inhibitor cocktail 
offered a similar protection to the dynorphin peptides, as that obtained by 
the reduction in the temperature. This however was not in agreement with 
the metabolism of the peptide which differed at 25°C in the presence of the 
inhibitor cocktail compared to that at 0°C in its absence. As discussed 
above, it seems likely that the competing peptide in the displacement of 
[3H]DAMGO and [3H]DPDPE is [Leu5]enkephalin or dynorphin 1-6 but at 
25°C, 50% of the radioactivity was identified as [Leu5]enkephalin whereas 
only 15% was observed at 0°C. However in addition to the temperature 
control of the metabolism, the temperature may also affect the binding 
properties of the ligands, by the alteration of the receptors or the ligands. 
An example of this has previously been shown that the binding capacities of 
dynorphin 1-8 and bremazocine were reduced four fold by the reduction of 
the incubation temperature from 25°C to 0°C [268]. 
4. 73 [125J]Dynorphin 1-8 Metabolism in Guinea Pig Cerebellum 
Homogenate at 25°C 
The metabolism of dynorphin 1-8 was performed in guinea pig cerebellum 
homogenate to complement the above data from the brain. The guinea pig 
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cerebellum has been shown to possess a higher level of 1C opioid receptors 
than 1.1. or o [55]. Therefore, if the metabolism of dynorphin 1-8 is a specific 
conversion to the o active [Leu5]enkephalin in tissues possessing this 
receptor, the lack of a o population in the cerebellum would imply that this 
peptide is not the active opioid in this tissue, and therefore such a 
converting enzyme may not be necessary. 
In the cerebellum at 25°C, dynorphin 1-8 was more stable affording a 
recovery of 26%, contrasting with only 8% in brain tissue. The conversion 
to [Leu5]enkephalin was however similar, with 12% being determined in 
cerebellum homogenate and 15% in brain. In the presence of the inhibitor 
cocktail there was no significant change in the recovery of dynorphin 1-8 to 
that determined in its absence but there was a much lower production of 
[Leu5]enkephalin, with only a 14% conversion to the pentapeptide 
contrasting with 49% in brain homogenates. The addition of 0.3J.!M cFP-
AAF-pAB increased the recovery of unmetabolised dynorphin 1-8 to 34% 
after 30 minutes, with approximately 25% of the radioactivity recovered as 
[Leu5]enkephalin. 
Such an increase in the dynorphin 1-8 by the addition of cFP-AAF-pAB 
along with the inhibitor cocktail had been expected but the accompanying 
increase in the production of [Leu5]enkephalin was quite surprising. It can 
be hypothesised that the brain tissue favourably transforms dynorphin 1-8 
to [Leu5]enkephalin, but that in cerebellum this conversion is not 
advantageous, hence its lower production. This increase in enkephalin 
observed in the cerebellum studies is not so much an increase in the release 
but a stabilisation of the peptide once formed, therefore creating this effect. 
Variable enzyme combinations in the brain and the cerebellum provides an 
explanation as to why this is not confirmed by studies in brain 
homogenates. 
The addition of lOO!lM cFP-AAF-pAB to the inhibitor cocktail in cerebellar 
homogenates offered a significantly higher protection of dynorphin 1-8 than 
in brain, the recoveries being 55% as opposed to 41%, but with little effect 
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on the levels of [Leu5]enkephalin being formed. This again provides an 
indication that these two tissues do not metabolise dynorphin 1-8 in an 
identical manner. Incubation of cerebellum with the inhibitor cocktail plus 
30J.1M kelatorphan recovered 43% of umnetabolised dynorphin 1-8 with a 
24.0% conversion to [Leu5]enkephalin, this protection being similar to that 
with 0.3J.1M cFP-AAF-pAB reflecting a similar situation as that observed in 
the brain. These results again show that dynorphin 1-8 is less susceptible 
to hydrolysis in the cerebellum than in the brain. The results however are 
not radically different, so it is difficult to make conclusions about the 
relative role of dynorphin 1-8 in these two CNS tissues, and of course 
different areas of these heterogeneous structures are likely to have different 
enzyme profiles also. 
4.74 Dynorphin 1-7 and Dynorphin 1-6 Metabolism in Guinea Pig Brain 
Homogenate at 25"C 
The metabolism of dynorphin 1-7 and dynorphin 1-6 was also examined. At 
25°C a rapid loss of both peptides was observed, with halflives of 3.5 and 
3.2 minutes for dynorphin 1-7 and dynorphin 1-6 respectively. This rate 
was decreased to different degrees by the preincubation of the homogenate 
with the inhibitor cocktail (captopril 100J.1M, bestatin 30J.1M and thiorphan 
0.3J.1M), which stabilised the dynorphin 1-6 (halflife 25 minutes) to a greater 
extent than dynorphin 1-7 (t112 of 10.5 minutes). 
Metabolism at 0°C occurred at a much slower rate, with a half life for 
dynorphin 1-7 of22 minutes and for dynorphin 1-6 of90 minutes. Inclusion 
of the inhibitor cocktail protected dynorphin 1-7, whereas no protection was 
offered to dynorphin 1-6. Although there is no supporting evidence, it can be 
suggested that dynorphin 1-6 may be subject to metabolism by an enzyme 
at 0°C, which is not hindered by the selected inhibitors, therefore the rates 
of the degrp!ation are identical. This enzyme may not necessarily be active 
in the hydrolysis of dynorphin 1-7 which would explain why the cocktail 
affords some stabilisation. Furthermore, in incubations at 0°C in the 
absence of inhibitors, a considerable proportion of [Leu5]enkephalin was 
recovered, with a maximum of 28% being isolated after a 30 minute 
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incubation. The quantity determined from all other incubation conditions 
was negligible. 
It has been shown by solution NMR that the preferred conformation of 
dynorphin 1-7 is folded whereas that of dynorphin 1-6 is a straight chain 
[290]. It is therefore possible that different sites on the peptide chain may 
be exposed or protected across the two peptides, and that this may also 
contribute to their different receptor selectivities discussed previously. 
4. 75 [125J]Dynorphin 1-8 Metabolism in Mouse vas Deferens at 25"C 
The metabolism of [125J]dynorphin 1-8 was performed in mouse vas 
deferens to quantify the peptide stabilisation in the presence of the same 
combinations of inhibitors used in the isolated tissue bioassays. Results 
showed that the presence of the inhibitor cocktail did not offer any 
protection to dynorphin 1-8, with a 5% recovery being determined after a 20 
minute contact time in both its absence and presence. In contrast 
however, the peptidase inhibitors caused an increase in the recovery of 
[Leu5]enkephalin, with 48% of the total radioactivity identified as such, in 
contrast to 15% in the absence of the inhibtor cocktail, after a 20 minute 
incubation. 
In light of these results, with a knowledge of a predominating population and 
receptor reserve of o receptors in the mouse vas deferens [243], and the o 
preference of [Leu5]enkephalin, the results from the mouse vas deferens 
bioassays in the presence of the inhibitor cocktail (captopril 30J.1M, bestatin 
30J.1M and thiorphan 0.3J.1M) can be considered. The naloxone Ke of 15nM 
determined against dynorphin 1-8 suggested interactions at K or o 
receptors. The large production of [Leu5]enkephalin evidenced in the 
metabolism studies suggests this is not antagonism of dynorphin 1-8 but 
that of [Leu5]enkephalin. The fact that [Leu5]enkephalin is present in such 
proportions was also reflected in the nor-BNI Ke of 17nM, a value 
associated with JliO activity, therefore demonstrating the pentapeptide 
agonism and a lack of 1C receptor interaction. 
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This does not however explain the naloxone Ke value of 4nM determined 
against dynorphin 1-8 in the absence of inhibitors. This does not appear to 
be naloxone antagonism at two different sites, since the equilibrium 
constant was accompanied by a Schild slope of unity, implying one receptor ~ 
site only. Furthermore, a nor-BNI Ke of0.05nM was observed with a Schild 
slope of unity suggesting there was no interaction at li or ~ sites. These 
results support the original reports [18] which proposed dynorphin 1-8 to be 
an endogenous ligand for the K receptor using guinea pig myenteric plexus 
as a model. The rather high affinity of naloxone is difficult to explain but 
does however exemplifY the difficulties of using non selective ligands to 
characterise receptors. 
Preincubation of tissues with the inhibitor cocktail (captopril 30~M, 
bestatin 30~M and thiorphan 0.3~M) plus 0.3~M of the E.C.3.4.24.15. 
inhibitor, cFP-AAF-pAB afforded a recovery of 40% unmetabolised 
dynorphin 1-8 after 20 minutes. Such a combination of inhibitors was also 
associated with a significant decrease in the [Leu5]enkephalin production, to 
27% of the total radioactivity recovered. The isolated tissue bioassays 
afforded a nor-BNI Ke with this combination of inhibitors of 5nM, a value 
lying between the concentrations associated with K and li interactions 
although closer to the li range. Although this equilibrium constant was 
determined by the single dose method due to the lack of availability of cFP-
AAF-pAB, the consideration of the similar quantities of dynorphin 1-8 and 
[Leu5]enkephalin present under these conditions, leads to the probability 
that the Ke value is a combination of antagonism of both peptides at their 
respective receptors. Such a claim must however be considered with 
caution due to the lack of information available about other active 
metabolites. 
Previous investigations have shown that in the metabolism of 
[3H]dynorphin 1-8 in the guinea pig myenteric plexus [281,283], in the 
presence of the inhibitor cocktail (captopril 10~M, bestatin 10~M and 
thiorphan 0.3~M), a 20 minute incubation with [3H]dynorphin 1-8 recovered 
38% unmetabolised. 
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This is accompanied by a [3H][Leu5]enkephalin production of 34%, 
therefore it can be suggested that the shallow Schild plot resulted from a 
competition of dynorphin 1-8 competing at the K receptor and 
[Leu5]enkephalin displaying agonism at the 1.1 receptors [38]. This was not 
observed in the mouse vas deferens which only afforded a 5% recovery of 
intact dynorphin 1-8 but with a large recovery of [Leu5]enkephalin as 
discussed above, which then acted at the preferred ll receptors. 
The differences between the two tissue preparations, result from the 
different peptide proportions obtained during metabolism, but their different 
receptor populations must also be considered. The lack of a functional ll 
receptor population in the guinea pig myenteric plexus, means that 
[Leu5]enkephalin can only act via 1.1 receptors with which it has less affinity, 
will also influence the observed equilibrium constants. The higher levels of 
[Leu5]enkephalin present in the incubations with the mouse vas deferens, 
plus the greater population of ll receptors, to which the pentapeptide 
exhibits selectivity, enhancing its activity. 
Further metabolism studies in the guinea pig myenteric plexus [283] have 
shown that a 30 minute preincubation with the cocktail plus 0.31J.M cFP-
AAF-pAB prior to the addition of [3H]dynorphin 1-8, recovered 71% of the 
octapeptide unmetabolised after a 20 minute contact time, with only 4% of 
radioactivity being converted to [3H][Leu5]enkephalin. This shows a high 
level of protection being offered to the Leu5-Arg6 bond by the E.C.3.4.24.15. 
inhibitor, which is not illustrated in the mouse vas deferens, suggesting 
further the lower presence of enzymes in this tissue preparation which 
specifically release [Leu5]enkephalin. The data also emphasis~he 
importance of not extrapolating data between tissues which will probably 
vary as a result oftheir different complement ofpeptidases [243,262]. 
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4.80 Conclusions 
Dynorphin 1-8 has been reported to possess K opioid receptor selectivity 
and to be an endogenous ligand for this receptor [17,19,37,38]. When 
examined in guinea pig brain homogenates, no K selectivity was observed, 
with some preference being displayed for the l5 receptors. 
The selectivity of dynorphin 1-8 was therefore examined in the mouse vas 
deferens, affording an y.neciuivocal naloxone equilibrium constant. Re-
examination with the selective antagonist nor-BNI, evidenced dynorphin 1-
8 to exhibit K selectivity whereas in the presence of the inhibitor cocktail 
(captopril 30J.1M, bestatin 30J.1M and thiorphan 0.3J.1M), in the absence or 
presence of 0.3J.1M cFP-AAF-pAB afforded l5 receptor affinity. This was 
explained by the examination of the metabolism of [125I]dynorphin 1-8 in 
guinea pig brain. The protection offered to dynorphin 1-8 by these inhibitors 
was poor, whereas the release of [Leu5]enkephalin was high, with up to 50% 
of the radioactivity being identified in this form in the presence of the 
inhibitor cocktail. This was reduced to 17% by the protection of the Leu5-
Arg6 bond by the inclusion of 100J.!M of the E.C.3.4.24.15. site directed 
inhibitor, cFP-AAF-pAB. 
A 300 fold weaker concentration of this inhibitor has been shown by 
Orlowski et al [198,202] to fully protect the Leu5-Arg6 bond in dynorphin 1-8 
in the presence of a partially purified form of the enzyme. Other authors 
believe that such a cleavage can be performed by other peptidases, and the 
evidence here suggests that this is probably so. 
The guinea pig cerebellum possesses a higher percentage of K receptors 
than the brain [55]. The capacity to metabolise dynorphin 1-8 was less in 
this tissue which may be a result of a lack of functional receptors which 
would be activated by its metabolite [Leu5]enkephalin, but there is little 
evidence to support this suggestion. 
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The 1C selectivity of the small prodynorphin peptides was assessed in the 
guinea pig myenteric plexus, to avoid the complications in data analysis 
caused by ll interactions. [LeuS]enkephalin and dynorphin 1-6 displayed Jl 
selectivity, whereas dynorphin 1-7 and dynorphin 1-8 afforded 1C selectivity, 
agreeing with previous investigators [38,47]. The proenkephalin peptides, 
[Met5]enkephalin, [Met5]enkephalin-Arg6-Phe7 and [Met5]enkephalin-Arg6-
Gly7-Leu8, were then examined in the same tissue preparation, all 
demonstrated Jl selectivity whereas [Met5]enkephalin-Arg6-Phe7 in tissues 
preincubated with the inhibitor cocktail displayed 1C selectivity. It is 
concluded therefore, that prodynorphin peptides of at least seven amino 
acids in size exhibit 1C selectivity, and the directing factor is most probably 
the basic pair of amino acids on the carboxy terminus, but their selectivity 
is not well illustrated as a result of their rapid metabolism in biological 
tissue preparations. Proenkephalin pep tides of seven and eight amino acids 
in size do not afford such a degree of K selectivity, therefore discounting the 
directing factor to be totally size orientated. 
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